Final PROGRAM

CTAD 2026

Clinical Trials on Alzheimer's Disease

November 16-19, 2026

Boston, MA (USA)

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

JPAD
THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE

TABLE OF CONTENTS

Organizing & Scientific Committees **03**

Editorial **04**

Lifetime Achievement Award **05**

Keynotes **06**

Scientific Sessions **07**

Monday, November 16 07

Tuesday, November 17 09

Wednesday, November 18 13

Thursday, November 19 18

Poster List **22**

CTAD Organizing Committee and Scientific Committee

Susan ABUSHAKRA (San Francisco, United States); Paul AISEN (San Diego, United States)*; Rebecca E. AMARIGLIO (Boston, United States); Patricia ANDREWS (Nashville, United States); Sandrine ANDRIEU (Toulouse, France)*; Davide ANGIONI (Toulouse, France); Laura D. BAKER (Winston-Salem, United States); Randall J. BATEMAN (St. Louis, United States); Karim BENNYS (Montpellier, France); Ram BISHNOI (Tampa, United States); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, United States); Maria CARRILLO (Chicago, United States); Mathieu CECCALDI (Marseille, France); Suzanne CRAFT (Winston-Salem, United States); Lucia CRIVELLI (Buenos Aires, Argentina); Jeffrey CUMMINGS (Las Vegas, United States); Steven DEKOSKY (Gainesville, United States); Michael C. DONOHUE (San Diego, United States); Rachelle DOODY (Houston, United States); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, United States); Howard FILLIT (New York, United States); Nick FOX (London, UK); Kristian Steen FREDERIKSEN (Copenhagen, Denmark); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Joshua GRILL (Los Angeles, United States); Michael GRUNDMAN (San Diego, United States); Harald HAMPEL (Nutley, United States); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Jakub HORT (Prague, Czech Republic); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, United States); Zaven KHACHATURIAN (Washington DC, United States); Miia KIVIPELTO (Stockholm, Sweden); Yan LI (St. Louis, United States); Jorge J. LLIBRE GUERRA (St. Louis, United States); Constantine G. LYKETSOS (Baltimore, United States); Gad A. MARSHALL (Boston, United States); Adam MECCA (New Haven, United States); Lefkos T. MIDDLETON (London, UK)*; José Luis MOLINUEVO (Valby, Denmark); Kyra O'BRIEN (Philadelphia, United States); Claire PAQUET (Paris, France); Robert PERNECZKY (Munich, Germany); Ronald PETERSEN (Rochester, United States); Elif PINAR COSKUN (Lexington, United States); Michael S. RAFII (San Diego, United States); Rema RAMAN (San Diego, United States); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, United States); Marwan SABBAGH (Phoenix, United States); Stephen SALLOWAY (Providence, United States); Pascual SANCHEZ-JUAN (Madrid, Spain); Nikolaos SCARMEAS (New York, United States); Rachel SCHINDLER (New York, United States); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, United States); Eric SIEMERS (Indianapolis, United States); Sietske SIKKES (Amsterdam, The Netherlands); Yong SHEN (Hefei, China); Jiong SHI (Hefei, China); Irina SKYLAR-SCOTT (Stanford, United States); Heather SNYDER (Chicago, United States); Maria SOTO (Toulouse, France); Reisa SPERLING (Boston, United States)*; Yaakov STERN (New York, United States); Duygu TOSUN (San Francisco, United States); Jacques TOUCHON (Montpellier, France)*; Maileen ULEP (Las Vegas, United States); Wiesje van Der FLIER (Amsterdam, The Netherlands); Christopher H. VAN DYCK (New Haven, United States); Bruno VELLAS* (Toulouse, France); Prashanthi VEMURI (Rochester, United States); Michael W. WEINER (San Francisco, United States)* Donna M. WILCOCK (Indianapolis, United States); Bengt WINBLAD (Stockholm, Sweden); Kirsten WRIGHT (Portland, United States); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member

Join Us at CTAD26: Advancing Alzheimer's Disease Clinical Research Together

The 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference will convene in Boston, USA, from November 16–19, 2026. For those of us who have watched our field transform over the past two decades, there is something fitting about returning to Boston — a city that has long been at the heart of Alzheimer's research — at what feels like a genuinely pivotal moment.

Since its founding in 2008, CTAD has grown into the premier global forum dedicated exclusively to Alzheimer's disease clinical research. What has always set CTAD apart is its format: all sessions take place in a single main ballroom, so that every investigator, clinician, industry scientist, and regulatory expert in attendance shares the same presentations and the same conversations. In a field where translation from bench to bedside depends on true interdisciplinary exchange, that shared experience matters. Some of the most consequential discussions I have witnessed in our field have happened in the hallways and roundtables during CTAD.

CTAD25 in San Diego offered a comprehensive picture of where the Alzheimer's clinical trials now stand. More than 2,850 international experts gathered to examine emerging data and evolving strategies across the full spectrum of Alzheimer's research. Sessions addressed disease-modifying therapies, gene- and cell-based approaches, vaccines, digital tools, and multimodal interventions, reflecting how far we have come but also how much remains to be done.

CTAD26 in Boston will carry that momentum forward. The questions we will be asking are more focused than even a few years ago: How do we define who needs to be treated with what and when? Who will benefit most from early intervention? How do we optimize combination approaches, not just tau and amyloid but including other emerging therapeutic mechanisms? What do biomarkers tell us about individualized disease trajectories that can inform more efficient trial design? These are the conversations that CTAD seeks to nurture and more...

I hope you will join us in Boston this November. We have made tremendous progress in Alzheimer's disease research due to the unwavering commitment of this community, and the open, cross-disciplinary collaborations that CTAD is designed to foster. There is no better place to continue that work than here in Boston, and we look forward to welcoming you all.

Reisa Sperling, MD

Harvard Medical School,
Brigham and Women's Hospital
Boston, MA (United States)

CTAD 2026
Lifetime Achievement Award

This year, the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Jeffrey Cummings, MD, in recognition of his foundational contributions to clinical trial methodology, drug development frameworks, and his decades of leadership in advancing the field through the annual Alzheimer's disease drug development pipeline analyses.



Jeffrey Cummings, MD, ScD

Joy Chambers-Grundy Professor of Brain Science

Director of the Chambers-Gundy Center for Transformative Neuroscience

Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV)

Biography

UNLV research professor Jeffrey L. Cummings is a neurologist globally recognized for his contributions to Alzheimer's research, drug development, and clinical trials. He serves as the Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at the Kirk Kerkorian School of Medicine's Department of Brain Health.

Dr. Cummings leads the UNLV Clinical Trials Observatory, the world's only research observatory devoted exclusively to analyzing the pipeline of Alzheimer's drugs in clinical trials to better inform drug development decisions. He also heads a biomarker observatory, which captures and categorizes emerging information on blood tests, brain scans, and digital devices related to Alzheimer's disease.

Prior to joining UNLV in 2019, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, as well as two UCLA entities — the Mary S. Easton Center for Alzheimer's Disease Research, and the Deane F. Johnson Center for Neurotherapeutics.

Named a "Rock Star of Science" by Gentleman's Quarterly, Dr. Cummings — a fellow of the American Academy for the Advancement of Science — has published 43 books and more than 900 peer-reviewed articles on neuropsychiatry, Alzheimer's disease, and clinical trials.

His numerous recognitions for his scientific and leadership contributions include the American Association of Geriatric Psychiatry's Distinguished Scientist Award, Melvin R. Goodes Prize for Excellence in Drug Development from the Alzheimer's Drug Discovery Foundation, Society for Behavioral and Cognitive Neurology's Lifetime Achievement Award, and the national Alzheimer's Association's Bengt Winblad Lifetime Achievement Award. In 2024, he was ranked by ScholarGPS as the world's top scholar for his lifetime contributions in the areas of dementia and drug development.

KEYNOTE

New Molecules in Phase 2b – Proof of Concept and Beyond

Monday, November 16 • 3:25 p.m. — 3:50 p.m.

CTAD 2026
Keynotes

A Glimpse of the Future: How Diagnostics, Therapies, Trials, and Concepts of Prevention Must Evolve

Geoffrey A. Kerchner, *MD, Vice President and Global Head of Neurodegeneration, F. Hoffmann-La Roche, Ltd., Basel (Switzerland)*

Geoffrey A. Kerchner, MD, PhD is a neurologist and neuroscientist serving as Vice President and Global Head of Neurodegeneration at F. Hoffmann-La Roche, Ltd., in Basel, Switzerland, where he oversees all late-stage clinical development efforts in Alzheimer's, Parkinson's, and Huntington's diseases. Over his career, Dr. Kerchner has contributed to the fight against Alzheimer's disease as a basic scientist, a clinical neuroimaging scientist, a clinician, a patient advocate, and a clinical trial site investigator before moving to Genentech/Roche in 2015. There, he led clinical development teams for semorinemab and gantenerumab, among other programs, before moving into leadership positions, first as VP and Head of Early Development in Neuroscience and Rare Diseases and then in his current role. Dr. Kerchner studied at Harvard College (AB summa cum laude), Washington University School of Medicine (MD, PhD), and UCSF (residency and fellowships), and served on the faculty at Stanford University School of Medicine.

Integration of Fluid Imaging and other Multimodal Biomarkers towards Optimizing Disease Understanding and New Therapeutics

Susan Landau, *PhD, Research Neuroscientist, Helen Wills Neuroscience Institute University of California, Berkeley, CA (United States)*

Dr Landau's research focuses on brain changes that occur in healthy aging and Alzheimer's disease. She uses a variety of neuroimaging techniques, other biomarkers, and health information to understand the neurophysiological processes underlying cognitive decline in Alzheimer's disease and related dementias. Her research has a particular emphasis on the roles of amyloid and tau, measured with positron emission tomography (PET), and neurodegeneration, measured with magnetic resonance imaging (MRI).

She is the principal investigator of POINTER Imaging study, an ancillary study to the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) trial. This 2-year clinical trial is examining the influence of multidomain lifestyle interventions on brain changes in at-risk older individuals across the U.S. She also oversees PET pipeline development and analysis in multisite longitudinal studies including the Alzheimer's Disease Neuroimaging Initiative (ADNI), the ADNI Vietnam War Veterans study, the ADNI Late Life Depression study, and the Standardized Centralized Alzheimer's & Related Dementia Neuroimaging (SCAN) study. She has led curation and quantification of over 8000 PET images acquired with a variety of PET tracers and has made this data available to the scientific community for research, education, and clinical trial development. Dr. Landau received the Human Amyoid Imaging Christopher Clark Award in 2018.

Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials

Allan Levey, *MD, PhD, Professor of Neurologyn Emory University's School of Medicine, Director, Emory's Alzheimer's Disease Research Center, Emory University, Atlanta, GA (Unites States)*

Allan Levey, MD, PhD, is a professor in the Department of Neurology at Emory University's School of Medicine, as well as the director of Emory's Alzheimer's Disease Research Center. He has secondary faculty appointments in the Departments of Pharmacology, Psychiatry and Behavioral Sciences.

Levey is an internationally recognized expert in neurodegenerative disorders. His work has contributed to understanding the brain systems and mechanisms involved in disorders such as Alzheimer's and Parkinson's diseases, as well as in identifying molecular targets for new therapeutic strategies. He has more than 250 research publications and has won several awards, including the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association, the Heikkila Research Scholar Award from the National Parkinson Foundation, the Health Advancement Research Award from Community Health Charities and the Team Hope Award for Medical Leadership from the Huntington's Disease Society of America. In addition, he was inducted into the Johns Hopkins Society of Scholars.

Levey consistently has been listed among one of the Best Doctors in America. His research interests include fundamental research into the cause of Alzheimer's disease and related neurodegenerative disorders, and development of new biomarkers and treatments.

Monday, November 16

2:15 p.m.
3:15 p.m.

POSTER WALKING TOUR

3:15 p.m.
3:25 p.m.

Welcome Ceremony & CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research

Presented to Jeffrey Cummings, MD, in recognition of his foundational contributions to clinical trial methodology, drug development frameworks, and his decades of leadership in advancing the field through the annual Alzheimer's disease drug development pipeline analyses.

Introduction by the CTAD Organizing Committee

Reisa Sperling, *Brigham and Women's Hospital Harvard Medical School, Boston (United States)*

Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (United States)*

Sandrine Andrieu, *Toulouse University Hospital and INSERM 1295, Toulouse (France)*

Rachelle Doody, *Houston, TX (United States)*

Lefkos Middleton, *Imperial College, London (United Kingdom)*

Jacques Touchon, *Montpellier University, Montpellier (France)*

Bruno Vellas, *IHU HealthAge, Toulouse University, Toulouse (France)*

Mike Weiner, *UCSF, San Francisco, CA (United States)*

3:25 p.m.
3:50 p.m.

KEYNOTE 1

New Molecules in Phase 2b – Proof of Concept and Beyond

Jeffrey Cummings *University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)*

Introduction: Bruno Vellas, *IHU HealthAge, Toulouse University, Toulouse (France)*

3:50 p.m.
4:50 p.m.

ORAL COMMUNICATIONS

3:50 p.m.

OC1 Top-Line Results of SINGER: A Two-Year Randomized Controlled Trial of Multidomain Lifestyle Intervention to Prevent Cognitive Decline

Kwong Hsia Yap[1], Liang Shen[2], David Matchar[3, 4], Helen Zhou[5, 6], Mitchell Kim Peng Lai[7], Xin Xu[8], Cynthia Huijun Chen[9], Laura Baker[10], Miia Kivipelto[11, 12, 13], Nagaendran Kandiah[14], Christopher Chen[1, 7]

[1]Memory, Ageing and Cognition Centre (MACC), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), [2]Singapore Clinical Research Institute - Singapore (Singapore), [3]Health Services and Systems Research Programme, Duke-NUS Medical School - Singapore (Singapore), [4]Division of General Internal Medicine, Department of Medicine, Duke University, Durham - North Carolina (United States), [5]Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), [6]Department of Electrical and Computer Engineering, National University of Singapore, - Singapore (Singapore), [7]Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), [8]School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, - Zhejiang (China), [9]Saw Swee Hock School of Public Health, National University of Singapore - Singapore (Singapore), [10]Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem - North Carolina (United States), [11]Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, - Stockholm (Sweden), [12]Ageing Epidemiology Research Unit, School of Public Health, Imperial College London - London (United Kingdom), [13]Institute of Public Health and Clinical Nutrition, University of Eastern Finland - Kuopio (Finland), [14]Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technological University - Singapore (Singapore)

4:05 p.m.

OC2 POLARIS-AD: A Global Phase 3 Trial of AR1001 in Early Alzheimer's Disease: Efficacy Outcomes at 52 Weeks and Safety Through the Extension Phase

Sharon Sha[1], Alireza Atri[2], Fernando Melgar-Somoza[3], Marzena Zboch[4], Do Hoon Kim[5], Yi Tang[6], Jennifer Lynch[7], Howard Chertkow[8], Sangyun Kim[9], David Greeley[10], James Rock[11], Fred Kim[11], Tianyang Xi[11], Jai Jun Choung[11]

[1]Stanford - Palo Alto (United States), [2]Banner Sun Health Research and Banner Alzheimer's Institutes - Sun City (United States), [3]Melgar-Caro MedCenter and Community Research - Miami (United States), [4]Wroclawskie Centrum Alzheimerowski - Wroclaw (Poland), [5]Chuncheon Sacred Heart Hospital - Chuncheon (Republic of Korea), [6]Xuanwu Hospital Capital Medical University - Beijing (China), [7]Glasgow NeuroClin - Motherwell (United Kingdom), [8]Baycrest Centre for Geriatric Care - Ontario (Canada), [9]Seoul National University College of Medicine - Seoul (Republic of Korea), [10]Northwest Neurological - Spokane (United States), [11]Aribio Co., Ltd - San Diego (United States)

4:20 p.m.

OC3 Ultrasensitive Immunoassay for Plasma eMTBR-243 Quantification

Alpana Singh[1], Marisa Denkinger[1], Geidy E. Serrano[1], Thomas G. Beach[1], Eric M. Reiman[2], Shorena Janelidze[3], Oskar Hansson[3], Niklas Mattsson-Carlgren[3], Pedro Rosa Neto[4], Nicholas Ashton[1]

[1]Banner Sun Health Research Institute - Sun City (United States), [2]Banner Alzheimer's Institute - Phoenix (United States), [3]Lund University - Lund (Sweden), [4]UT Southwestern Medical Center - Austin (United States)

4:35 p.m.

OC4 Plasma p-tau217 outperforms neuroimaging biomarkers in predicting the risk of cognitive impairment in a multi-cohort study

Colin Birkenbihl[1], Madison Cuppels[1], Diana Townsend[1], Gillian Coughlan[1], Mabel Seto[1], Jane Brown[1], Michael Properzi[1], Annie Li[1], Bryan James[2], Robert Rissman[3], Melissa Petersen[4], Tobey Betthauser[5], Doreen Rentz[1], Reisa Sperling[1], Rachel Buckley[1]

[1]Mass General Brigham - Boston (United States), [2]Rush Alzheimer's Disease Center - Chicago (United States), [3]University of Southern California - Los Angeles (United States), [4]University of North Texas - Fort Worth (United States), [5]University of Wisconsin–Madison - Madison (United States)

4:50 p.m.
5:30 p.m.

SYMPOSIUM 1

Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab

Chair: Tammie L.S. Benzinger, Washington University in St. Louis -St. Louis, Missouri, (United States)

Presentation 1 Trontinemab in Alzheimer's disease – novel pharmacodynamic insights from the ongoing Phase Ib/IIa Brainshuttle™ AD study

Luka Kulic, *F. Hoffmann-La Roche Ltd - Basel (Switzerland)*

Presentation 2 Advanced imaging results from the Brainshuttle™ AD study with trontinemab in Alzheimer's disease

Gregory Klein, *F. Hoffmann-La Roche Ltd - Basel (Switzerland)*

Presentation 3 Brain delivery and distribution of the novel Brainshuttle™ Aβ-targeting antibody trontinemab in participants with Alzheimer's disease measured with ^{89}Zr positron emission tomography

Elsmarieke Van De Giessen, *Amsterdam UMC, Vrije Universiteit - Amsterdam (The Netherlands)*

5:30 p.m.
6:15 p.m.

ORAL COMMUNICATIONS

5:30 p.m.

OC5 Agentic Artificial Intelligence in Alzheimer's Disease Clinical Trials: From Data-Driven Discovery to Adaptive Design Optimization and Statistical Validation

Randall BATEMAN, Eric MCDADE , Yan LI, Guoqiao WANG

Washington University in St Louis, St Louis, United States

5:45 p.m.

LB01 Spectris Treatment in Mild-to-Moderate Alzheimer's Disease: Topline Results and Secondary Analyses From the HOPE Pivotal Study

Roy HAMILTON[1], Ralph KERN[2], Robbert ZUSTERZEEL[2], Marwan SABBAGH[3]

[1]Department of Neurology, University of Pennsylvania, Philadelphia, United States, [2]Cognito Therapeutics Inc., Cambridge, United States, [3]Barrow Neurological Institute,, Phoenix, United States

6:00 p.m.

OC6 Long-Term Outcomes with Lecanemab in Early Alzheimer's Disease: Initial Findings Through 60-Months of Clarity AD Open-Label Extension

Christopher VAN DYCK[1], David LI[2], Michio KANEKIYO[2], Shobha DHADDA[2], Michelle GEE[3], Steven HERSCH[2], Michael IRIZARRY[2], Lynn KRAMER[2]

[1]Yale University School of Medicine, New Haven, United States, [2]Eisai Inc., Nutley, United States, [3]Eisai Ltd., Hatfield, United Kingdom

6:15 p.m.
7:15 p.m.

CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association

ALZHEIMER'S ASSOCIATION

Tuesday, November 17

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:10 a.m.

SYMPOSIUM 2

When Target Engagement Is Not Enough: Lessons from Posdinemab on Bridging Tau Biology to Clinical Outcomes

Chair: Fiona Elwood, Johnson & Johnson, Cambridge, MA, USA

Presentation 1 Spatial Determinants of Posdinemab's Effect on Tau PET
Ziad S. Saad, *Johnson & Johnson, San Diego, CA (United States)*

Presentation 2 CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Autonomy Phase 2 Clinical Trial
Gallen Triana-Baltzer, *Johnson & Johnson, San Diego, CA (United States)*

Presentation 3 Biomarker Associations with Cognition: Results from the Autonomy Phase 2 Clinical Trial
Gil D. Rabinovici, *University of California, San Francisco (UCSF) - San Francisco, CA (United States)*

9:10 a.m.
9:35 a.m.

KEYNOTE 2

A Glimpse of the Future: How Diagnostics, Therapies, Trials, and Concepts of Prevention Must Evolve

Geoffrey A. Kerchner, *MD, Vice President and Global Head of Neurodegeneration, F. Hoffmann-La Roche, Ltd., Basel (Switzerland)*

Introduction: Reisa Sperling, *Brigham and Women's Hospital Harvard Medical School - Boston (United States)*

9:35 a.m.
10:35 a.m.

ORAL COMMUNICATIONS

9:35 a.m.

OC7 Efficacy and Safety of Remlifanserin in Patients With Alzheimer's Disease Psychosis

Jeffrey Cummings[1], Wyllians Vendramini Borelli[2], Clive Ballard[3], Maria E. Soto-Martin[4], Samantha Friend[4], Becky Howell[5], Christine Murphy[4], Peter Zhang[5], Xiaoshu Feng[5], Mona Darwish[5], Bryan Dirks[5], Sanjeev Pathak[5]

[1]Kirk Kerkorian School of Medicine, University of Nevada - Las Vegas, Nevada (United States), [2]Memory Center at the Hospital Moinhos de Vento - Porto Alegre, Rio Grande do Sul (Brazil), [3]University of Exeter Medical School - Exeter (United Kingdom), [4]Acadia Pharmaceuticals Inc. - San Diego, California (United States), [5]Acadia Pharmaceuticals Inc. - Princeton, New Jersey (United States)

9:50 a.m.

OC8 Clinical Evidence for Disease Modification by Amyloid-Targeting Antibodies

Lon Schneider[1], Guoqiao Wang[2], Richard Kennedy[3], Gary Cutter[3], Robert Howard[4]
[1]USC Keck School of Medicine - Los Angeles (United States), [2]Washington University in St. Louis - St. Louis (United States), [3]University of Alabama, Birmingham - Birmingham (United States), [4]University College London - London (United Kingdom)

10:05 a.m.

OC9 Topline results from the Phase 2b PRImus-AD trial: Safety and efficacy of oral PRI-002 in early AD

Oliver Peters[1, 2], Dagmar Jürgens[2, 3], Gerhard Tischler[3], Tina Bartsch[3], Lorenzo Bulli[3], Katja Lindner[3], Julie-Anne Gabelich[3], Julia Post-Schulz[3], Gunther Kauselmann[2, 3], Knut Adermann[2, 3], Kathrin Zeiger[3], Alexander Brener[3], Dieter Willbold[2, 4]
[1]Charité - Universitätsmedizin Berlin - Berlin (Germany), [2]Priavoid - Düsseldorf (Germany), [3]PRInnovation - Düsseldorf (Germany), [4]Institut für Pysikalische Biologie, Heinrich-Heine Universität Düsseldorf - Düsseldorf (Germany)

10:20 a.m.

OC10 Sex Differences in Plasma p-tau217, Amyloid-β, and Tau-PET in Cognitively Unimpaired Adults from the AHEAD International Screening Cohort

Gillian Coughlan[1], Madison Cuppels[1], Aaron Schultz[1], Keith Johnson[1], Robert Rissman[2], Doris Molina-Henry[2], Michael Donohue[2], Oliver Longford[2], Paul Aisen[2], Joel Braunstein[3], Michael Irizarry[4], Shobha Dhadda[4], Rachel Buckley[1], Reisa Sperling[1], Ahead 3-45 Study Team[5]

[1]Mass General Brigham, Department of Neurology - Boston (United States), [2]University of Southern California Alzheimer Therapeutic Research Institute - San Diego (United States), [3]C²N Diagnostics - St. Louis (United States), [4]EISAI - Nutley (United States), [5]University of Southern California, Alzheimer Clinical Trials Consortium - San Diego (United States)

10:35 a.m.
11:05 a.m.

Coffee Break — Poster Session and Rising Star Showcase in Gloucester, Level 3

11:05 a.m.
11:45 a.m.

SYMPOSIUM 3

Remote Digital Biomarkers in Alzheimer's Disease Clinical Trials: From Scalable Prescreening to Sensitive AI-Enabled Assessment

Co-chairs: Gustavo A. Jimenez-Maggiora, Alzheimer's Therapeutic Research Institute (ATRI), Epstein Family Center for Alzheimer's Disease Research, Keck School of Medicine of USC, San Diego, CA – (United States)
Duygu Tosun,— University of California, San Francisco (UCSF) - San Francisco, CA (United States)

Presentation 1 The voice Clinical Dementia Rating® (vCDR) to facilitate clinical assessment for dementia research and trials using a generative AI powered conversational agent
Rachel L. Nosheny, *University of California, San Francisco (UCSF) - San Francisco, CA (United States)*

Presentation 2 Using digital multi-day learning curves for scalable early detection and tracking of subtle cognitive decline in preclinical AD
Kathryn V. Papp, *Center for Alzheimer Research and Treatment, Brigham and Women's Hospital and Massachusetts General Hospital; Harvard Medical School -Boston, MA (United States)*

Presentation 3 Real world feasibility, utility and generalizability of self-administered speech-based testing for scalable pre-screening for Mild Cognitive Impairment: results from the full ADNI4 digital cohort
Emil Fristed, *Novoic Ltd.; Coagen Limited – London (United Kingdom)*

11:45 a.m.
12:20 p.m.

BIOTECH SHOWCASE

Biotech Showcase and introductory panel

12:02 p.m.

BIOTECH SHOWCASE 1 Phase 2a AD Trial Results: NTRX-07 Reduces Neuroinflammation and Inhibits Neurodegeneration Following 28-days of Treatment
Joseph Foss[1], Marianna Kiraly[1], Peter Kovacs[2], Tony Giordano[1]
[1]NeuroTherapia, Inc. - Cleveland (United States), [2]CRU Global - Budapest (Hungary)

12:08 p.m.

BIOTECH SHOWCASE 2 A Next-Generation circRNA Blood Biomarker Platform for Alzheimer's Disease Detection, Progression Prediction, and Clinical Deployment
Nikolaos Mellios[1], Bridget Phillips[2], Jessie Sanford[2], Vaibhav Janve[3], Grigorios Papageorgiou[3], John Morris[2], Joel Perlmutter[2], Paul Kotzbauer[2], Richard Perrin[2], Timothy Hohman[3], Laura Ibanez[2], Carlos Cruchaga[2]
[1]Circular Genomics - San Diego (United States), [2]Washington University School of Medicine - St. Louis (United States), [3]Vanderbilt University Medical Center - Nashville (United States)

12:14 p.m.

BIOTECH SHOWCASE 3 Sinaptica Therapeutics, Inc. ~ Precuneus-directed TMS-EEG precision-neuromodulation platform
Giacomo Koch[1,2,3]
[1]Sinaptica Therapeutics - Cambridge (United States), [2]Santa Lucia Foundation IRCCS – Rome, Italy, [3]University of Ferrara – Ferrara, Italy

12:20 p.m.
1:35 p.m.

Lunch and poster sessions

1:35 p.m.
2:35 p.m.

ORAL COMMUNICATIONS

1:35 p.m.

OC11 A Unified Timeline of Alzheimer's Disease: Linking Amyloid-β to Cognitive Decline

Rosita Shishegar[1], Timothy Cox[2], Marcela Cespedes[3], Suzanne Schindler[4], Tammie Benzinger[5], Christopher C. Rowe[6], Christopher J. Fowler[7], Stephanie R. Rainey-Smith[8, 9, 10], Simon Laws[11], Mike Weiner[12], John Morris[4], Colin L. Masters[13], Hamid Sohrabi[14], Paul Maruff[15], James D. Doecke[3, 11]

[1]The Australian e-Health Research Centre, CSIRO - Parkville (Australia), [2]The Australian e-Health Research Centre, CSIRO - Canberra (Australia), [3]The Australian e-Health Research Centre, CSIRO - Herston (Australia), [4]Department of Neurology, Washington University School of Medicine - St Louis (United States), [5]Washington University School of Medicine - St Louis (United States), [6]Austin Health - Heidelberg (Australia), [7]The Florey Institute, The University of Melbourne - Parkville (Australia), [8]Australian Alzheimer's Research Foundation - Perth (Australia), [9]Centre for Precision Health and Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University - Joondalup, [10]Centre for Healthy Ageing, Health Future Institute, Murdoch University - Murdoch, [11]Centre for Precision Health and Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), [12]University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Medical Center - San Francisco (United States), [13]Alzheimer's Research Australia, University of Western Australia - Perth (Australia), [14]Centre for Healthy Ageing, Health Future Institute, Murdoch University - Murdoch (Australia), [15]Cogstate Ltd. - Parville (Australia)

1:50 p.m.

OC12 When Plasma ptau217 and AβPET Disagree: Factors Associated With Biomarker Concordance and Discordance Across Ethnoracial Groups

Mahnaz Shekari[1], Tessa Harrison[1], Yishu Chao[1], Robert Rissman[2], Sid O'Bryant[3], Petersen Melissa[4], William J Jagust[1], Susan M. Landau[1]

[1]University of California - Berkeley (United States), [2]University of California - San Diego (United States), [3]University of North Texas Health Science Center - Texas (United States), [4]Institute for Translational Research, University of North Texas Health Science Center - Texas (United States)

2:05 p.m.

OC13 Lecanemab Treatment in Real-World Settings Across Multiple Countries: A Meta-Analysis on ARIA Rates and Safety Profiles in Clinical Practice

Samuel Dickson[1], John Whetten[1], Chenge Zhang[1], Suzanne Hendrix[1], Katherine Youmans-Kidder[2], Daryl Jones[2]

[1]Pentara Corporation - Salt Lake City (United States), [2]Eisai Inc. - Nutley (United States)

2:20 p.m.

OC14 Detecting cognitive decline in preclinical AD over 1.5 years using digital cognitive assessments

Hairin Kim[1], Mark Dubbelman[1], Lex Minto[1], Daniel Soberanes[1], Vivienne Lubbat[1], Dorene Rentz[1], Gad Marshall[1], Reisa Sperling[1], Laura Baker[2], Mark Espeland[2], Susan Landau[3], Rebecca Amariglio[1], Kathryn Papp[1]

[1]Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), [2]Department of Internal Medicine, Wake Forest University School of Medicine - Winston-Salem (United States), [3]Helen Wills Neuroscience Institute (SL), University of California - Berkeley (United States)

2:35 p.m.
3:15 p.m.

SYMPOSIUM 4

Neuroinflammation in Alzheimer's Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk

Chair: Malú Gámez Tansey, Neuroscience Research Institute, Indiana University School of Medicine – Indianapolis, IN (United States)

Presentation 1 Central-Peripheral Neuroimmune Crosstalk: Targeting Immune Dysfunction to Reduce Neurodegenerative Disease Progression

Malú Gámez Tansey, *Neuroscience Research Institute, Indiana University School of Medicine – Indianapolis, IN (United States)*

Presentation 2 NLRP3 regulates microglial immune and metabolic function in dementia

Róisín M. McManus, *German Center for Neurodegenerative Diseases (DZNE), Venusberg Campus - Bonn (Germany)*

Presentation 3 The NLRP3 inflammasome as a therapeutic target in Alzheimer's disease: biomarker, preclinical evidence and Phase I healthy participants' safety data of the oral inhibitor RG6434

Gennaro Pagano, *F. Hoffmann-La Roche Ltd - Basel (Switzerland)*

3:15 p.m.
4:15 p.m.

ORAL COMMUNICATIONS

3:15 p.m.

OC15 Treatment with Pepinemab, Anti-SEMA4D Blocking Antibody, Reduces a Unique Astrocyte Subset (Ast10) Correlated with Cognitive Decline and Associated Biomarkers of Synaptic Loss in People with Early-Stage AD

Elizabeth Evans[1], Terrence Fisher[1], Leslie Balch[1], Natacha Comandante-Lou[2], Vikas Mishra[1], John Leonard[1], Loretta Mueller[1], Alan Howell[1], Charlotte E. Teunissen[3], Lisa Vermunt[3], Anton Porsteinsson[4], Hyun Keun Cho[5], Howard H. Feldman[5], Lon Scheider[6], Maurice Zauderer[1]

*[1]Vaccinex, Inc - Rochester (United States), [2]Columbia University Irving Medical Center - New York (United States), [3]Amsterdam UMC - Amsterdam (The Netherlands), [4]University of Rochester, *on behalf of SIGNAL-AD investigators - Rochester (United States), [5]University of California, San Diego - San Diego (United States), [6]University of Southern California, Keck School of Medicine - Los Angeles (United States)*

3:30 p.m.

OC16 Plasma Tau Isomerization at Residue D54 as a Scalable Biomarker of Brain Tau Aggregation in Early-Onset Alzheimer's Disease

Nicolas R. Barthelemy[1], Soumya Mukherjee[1], Yingxin He[1], Vitaliy Ovod[1], Kanta Horie[1], Rama Koppisetti[1], Ani Eloyan[2], Dustin B. Hammers[3], Kelly N. Nudelman[3], Maria C. Carrillo[4], Bradford C. Dickerson[5], Gil D. Rabinovici[6], Liana G. Apostolova[3], Randall J. Bateman[1], Jeffrey L. Dage[1]

[1]Washington University - St. Louis (United States), [2]Brown University - Providence (United States), [3]Indiana University - Indianapolis (United States), [4]Alzheimer's Association - Chicago (United States), [5]Harvard Medical School - Charlestown (United States), [6]UCSF - San Fransisco (United States)

3:45 p.m.

OC17 Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts

Richard Haarburger[1], James Mbinta[2], Siu Yuat Wong[1], Alex Wang[2], Colin Simpson[3], Noah Stegehuis[1], Till Baernighausen[4], Greg Martin[5], Yoram Barak[6], Andrew Sporle[3], Aliitasi Su'a-Tavalla[2], Pascal Geldsetzer[1]

[1]Stanford University - Stanford (United States), [2]Victoria University - Wellington (New Zealand), [3]University of Auckland - Auckland (New Zealand), [4]Heidelberg University - Heidelberg (Germany), [5]New Zealand Ministry of Health - Wellington (New Zealand), [6]Dunedin School of Medicine - Dunedin (New Zealand)

4:00 p.m.

OC18 Metabolic-Inflammatory Burden Identifies Attenuated Responders to Lifestyle Intervention and Supports GLP-1RA Combination-Trial Design: Evidence from the FINGER study

Adrian Noriega De La Colina[1, 2, 3], Arvid Gollwitzer[1, 2], Anna Matton[4, 5, 6], Francesca Mangialasche[7, 5, 6], Li-Huei Tsai[1, 8], Alina Solomon[6, 4, 9], Tiia Ngandu[6, 9], Giovanni Traverso[1, 2, 3, 10], Miia Kivipelto[4, 5, 11]

[1]Broad Institute of MIT and Harvard - Cambridge (United States), [2]Massachusetts Institute of Technology - Cambridge (United States), [3]Brigham and Women's Hospital - Boston (United States), [4]Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), [5]Division of Neurogeriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), [6]FINGERS Brain Health Institute - Stockholm (Sweden), [7]Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden) - Solna (Sweden), [8]The Picower Institute for Learning and Memory - Cambridge (United States), [9]Institute of Clinical Medicine/Neurology, University of Eastern Finland - Kuopio (Finland), [10]Koch Institute for Integrative Cancer Research, MIT - Cambridge (United States), [11]FINGERS Brain Health Institute - Stockholm (Sweden)

4:15 p.m.
4:45 p.m.

Coffee Break — Poster Session and Rising Star Showcase

4:45 p.m.
5:25 p.m.

LATE BREAKING SYMPOSIUM 1

Additional biomarker and clinical findings from the Phase 2 CELIA study of diranersen in early Alzheimer's disease

Adrian COLES, Jessica COLLINS, Gioacchino CURIALE, Amanda EDWARDS, Ellen HUANG, Melanie SHULMAN

Biogen, Cambridge, United States

Wednesday, November 18

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:30 a.m.

ORAL COMMUNICATIONS

8:30 a.m.

OC19 Brain-Derived pTau217 Outperforms 328 Plasma Proteins for Association with Amyloid and Tau Accumulation and Cognitive Progression in the A4 and LEARN Studies

Robert RISSMAN[1], Michael DONOHUE[1], Joanne BEER[2], Clare PATERSON[2], Rema RAMAN[1], Sara ABDEL-LATIF[1], James BARLOW[1], Sahar SALEHI[1], Gustavo JIMENEZ-MAGGIORA[1], Richard GALLARDO[1], Keith JOHNSON[3], Paul AISEN[1], Reisa SPERLING[3]
[1]University of Southern California, San Diego, United States, [2]Alamar Biosciences, Freemont, United States, [3]Mass General Research Institute, Boston, United States

8:45 a.m.

OC20 Tau stable isotope labelling kinetics (SILK) and fluid biomarker response to NIO752 – tau MAPT antisense oligonucleotide: an unblinded interim analysis of a phase 1B trial in Alzheimer's disease

Aram ASLANYAN[1], Nicolas BARTHÉLEMY[2], Chihiro SATO[2], Don ELBERT[3], Catherine MUMMERY[1], Lisa FRENCH[1], Guoqiao WANG[2], Nupur GHOSHAL[2], Eric MCDADE[2], Randall BATEMAN[2], Ross PATERSON[1]
[1]UCL, London, United Kingdom, [2]Washington University St Louis, St Louis, United States, [3]University of Washington, Seattle, United States

9:00 a.m.

OC21 Psychosis symptoms associated with AD improve with short- and long-term open-label KarXT treatment

Jeffrey CUMMINGS[1], Ninoslav MIMICA[2], Ashish SHAH[3], Janette GARNER[3], Codrin LUNGU[3], Antonio OLIVEROS-CID[4], George GROSSBERG[5]
[1]Kirk Kerkorian School of Medicine, University of Nevada at Las Vegas, Las Vegas, United States, [2]University Psychiatric Hospital Vrapče and University of Zagreb School of Medicine, Zagreb, Croatia, [3]Bristol Myers Squibb, Princeton, United States, [4]Hospital Reina Sofía, Tudela, Spain, [5]Saint Louis University School of Medicine, St. Louis, United States

9:15 a.m.

OC22 Estimating 15-Year absolute risk of cognitive impairment in cognitively unimpaired older adults with Alzheimer disease biomarkers based on amyloid PET or plasma %p-tau217

Sarah HARTZ , Lisa HAYIBOR, Shinjini KUNDU, Randall BATEMAN, Tammie BENZINGER, Brian GORDON, John MORRIS, Krista MOULDER, Jessica MOZERSKY, Kellen PETERSEN, Guoqiao WANG, Suzanne SCHINDLER, Walter KUKULL, Chengjie XIONG
Washington University, St. Louis, United States

9:30 a.m.
9:55 a.m.

KEYNOTE 3

Integration of Fluid Imaging and other Multimodal Biomarkers towards Optimizing Disease Understanding and New Therapeutics

Susan Landau, *PhD, Research Neuroscientist, Helen Wills Neuroscience Institute University of California, Berkeley, CA (United States)*

Introduction: Michael Weiner, *University of California, San Francisco – San Francisco, CA (United States)*

9:55 a.m.
10:25 a.m.

ORAL COMMUNICATIONS

Session on Study Design and Phase 1/Phase 2a Studies

9:55 a.m.

OC23 PrevenTRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer's disease at high risk of clinical decline

Reisa Sperling[1], Catherine Mummery[2], Jeffrey L. Cummings[3], Gil Rabinovici[4], Stephen Salloway[5], Henrik Zetterberg[6], Juan Fortea[7], Frank G. Boess[8], Christopher Lane[9], Marion Monchalin[8], Paul Delmar[8], Luka Kulic[8], Hanno Svoboda[8], Geoffrey A. Kerchner[8], Janice Smith[9]

[1]Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), [2]Queen Square Institute of Neurology, University College London - London (United Kingdom), [3]Chambers-Grundy Center for Transformative Neuroscience, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas - Las Vegas (United States), [4]Weill Institute for Neurosciences, Department of Radiology and Biomedical Imaging, University of California San Francisco - San Francisco (United States), [5]Warren Alpert Medical School, Brown University - Providence (United States), [6]Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden), [7]Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Antoni Maria Claret - Barcelona (Spain), [8]F. Hoffmann-La Roche Ltd - Basel (Switzerland), [9]Roche Products Ltd - Welwyn Garden City (United Kingdom)

10:05 a.m.

OC24 Results of a Phase 1 Trial of Intracerebroventricular Injection of Autologous, Wnt-Activated, Adipose-Derived Stem Cells for Alzheimer's Disease; a First-in-Human Study

Christopher Duma[1], Jessica Buxton[2], Hans Keirstead[3], Gabriel Nistor[2], Robert Lynn[2], Sawyer Farmer[2], Ashley Harris[2], Karlyssa Chung[2], Nathaniel Cho[2], Zoe Hareng[2], Jason Bock[2], Benjamin Rapaport[2], Gustavo Alva[1]

[1]Hoag Memorial Hospital - Newport Beach, CA (United States), [2]Regeneration Biomedical, Inc. - Newport Beach, CA (United States), [3]Aivita Biomedical, Inc. – Irvine, CA (United States)

10:15 a.m.

OC25 A phase 2 randomized, controlled trial of MK-2214, a novel antibody targeting pS413 tau, in early Alzheimer's disease: Study rationale and design

W. Joseph Herring[1], Yuchuan Wang[1], Li He[1], Yuki Mukai[1], Christine Furtek[1], Angela Gee[1], Andrei Popescu[1], Seth Robey[1], Michael F. Egan[1]

[1]Merck & Co., Inc. – Rahway, NJ (United States)

10:25 a.m.
11:00 a.m.

Coffee Break — Poster Session and Rising Star Showcase

11:00 a.m.
11:40 a.m.

SYMPOSIUM 5

Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings

Chair: Marwan Sabbagh, Barrow Neurological Institute - Phoenix, AZ (United States)

Presentation 1 Real-World Lecanemab Utilization and Outcomes from Initiation Through Maintenance Therapy in Early Alzheimer's Disease: A Multicenter Retrospective Study (LEADER)

Jose Soria, *The Neuron Clinic - Chula Vista, CA (United States)*

Presentation 2 Sex-Based Outcomes of Lecanemab in Early Alzheimer's Disease: A Multicenter, Real-World, Retrospective Study (LEADER)

Tinatin Chabrashvili, *SUNY Upstate Medical University - New York, NY (United States)*

Presentation 3 At-Home Subcutaneous Lecanemab Administration: A Multicenter, Real-World, Retrospective Study (LEADER)

Brent Berry, *Minneapolis Clinic of Neurology - Minneapolis, MN (United States)*

11:40 a.m.
12:25 p.m.

ORAL COMMUNICATIONS

11:40 a.m.

OC26 Using Plasma P-tau217 and APOE Genotype to Predict Onset of Symptoms of Alzheimer's Disease

Yuexuan Xu[1], Tamil Gunasekaran[1], Yian Gu[1], Lawrence Honig[1], Jennifer Manly[1], Adam Brickman[1], Corinne Engelman[2], Sterling Johnson[2], David Bennett[3], Sid O'Bryant[4], Caghan Kizil[1], Badri Vardarajan[1], Richard Mayeux[1]

[1]Columbia University - New York (United States), [2]University of Wisconsin-Madison - Madison (United States), [3]Rush University - Chicago (United States), [4]University of North Texas Health Science Center - Fort Worth (United States)

11:55 a.m.

OC27 AAV2-BDNF Gene Therapy in Alzheimer's Disease and Mild Cognitive Improvement Improves FDG-PET in Memory Circuitry

Yilong Ma[1], Gabriel Leger[2], Douglas Scharre[3], Andrea Davis[3], Kai Christman[2], Sara Rahman[2], Russell Lonser[3], Krystopf Bankiewicz[3], David Eidelberg[1], Bradley Elder[3], Mark Tuszynski[2]

[1]Feinstein Institute for Medical Research – Manhasset, NY (United States), [2]UC San Diego - La Jolla, CA (United States), [3]Ohio State University – Columbus, OH (United States)

12:10 p.m.

OC28 Leveraging the Global Neurodegeneration Proteomics Consortium Dataset to Identify Plasma Proteomic Profiles Associated with Alzheimer's Disease Progression and Biological Endotypes

Jennifer Panlilio[1], Lydia Wu[2], Olga Kahn[1], Jennifer Hsiao-Nakamoto[1], Varsha Krish[2], Farhad Imam[2], Ilya Barshai[3], Sergey Feldman[3], Laura Nisenbaum[4], Aishwarya Sukumar[2]
[1]Diagnostics Accelerator, Alzheimer's Drug Discovery Foundation - New York (United States), [2]Gates Ventures - Seattle (United States), [3]Data Cowboys - Seattle (United States), [4]Alzheimer's Drug Discovery Foundation - New York (United States)

12:25 p.m.
1:40 p.m.

Lunch and Poster Sessions

1:40 p.m.
3:25 p.m.

ORAL COMMUNICATIONS

1:40 p.m.

OC29 Prognostic value of plasma p-tau217 for short- and long-term risk of cognitive impairment

Marisa N. DENKINGER[1], Valentina GHISAYS[1,2], Wagner S. BRUM[1], Geidy E. SERRANO[1], Adam MECCA[3], Sylvia VILLENEUVE[4], Pedro ROSA NETO[5], Alexa PICHET BINETTE[6], Rhoda AU[7], Michael ALOSCO[8], Elizabeth HEAD[9], Sterling C. JOHNSON[10], Eric M. REIMAN[2], Jessica B. LANGBAUM[2], Nicholas J. ASHTON[1,2]
[1]Banner Sun Health Research Institute, Sun City, United States, [2]Banner Alzheimer's Institute, Phoenix, United States, [3]Department of Psychiatry, Yale School of Medicine, New Haven, United States, [4]Douglas Research Centre, McGill University, Montreal, United States, [5]Translational Neuroimaging Laboratory, Douglas Hospital, The McGill University Research Centre for Studies in Aging, McGill University, Montreal, United States, [6]Institut Universitaire de Gériatrie de Montréal Research Center, Montreal, United States, [7]Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study Framingham, Boston, United States, [8]Boston University CTE Center and Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, United States, [9]University of California, Irvine School of Medicine, Irvine, United States, [10]Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, United States

1:55 p.m.

OC30 LM11A-31 reduces CSF levels of eMTBR-tau243: a retrospective analysis of a phase 2a safety and exploratory biomarker trial in mild-moderate Alzheimer's disease

Frank LONGO[1], Stephen MASSA[2], Taylor SCHMITZ[3], Mark ADAMS[4], Shin-Cheng TZENG[4], Philip VERGHESE[4], Hayley SHANKS[3]
[1]Stanford University, Palo Alto, United States, [2]SFVAHCS/UCSF, San Francisco, United States, [3]Western University, London, Canada, [4]C[2]N Dignostics LLC, St Louis, United States

2:10 p.m.

OC31 Relative Impact of Multidomain Lifestyle Interventions on Cardiovascular Risk Factor Change and Cognition over 24 months in the U.S. POINTER TRIAL

Rachel A WHITMER[1], Iris LENG[2], Laura BAKER[2], Maria C CARRILLO[3], Heather SNYDER[3], Rema RAMAN[4], Sarah FARIAS TOMASZEWSKI[5], Mark ESPELAND[2]
[1]University of California, Davis, United States, [2]Wake Forest University, Winston Salem, United States, [3]Medical and Scientific Relations, Alzheimer's Association, Chicago, United States, [4]University of Southern California, Los Angeles, United States, [5]University of California Davis, Davis, United States

2:25 p.m.

OC32 Calibrated age of onset for amyloid positivity from plasma %p-tau217 leads to better design and improved representation of Black Americans in Alzheimer disease clinical trials: Simpson's paradox

Chengjie XIONG[1], Ruijin LU[1], Jingqin LUO[1], Suzanne SCHINDLER[1], Tammie BENZINGER[1], David WOLK[2], Leslie SHAW[2], Carey GLEASON[3], James LAH[4], Reisa SPERLING[5], Keith JOHNSON[5], Erik ROBERSON[6], Krista MOULDER[1], David HOLTZMAN[1], John MORRIS[1]
[1]Washington University, St. Louis, United States, [2]University of Pennsylvania, Philadelphia, United States, [3]University of Wisconsin, Madison, United States, [4]Emory University, Atlanta, United States, [5]Harvard University, Boston, United States, [6]University of Alabama, Birmingham, United States

2:40 p.m.

OC33 Harmonizing plasma pTau217 across immunoassay platforms: the Unified pTau217 Score (Uniτs)

Wagner S. Brum[1], Marisa N. Denkinger[2], Alpana Singh[2], Tainá Marques[2], Lennessa Mazo[3], Rachael E. Wilson[4], Ramiro Eduardo Rea Reyes[4], Henrik Zetterberg[5], Antoine Leuzy[1], Valentina Ghisays[6], Reisa A. Sperling[7], Eric M. Reiman[6], Jessica B. Langbaum[6], Sterling C. Johnson[4], Nicholas J. Ashton[6]
[1]ZRO Imaging - Santiago De Compostela (Spain), [2]Banner Sun Health Research Institute - Sun City (United States), [3]Arizona State University - Phoenix (United States), [4]University of Wisconsin–Madison - Madison (United States), [5]University of Gothenburg - Gothenburg (Sweden), [6]Banner Alzheimer's Institute - Phoenix (United States), [7]Harvard Medical School - Boston (United States)

2:55 p.m.

OC34 Rapamycin modulates disease-relevant processes in the central nervous system of patients with early Alzheimer's disease: data from PET, MRI and CSF with long-term follow-up

Jonas E. Svensson[1], Ruben Dörfel[1], Martin Schain[2], Martin Bolin[1], Simona Sacuiu[1], Göran Hagman[1], Anton Forsberg Morén[1], Miia Kivipelto[1], Sangram Nag[1], Pontus Plavén-Sigray[1]
[1]Karolinska Institutet - Stockholm (Sweden), [2]Antaros Medical - Mölndal (Sweden)

3:10 p.m.

OC35 Longitudinal characterization of tau PET accumulation and spread anchored to amyloid and tau positivity timelines

Samira Maboudian[1], Karly Cody[2], William Coath[1], Julie Oomens[1], Jacob Morse[1], Hailey Bruzzone[1], Ramiro Rea Reyes[1], Matthew Zammit[1], Bradley Christian[1], Sanjay Asthana[1], Nathaniel Chin[1], Jessica Caldwell[1], Sterling Johnson[1], Tobey Betthauser[1]

[1]University of Wisconsin – Madison - Madison (United States), [2]University of California San Francisco - San Francisco (United States)

3:25 p.m.
4:00 p.m.

Coffee break — Poster session and Rising Star Showcase

4:00 p.m.
5:00 p.m.

ORAL COMMUNICATIONS

4:00 p.m.

OC36 Beyond amyloid and tau: Hippocampal volume and cognitive performance in the AHEAD-345 Study screening cohort

Benjamin Zide[1], Aaron Schultz[1], Michael Properzi[1], Michael Rafii[2], Gustavo Jimenez-Maggiora[2], Michael Donohue[2], Oliver Langford[2], Paul Aisen[2], Jin Zhou[3], Michael Irizzary[3], Shobha Dhadda[3], Keith Johnson[1], Rachel Buckley[1], Reisa Sperling[1], On Behalf Of The Ahead 3-45 Study Team[4]

[1]Center for Alzheimer Research and Treatment, Mass General Brigham, Harvard Medical School - Boston, Ma (United States), [2]Epstein Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), [3]Eisai Inc. - Nutley, Nj (United States), [4]AHEAD 3-45 Study Team, Alzheimer Clinical Trials Consortium (United States)

4:15 p.m.

OC37 Comparison of MK6240, Flortaucipir, PI2620 and RO948 tau PET tracers and plasma pTau217 across the Alzheimer's disease continuum

Guilherme Povala[1], Bruna Bellaver[1], Pamela C. L. Ferreira[1], Firoza Z. Lussier[1], Livia Amaral[1], Juan Fortea[2], Thomas K. Karikari[1], David N. Soleimani-Meigooni[3], Val J. Lowe[4], Hwamee Oh[5], Brian A. Gordon[6], Belen Pascual[7], Pedro Rosa-Neto[8], Suzanne Baker[9], Tharick A. Pascoal[1]

[1]University of Pittsburgh, Department of Psychiatry - Pittsburgh (United States), [2]Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), [3]University of California San Francisco, Edward and Pearl Fein Memory and Aging Center - San Francisco (United States), [4]Mayo Clinic, Department of Radiology - Rochester (United States), [5]Brown University, Department of Psychiatry and Human Behavior - Providence (United States), [6]Washington University in St. Louis, Department of Radiology - St. Louis (United States), [7]Houston Methodist Research Institute and Weill Cornell Medicine, Department of Neurology - Houston (United States), [8]Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute - Montréal (Canada), [9]Lawrence Berkeley National Laboratory - Berkeley (United States)

4:30 p.m.

OC38 Characterization of US Real-World Patients Receiving Donanemab with Modified Titration Using the NeuroDiscovery AI Database and the ALZ-NET Registry

Armen Moughamian[1], Paul Schulz[2], Drew Spargo [3], Erin Gautier Doty [3], J. Scott Andrews[3], Krista M. Schroeder[3], Chuanjie Deng [3], Ju Ji [3], Xueqing Huang [3], Vamsi Chandra Kasivajjala[4], Akash Bhushan[5], Anand K Srirampurapu[5], Ann Hartry [3]

[1] Ray Dolby Brain Health Center, Sutter Health, San Francisco, CA, United States [2] McGovern Medical School, UTHealth, Houston, TX, United States [3]Eli Lilly and Company, Indianapolis, IN, USA [4]NeuroDiscovery AI, Alpharetta, GA, USA [5]NeuroDiscovery AI, Bangalore, Karnataka, India

4:45 p.m.

OC39 Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer's Disease Progression

Menghan Liu[1], Katherine Gong[1], Yike Chen[1], Ying Xu[1], Jigyasha Timsina[1], John Budde[1], John Morris[1], Marco Giorgetti[2], David Holtzman[1], Jeremiah Hinson[2], Scott Levin[2], Suzanne Schindler[1], Kausik Das[2], Muhammad Ali[1], Carlos Cruchaga[1]

[1]Washington University School of Medicine - St. Louis, M[0] (United States), [2]Danaher Diagnostics - Washington DC (United States)

5:00 p.m.
5:20 p.m.

BIOTECH SHOWCASE

Biotech Showcase and introductory panel

5:02 p.m.

BIOTECH SHOWCASE 4 A First-in-Class CNS-Penetrant Small Molecule Targeting APOE4-mediated Neurovascular Dysfunction in Alzheimer's Disease

Caghan Kizil[1], Badri Vardarajan[1], Richard Mayeux[1]

[1]Department of Neurology, Columbia University Irving Medical Center - New York City (United States) Late breaking Biotech Showcase sessions

5:08 p.m.

BIOTECH SHOWCASE 5Temporal Biodynamics: An AI Platform for Identification of Stage-Relevant Targets and Biomarkers

Sandra J. ENGLE[1], Joseph ZULLO[1], Joseph J. RAYMOND[1], Tanya JAIN[1], Michelle CHEN[1], Parth NATEKAR[1], Baixue YAO[1], Anna RUSNAK[1], Sachit SAKSENA[2], Artem SOKOLOV[1]

[1]Etiome, Cambridge, United States, [2]Flagship Pioneering, Cambridge, United States

5:14 p.m. **BIOTECH SHOWCASE 6 Multimodal AI for early prediction and precision stratification in ADRD**

Zoe KOURTZI[1], Felix BREACH[1], Tino PETER[2], Welchman ANDREW[3]
[1]Univ Cambridge, Prodromic, Cambridge, United Kingdom, [2]Univ of Birmingham, Birmingham, United Kingdom, [3]Prodromic, Cambridge, United Kingdom

5:20 p.m. End of the conference day

Thursday, November 19

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:10 a.m.

SYMPOSIUM 6

Lessons from The Life's end Benefits of cannaBidiol and tetrahydrocannabinol (LiBBY) Study: Efficacy, Implementation, and Future Therapeutic Development in Advanced Dementia

Chairs: Olga Brawman-Mintzer, *Medical University of South Carolina* and Ralph H. Johnson, *VA Health Care System - Charleston, SC (United States)*

Presentation 1 Domain-Specific Effects of THC/CBD on Agitation in Advanced Dementia: Cohen-Mansfield Agitation Inventory Analyses from the LiBBY Study Presentation
Jacobo Mintzer, *Medical University of South Carolina, Charleston, South Carolina (United States)*

Presentation 2 Effects of THC/CBD on NPI-Q Agitated Symptoms in Advanced Dementia: Results from the Double-Blind, Placebo-Controlled LiBBY Study
Brigid Reynolds, *Georgetown University, Washington, DC, United States*

Presentation 3 Advancing Trials in Dementia: Lessons from LiBBY and a Future Research Agenda for the Alzheimer's Clinical Trial Consortium (ACTC)
Paul Aisen, *University of Southern California, La Jolla, California (United States)*

9:10 a.m.
10:10 a.m.

ORAL COMMUNICATIONS

9:10 a.m.

OC40 Early versus delayed cognitive effects of donanemab and lecanemab in early Alzheimer's disease: 24-month real-world trajectories and drug-specific baseline predictors of response

Yuki Kujuro[1]
[1]*Tachikawa Hospital - Tokyo (Japan)*

9:25 a.m.

OC41 CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression

Xuemei Zeng[1], Marissa F. Farinas[1], Michel N. Nafash[1], Neelesh Nadkarni[1], C. Elizabeth Shaaban[1], Tharick A. Pascoal[1], Victor L. Villemagne[1], Beth E. Snitz[1], Milos D. Ikonomovic[1], Julia K. Kofler[1], M. Ilyas Kamboh[1], Annie D. Cohen[1], Oscar L. Lopez[1], Thomas K. Karikari[1]
[1]*University of Pittsburgh - Pittsburgh (United States)*

9:40 a.m.

OC42 Understanding intermediate values in two-point thresholds for PET, CSF, and plasma biomarkers across cohorts and p-tau217 assays

Jacob Ziontz[1], Ganna Blazhenets[1], Zoe Lin[1], John Kornack[1], Susan Landau[2], Leslie Shaw[3], Jeffrey Dage[4], Dustin Hammers[4], Ani Eloyan[5], Robert Koeppe[6], Maria Carrillo[7], Bradford Dickerson[8], Liana Apostolova[4], Gil Rabinovici[1], Renaud La Joie[1]
[1]*University of California, San Francisco - San Francisco, CA (United States),* [2]*University of California, Berkeley - Berkeley, CA (United States),* [3]*University of Pennsylvania – Philadelphia, PA (United States),* [4]*Indiana University – Bloomington, IN (United States),* [5]*Brown University – Providence, RI (United States),* [6]*University of Michigan - Ann Arbor, MI (United States),* [7]*Alzheimer's Association – Chicago, IL (United States),* [8]*Massachussetts General Hospital – Boston, MA (United States)*

9:55 a.m.

OC43 Diagnostic Performance of the Fujirebio Lumipulse Plasma p-tau217 and p-tau217/Aβ42 Assays for Detection of Amyloid Pathology in Cognitively Unimpaired Individuals

Daniel Figdore[1], Jeremy Syrjanen[1], Joshua Bornhorst[1], Jonathan Graff-Radford[1], Prashanthi Vemuri[1], David Knopman[1], Clifford Jack[1], Ronald Petersen[1], Alicia Algeciras-Schimnich[1]
[1]*Mayo Clinic - Rochester (United States)*

10:10 a.m.
10:40 a.m.

Coffee Break — Poster Session and Rising Star Showcase

10:40 a.m.
11:05 a.m.

KEYNOTE 4

Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials

Allan Levey, *Professor of Neurology, Emory University's School of Medicine, Emory's Alzheimer's Disease Research Center, Emory University - Atlanta, GA (United States)*

Introduction: Paul Aisen, *ATRI-USC – La Jolla, CA (United States)*

11:05 a.m.
12:05 p.m.

ORAL COMMUNICATIONS

11:05 a.m.

OC44 The relationship between P-tau217 blood tests and neuropathology at autopsy in cognitively unimpaired individuals

Samantha BURNHAM[1], Amanda MORRIS[1], Marisa DENKINGER[2], Taina M. MARQUES[2], Alpana SINGH[2], Geidy SERRANO[2], Brandy R. MATTHEWS[1], Thomas BEACH[2], Mark MINTUN[1], Nicholas J. ASHTON[2]

[1]Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, United States, [2]Banner Sun Health Research Institute, Sun City, AZ, USA, Sun City, United States

11:20 a.m.

OC45 When Is Amyloid Really Cleared? Discordance Between Centiloid Quantification and Visual Reads after Treatment

Renaud LA JOIE , Marlene LIN, Yingbing WANG, David SOLEIMANI-MEIGOONI, Tara ELLINGSON, Hong NGUYEN, Ganna BLAZHENETS, Corrina FONSECA, Jake LEVY, Julio ROJAS-MARTINEZ, Melanie STEPHENS, Nhat BUI, Peter LJUBENKOV, Lawren VANDEVREDE, Gil RABINOVICI

UCSF, San Francisco, United States

11:35 a.m.

OC46 Cognitive change across the healthy adult lifespan, ages 36 to 108: Associations with modifiable risk factors and ADRD plasma biomarkers

Steven ARNOLD[1], Pia KIVISÄKK[1], Chao-Yi WU[1], Edmarie GUZMAN-VELEZ[2], Brandon YATES[1], Yue HONG[1], Hrioko DODGE[1], David SALAT[1]

[1]Massachusetts General Hospital / Harvard Medical School, Boston, United States, [2]Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, United States

11:50 a.m.

OC47 PROTECT-Cog: A Large, Global Randomized Phase 3 Trial of Combined Multidomain Lifestyle Intervention With and Without a Metabolic Targeting Drug to Benefit Cognitive Performance and Mitigate Decline in At-Risk Older Adults

Alireza ATRI[1], Laura D BAKER[2], Lucia CRIVELLI[3], Mark ESPELAND[2], Miia KIVIPELTO[4], Markku PELTONEN[5], Rema RAMAN[6], Heather M SNYDER[7], Ari SOLOMAN[8], Rachel A WHITMER[9], Maria C CARRILLO[7]

[1]Banner Research, Director of Banner Sun Health Research Institute, Sun City, United States, [2]Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, United States, [3]Department of Cognitive Neurology, FLENI, Buenos Aires, Argentina, [4]Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institute, Stockholm, Sweden, [5]Finnish Institute for Health and Welfare, Helsinki, Finland, [6]Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [7]Medical and Scientific Relations and Medical Affairs Division, Alzheimer's Association, Chicago, United States, [8]Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland, [9]Department of Public Health Sciences and Neurology, University of California, Davis, Davis, United States

12:05 p.m.
1:05 p.m.

Lunch and Poster Sessions

1:05 p.m.
3:50 p.m.

ORAL COMMUNICATIONS

1:05 p.m.

OC48 Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study

Rui MU , Anna HOFMANN, Katherine GONG, Menghan LIU, Alex ROUSSAK, Madeline PACZYNSKI, Zachary POSEY, Aditi GUPTA, Tammie BENZINGER, David HOLTZMAN, John MORRIS, B.Joy SNIDER, Randall BATEMANN, Suzanne SCHINDLER, Carlos CRUCHAGA

Washington University School of Medicine, Saint Louis, United States

1:20 p.m.

OC49 ARO-MAPT, a Subcutaneously Delivered Shuttled siRNA Silencing Tau Production: Early Phase 1 Safety, Tolerability, and Pharmacodynamic Results in Healthy Volunteers

Catherine MUMMERY[1], Rohit KATIAL[2], Saffron CALMAN-O'DONNELL[2], Roger CHANG[3], Dylon CHEN[3], Ian COHEN[4], David JAKABEK[5], Bruce BREW[5], Emma DEVENNEY[6], Richard BERGERON[7], Ran FU[3], Grigoriy SHEKHTMAN[3], James HAMILTON[3], Sharon COHEN[4]

[1]University College London, London, United Kingdom, [2]New Zealand Clinical Research, Auckland, New Zealand, [3]Arrowhead pharmaceuticals, Pasadena, United States, [4]Toronto Memory Programme, Toronto, Canada, [5]St. Vincent's Hospital Sydney, Sydney, Australia, [6]NeuRA, Randwick, Australia, [7]The Memory Clinic, Montreal, Canada

1:35 p.m.

OC50 Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy

Kanta HORIE , Pallavi SACHDEV, Han YIN, Steven HERSCH, Lynn KRAMER, Shobha DHADDA, Michael IRIZARRY

Eisai Inc., Nutley, United States

1:50 p.m.

OC51 Plasma eMTBR-tau as a biomarker for chronic traumatic encephalopathy tau tangle neuropathology

Annalise E. MINER1, Thor D. STEIN1, Ann C. MCKEE1, Jesse MEZ1, Breton M. ASKEN2, Henrik ZETTERBERG3, Christopher J. NOWINSKI4, Jeremy A. TANNER5, Martha E. SHENTON6, Jeffrey L. CUMMINGS7, Eric M. REIMAN8, Robert A. STERN1, Gil D. RABINOVICI9, Nicholas J. ASHTON8, Michael L. ALOSCO1

1Boston University CTE Center and Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, United States, 2Department of Clinical and Health Psychology, University of Florida, Gainesville, United States, 3Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital,, Mölndal, Sweden, 4Concussion & CTE Foundation, Boston, United States, 5Department of Neurology, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, United States, 6Psychiatry Neuroimaging Laboratory, Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Harvard Medical School, Somerville, United States, 7Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, United States, 8Banner Alzheimer's Institute, Phoenix, United States, 9Edward & Pearl Fein Memory and Aging Center, Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, United States

2:05 p.m.

OC52 A proof of concept trial of MIB-626, a sirtuin-NAD+ activator, in mild Alzheimer's disease dementia

Gad Marshall[1], Karol Pencina[2], Valentine Shang[2], Daniel Press[3], Scott McGinnis[4], Seth Gale[4], Pamela Friedman[4], Soyoung Lee[4], Ricardo Salazar[5], Brahyan Galindo Mendez[4], Kirsten Glennon[4], Danielle Lavey[4], Alexander Lin[1], Shalender Bhasin[2]

[1]Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), [2]Section on Men's Health, Aging and Metabolism, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), [3]Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School – Boston, MA (United States), [4]Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), [5]Division of Geriatric Psychiatry, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States)

2:20 p.m.

OC53 Distinct baseline topographies and short-interval spatiotemporal spread of [18F]MK-6240 tau PET in preclinical AD

Stephanie Doering[1, 2], Praveen Honhar[1, 2], Amal Tiss[2], Charles Chen[1, 2], Elliott Slade[2], Emma Thibault[2], Jackson Thompson[2], Eva Pintucci[2], Alex Becker[2], Michelle Farrell[2], Reisa Sperling[2], Julie Price[1, 2], Keith Johnson[2], Jessie Fanglu Fu[1, 2]

[1]Athinoula A. Martinos Center for Biomedical Imaging - Charlestown, MA (United States), [2]Massachusetts General Hospital, Harvard Medical School - Boston, MA (United States)

2:35 p.m.

OC54 Amyloid and Tau PET Biological Staging Across Ethnoracial Groups in a Multi-Cohort Alzheimer's Disease Study

Andrzej Sokolowski[1], Karly Cody[1, 2], Lucah Medina Guerra[1], Isha Sai[1], Emily Johns[1], Alaina Durant[3], Derek Archer[3], Raul Vintimilla[4], Sid O'Bryant[4], Timothy Hohman[3], Christina Young[5, 6], Elizabeth Mormino[1]

[1]Department of Neurology and Neurological Sciences, Stanford University – Stanford, CA (United States), [2]Department of Neurology, University of California San Francisco - San Francisco, CA (United States), [3]Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center – Nashville, TN (United States), [4]Institute for Translational Research University of North Texas Health Science Center, - Fort Worth, TX (United States), [5]Department of Radiology, UC Davis – Davis, CA (United States), [6]Department of Neurology, UC Davis, - Davis, CA (United States)

2:50 p.m.

OC55 Biomarker Associations and Outcome Performance in Preclinical Alzheimer Disease Trials

Michael DONOHUE[1], Oliver LANGFORD[1], Philip INSEL[2], Rema RAMAN[1], Michael RAFII[3], Reisa SPERLING[4], Paul AISEN[1]

[1]USC Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, Ca, United States, [2]Department of Psychiatry, University of California, San Francisco, San Francisco, Ca, United States, [3]USC Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), San Diego, Ca, United States, [4]Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Ma, United States

3:05 p.m.

OC56 [^{18}F]MODAG-009 PET imaging of alpha-synuclein pathology in the presence of amyloid-beta and tau co-pathology across the AD-DLB spectrum

Armin GIESE[1], Daniel BLEHER[2], Ann-Kathrin GROTEGERD[2], Felix SCHMIDT[1], Daniel WECKBECKER[1], Andrei LEONOV[1], Sergey RYAZANOV[1], Viktoria RUF[3], Andreas MAURER[4], Christian GRIESINGER[5], Ken MAREK[6], Roger GUNN[7], Johannes LEVIN[1], Matthias BRENDEL[8], Kristina HERFERT[2]

[1]MODAG GmbH, Wendelsheim, Germany, [2]University of Tübingen, Tübingen, Germany, [3]Ludwig-Maximilians-University, München, Germany, [4]HZDR, Dresden, Germany, [5]MPI Multidisciplinary Sciences, Göttingen, Germany, [6]Institute for Neurodegenerative Disorders, New Haven, United States, [7]XingImaging, New Haven, United States, [8]Klinikum der Universität München, München, Germany

3:20 p.m.

OC57 Cross-platform performance of plasma p-tau217 assays for predicting amyloid PET positivity across cohorts

Sonal SUKREET[1], Jennifer NGOLAB[1], Michael C. DONOHUE[1], Oliver LANGFORD[1], Rema RAMAN[1], Sara ABDEL-LATIF[1], Gustavo A. JIMENEZ-MAGGIORA[1], Michael S. RAFII[1], Hartmuth C. KOLB[2], Sterling C. JOHNSON[3], Jasmeer CHATWAL[4], Keith A. JOHNSON[4], Paul S. AISEN[1], Reisa A. SPERLING[4], Robert A. RISSMAN[1]

[1]Epstein Family Alzheimer's Therapeutic Research Institute, San Diego, United States, [2]Enigma Biomedical Group, San Diego, United States, [3]University of Wisconsin, Wisconsin, United States, [4]Harvard Medical School, Boston, United States

3:35 p.m.

OC58 Plasma %p-tau217 and Aβ42/Aβ40 provide complementary information about amyloid PET below 20 Centiloids: Baseline findings from the Alzheimer's Plasma Extension Study

Doris MOLINA-HENRY[1], Andy LIU[1], Oliver LANGFORD[1], Michael DONOHUE[1], Rema RAMAN[1], Joel BRAUNSTEIN[2], Gustavo JIMENEZ-MAGGIORA[1], Robert RISSMAN[1], Keith JOHNSON[2], Paul AISEN[1], Reisa SPERLING[2]

[1]USC Epstein Family Alzheimer's Therapeutic Research Institute, San Diego, United States, [2]Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, United States

3:50 p.m.
4:10 p.m.

BIOTECH SHOWCASE

Biotech Showcase and introductory panel

3:52 p.m.

BIOTECH SHOWCASE 7 Restoring Proteostasis in Alzheimer's Disease with Buntanetap, a Small-Molecule Translational Inhibitor of Neurotoxic Proteins

Alexander MORIN, Maria MACCECCHINI

Annovis Bio, Malvern, United States

3:58 p.m.

BIOTECH SHOWCASE 8 In silico simulation of clinical trials for Alzheimer's disease and related dementias

Min Gyeong KIM[1], Yeong-Hun SONG[1,2], Yeon-Jeong LEE[1], Jeong-Yeon SONG[1], Junseo LEE[1,3], Euijeong SONG[1], Soohyun PARK[1], Seok HONG[1,2], Ahyun CHOI[1,2], Joon-Kyung SEONG[1,2,3], Wha Jin LEE[1]

[1]Neuroxt, Inc., Seoul, Korea, Republic of, [2]Department of Artificial Intelligence, Korea University, Seoul, Korea, Republic of, [3]School of Biomedical Engineering, Korea University, Seoul, Korea, Republic of

4:04 p.m.

BIOTECH SHOWCASE 9 iMediSync Inc. — iSB-M: AI-based QEEG Biomarker Platform for Alzheimer's Disease and Lewy Body Comorbidity

Seung Wan KANG[1], Nam Heon KIM[1], Jun Yeop KIM[1], Daekeun KIM[1], Dong Won YANG[2], Seong Hye CHOI[3], Young Chul YOUN[4], Byoung Seok YE[5]

[1]iMediSync, Inc., Seoul, Korea, Republic of, [2]The Catholic University of Korea, Seoul, Korea, Republic of, [3]Inha University School of Medicine, Incheon, Korea, Republic of, [4]Chung-Ang University College of Medicine, Seoul, Korea, Republic of, [5]Yonsei University College of Medicine, Seoul, Korea, Republic of

4:10 p.m. End of the conference

Posters List

CLINICAL TRIALS – PHASE IIB & III	P.23
CLINICAL TRIALS – PHASE I & IIA	P.28
IMAGING (MRI & PET)	P.32
ARTIFICIAL INTELLIGENCE-DRIVEN INNOVATION IN ALZHEIMER'S THERAPEUTICS	P.38
EPIDEMIOLOGY	P.40
NEW HYPOTHESES – NEW THERAPEUTIC APPROACHES FOR AD	P.44
NON-PHARMACOLOGIC INTERVENTIONS	P.47
BIOMARKERS (CSF & PLASMA)	P.51
PRE-CLINICAL, EARLY DISCOVERY AND MECHANISTIC RESEARCH	P.64
TRIAL DESIGN, STATISTICAL INNOVATION, AND ANALYTICAL FRAMEWORKS	P.68
COGNITIVE AND FUNCTIONAL OUTCOMES	P.73
DIGITAL ENDPOINTS, REMOTE MONITORING, AND CONNECTED HEALTH TOOLS	P.77
REAL-WORLD DATA, REGISTRIES & IMPLEMENTATION SCIENCE	P.81
BIOTECH SHOWCASE	P.87

CLINICAL TRIALS – PHASE IIB & III

P001 Continuous vs. Finite Dosing Until Amyloid Plaque Clearance in Early Alzheimer's Disease: A Horizontal Matching Analysis of Long-Term Clinical Trajectories for Lecanemab and Donanemab

Presenteur : Suzanne Hendrix

Suzanne Hendrix[1], John Whetten[1], Samuel Dickson[1], Kent Hendrix[1], Alireza Atri[2], Mary Sano[3], Chris Van Dyck[4]
[1]Pentara Corporation, Millcreek, United States, [2]Banner Health, Sun City, United States, [3]Mount Sinai School of Medicine, New York, United States, [4]Yale School of Medicine, New Haven, United States

P002 Updated Projections Confirm Long-Term Benefits of Continuous Lecanemab: 10 Years of Treatment Could Delay Moderate Disease by 18.7 Years

Presenteur : Suzanne Hendrix

Suzanne Hendrix[1], John Whetten[1], Garrett Duncan[1], Samuel Dickson[1], Katherine Youmans-Kidder[2], Daryl Jones[2]
[1]Pentara Corporation, Millcreek, United States, [2]Eisai Inc., Nutley, United States

P003 Utility of Clinically Scalable Biomarkers for Prescreening in Preclinical Alzheimer's Disease: Insights from RETAIN

Presenteur : Anahita Kyani

Anahita Kyani[1], Federico Parisi[2], Adria Mallol-Ragolta[3], Casey Vanderlip[1], Macarena Garcia Valdecasas Colell[2], Stephanie Slania[4], Charmaine Demanuele[2], Nicklas Linz[5], Johannes Tröger[5], Gayle Wittenberg[6], Arthur Simen[7], Fiona Elwood[7], Rachel Kolster[7], Ziad Saad[8], Tricia Thornton-Wells[7]
[1]Johnson & Johnson Innovative Medicine, Neuroscience Data Science, Digital Health & Artificial Intelligence (DDSAI), United States, La Jolla, United States, [2]Johnson & Johnson Innovative Medicine, Neuroscience Data Science, Digital Health & Artificial Intelligence (DDSAI), United States, Cambridge, United States, [3]Johnson & Johnson Innovative Medicine, Neuroscience Data Science, Digital Health & Artificial Intelligence (DDSAI), United States, Beerse, Belgium, [4]Johnson & Johnson Innovative Medicine, Neuroscience Data Science, Digital Health & Artificial Intelligence (DDSAI), United States, Pennsylvania, United States, [5]ki:elements GmbH, , Germany, [6]Johnson & Johnson Innovative Medicine, Neuroscience, United States, New Jersey, United States, [7]Johnson & Johnson Innovative Medicine, Neuroscience, United States, Cambridge, United States, [8]Johnson & Johnson Innovative Medicine, Neuroscience, United States, La Jolla, United States

P004 A Network Meta Analysis of anticipated Disease Modifying Therapies for Early-Stage Alzheimer's Disease: A Focus on the Next Ten Years

Presenteur : Heather Eames

Heather Eames[1, 2], David Mc Connell[1, 2], Cliona Flynn[1, 2], Sinead O'Neill[1, 2], Marie Harte[1, 3], Belinda Hernandez[1], Sean Kennelly[1], Roisin Adams[1], Laura McCullagh[1]
[1]Trinity College Dublin, Dublin, Ireland, [2]National Centre for Pharmacoeconomics, Dublin, Ireland, [3]Tallaght University Hospital, Dublin, Ireland

P005 SPINOZA: Rationale and Design of a Phase 2b Trial of Obicetrapib in APOE-Stratified Preclinical Alzheimer's Disease

Presenteur : Andrew Hsieh

Michael Davidson, Marc Ditmarsch, Andrew Hsieh, Ashley Walker, Adam Johnson, John Kastelein
NewAmsterdam Pharma, Naarden, The Netherlands

P006 Plasma Biomarker Screening for Amyloid Status in the BenfoTeam randomized controlled trial in Early Alzheimer's Disease

Presenteur : Jose Luchsinger

Jose Luchsinger[1], Howard Feldman[2], Hyun Cho[2], Adam Tran[2], Andrew Mackelfresh[2], Bryce Truver[2], Jody-Lynn Lupo[2], Carolyn Revta[2], Tim West[3], Philip Verghese[3], Gary Gibson[4]
[1]Columbia University Irving Medical Center, New York, United States, [2]University of California-San Diego, La Jolla, United States, [3]C2N Diagnostics LLC, St. Louis, United States, [4]Weil Cornell Medicine, New York, United States

P007 Beyond Amyloid Clearance: CSF Proteomics Reveals Proteome-Wide CNS Remodeling Following Lecanemab Treatment

Presenteur : Pallavi Sachdev

Pallavi Sachdev[1], Taeko Kamakura[2], Yuanqing Ye[1], Kazuhiro Tahara[2], Kenji Kita[3], Kristin Wildsmith[1], Hongmei Niu[1], Michael Irizarry[1], Lynn Kramer[1], Shobha Dhadda[1], Kanta Horie[1]
[1]Eisai Inc., Nutley, United States, [2]Eisai Co., Ltd., Tsukuba, Japan, [3]Sunplanet Co., Ltd., Tsukuba, Japan

P009 Exploratory Clinical Cognition and Biomarker Outcomes of RY01 in Patients with Alzheimer's Disease: An Investigator-Initiated Trial

Presenteur : Hong Ye

Hong Ye[1], Tao Jiang[2], Qingwei Tian[1], Xiumei Wang[2], Caimeng Qin[3], Ningmao Jiang[3]
[1]Ruiyi Pharmaceutical, Shenzhen, China, [2]Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, [3]Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China

P010 Effect of Intensive vs Standard Blood Pressure Control According to APOE ε4 Genotype: A Secondary Analysis of SPRINT

Presenteur : Yizhe Xu

Yizhe Xu[1], Jeremy Pruzin[2], Tom Greene[3], Jeff Williamson[4], David Reboussin[5], Nicholas Pajewski[5], Michael Klein[6], Wai-Yingwendy Yau[7, 8], Eric Reiman[2], Mark Supiano[9], Nicholas Ashton[10], Jasmeer Chhatwal[7, 8], Adam Bress[3, 11]
[1]Division of Epidemiology, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Slc, United States, [2]Banner Alzheimer's Institute, Phenoix, United States, [3]Divisions of Health System Innovation and Research, and Biostatistics, Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, University of Utah, Slc, United States, [4]Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, and Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest University School of Medicine, Winston-Salem, United States, [5]Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, United States, [6]Genomics Core, Health Sciences Center Core Research Facility, University of Utah, Slc, United States, [7]Department of Neurology, Harvard Medical School, Boston, United States, [8]Department of Neurology, Mass General Brigham, Boston, United States, [9]Division of Geriatrics, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Slc, United States, [10]Banner Sun Health Research Institute, Sun City, United States, [11]George E. Wahlen Department of Veterans Affairs Medical Center, Slc, United States

P011 The Effects of Oral Valiltramiprosate on Plasma p-tau217 and p-Tau217/Aβ42 Ratio in APOE4/4 Homozygotes and their Correlations to Clincial and Imaging Outcomes: Results of Phase 3 APOLLOE4 Clinical Trial in Early AD

Presenteur : John Hey

John Hey[1], Susan Abushakra[1], Fanny Elahi[2], Earvin Liang[1], Patrick Kesslak[1], Jeremy Yu[1], Brian Roth[1], Susan Flint[1], Adem Albayrak[1], Elitza Hristova[1], Aidan Power[1], Martin Tolar[1]
[1]Alzheon, Framingham, United States, [2]Icahn School of Medicine at Mt. Sinai, New York, United States

P012 The Oral Anti-Amyloid Agent Valiltramiprosate Reduces Spontaneous ARIA Rates in APOE4/4 Early AD Subjects: Results of the Phase 3 Placebo-Controlled APOLLOE4 Trial

Presenteur : S. Abushakra

S. Abushakra[1], E. Liang[1], M. Sabbagh[2], S. Cohen[3], D. Watson[4], E. Macsweeney[5], J. Sampalis[6], J. Barakos[7], J. Kesslak[1], J. Hey[1], S. Flint[1], R. McLaine[1], A. Albayrak[1], A. Power[1], M. Tolar[1]
[1]Alzheon, Inc, Framingham, Ma, United States, [2]Barrow Neurological Institute, Phoenix, Az, United States, [3]Toronto Memory Clinic, Toronto, On, Canada, [4]Alzheimer's Research and Treatment Center, Wellington, Fl, United States, [5]Re:Cognition Health, London, United Kingdom, [6]McGill University and Université de Montréal, , Canada, [7]Clario Inc. & Pacific Medical Center, San Francisco, Ca, United States

P013 Effects of Valiltramiprosate on Plasma P-tau217 and Select Pro-Inflammatory and Vascular Injury Biomarkers with the NULISA CNS Panel: Exploratory Analyses from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD

Presenteur : Susan Abushakra

Susan Abushakra[1], John A Hey[1], F. Elahi[2], David Watson[3], Aidan Power[1], Marwan Sabbagh[4], Sharon Cohen[5], Earvin Liang[6], E. Hristova[6], J. Patrick Kesslak[6], Susan Flint[6], Adem Albayrak[6], Martin Tolar[6]
[1]Alzheon, Inc., Framingham, Ma, United States, [2]Mt. Icahn School of Medicine, Mt. Sinai, New York, Ny, United States, [3]Alzheimer's Research and Treatment Center, Wellington, Fl, United States, [4]Barrow Neurological Institute, Phoenix, Az, United States, [5]Toronto Memory Program, Toronto, On, Canada, [6]Alzheon, Inc, Framingham, Ma, United States

P014 PUFA Trial Ancillary Biomarker Study: n-3 polyunsaturated fatty acids lower plasma soluble ICAM-1 and NfL in older adults with cerebral small vessel disease

Presenteur : Gene Bowman

Yan Gao[1], Lynne Shinto[2], Charles Murchison[3], Hiroko Dodge[1], Pia Kivisakk[1], Steven Aronold[1], Jeffrey Kaye[2], Joseph Quinn[2], Lisa Silbert[2], Rudolph Tanzi[1], Gene Bowman[1]
[1]Harvard-MGB, Boston, United States, [2]OHSU, Portland, United States, [3]UAB, Birmingham, United States

P015 ALTITUDE-AD: Baseline characteristics of participants randomized in a phase 2 trial of sabirnetug in early Alzheimer's disease

Presenteur : Linda Pao

Linda Pao[1], Todd Feaster[2], Maddelyn Hyland[2], Gopalan Sethuraman[2], Eric Siemers[2]
[1]Jem Research Institute, Atlantis, Fl, United States, [2]Acumen Pharmaceuticals, Newton, Ma, United States

P016 Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease

Presenteur : Loes Rutten-Jacobs

Loes Rutten-Jacobs[1], Venissa Machado[1], Paul Edison[2], Catherine Mummery[3], Alessandro Padovani[4], Malu G. Tansey[5], Silke Simon[1], Celine Adessi[1], Nikhat Parkar[6], Nima Shariati[1], Bastian Zinnhardt[1], Gabriel Schnetzler[1], Geoffrey A. Kerchner[1], Luka Kulic[1], Gennaro Pagano[1]
[1]F. Hoffmann-La Roche Ltd, Basel, Switzerland, [2]Faculty of Medicine, Imperial College London, London, United Kingdom, [3]Queen Square Institute of Neurology, University College London, London, United Kingdom, [4]Institute of Neurology, University Hospital ASST Spedali Civili of Brescia, Brescia, Italy, [5]Department of Neurology, Indiana University School of Medicine, Stark Neuroscience Research Institute - Indianapolis, Indianapolis, United States, [6]Roche Products Ltd, Welwyn Garden City, United Kingdom

P017 The unique mode of action of the orally applied PRI-002 and its confirmed target engagement in the phase 2b study PRImus-AD

Presenteur : Dieter Willbold

Dieter Willbold[1, 2], Dagmar Jürgens[1, 3], Gerhard Tischler[3], Tina Bartsch[3], Gunther Kauselmann[3, 1], Knur Adermann[3, 1], Lorenzo Bulli[3], Katja Lindner[3], Julia Post-Schulz[3], Julie-Anne Gabelich[3], Alexander Brener[3], Kathrin Zeiger[3], Oliver Peters[1, 4]
[1]Priavoid GmbH, Düsseldorf, Germany, [2]Institut für Physikalische Biologie, Heinrich Heine University Düsseldorf, Düsseldorf, Germany, [3]PRInnovation GmbH, Düsseldorf, Germany, [4]Department of Psychiatry and Neuroscience, Charité - Universitätsmedizin Berlin, Berlin, Germany

P018 PRImus-AD: Biomarker Profile Data of the phase 2b study treating early AD patients with the novel drug candidate PRI-002

Presenteur : Alexander Brener

Alexander Brener[1], Julia Post-Schulz[1], Dagmar Jürgens[2], Gerhard Tischler[1], Tina Bartsch[1], Gunther Kauselmann[2], Knut Adermann[2], Kathrin Zeiger[1], Katja Lindner[1], Lorenzo Bulli[1], Julie-Anne Gabelich[1], Dieter Willbold[2], Oliver Peters[2]
[1]PRInnovation GmbH, Düsseldorf, Germany, [2]Priavoid GmbH, Düsseldorf, Germany

P019 Design of a phase 3 clinical trial of the oral p38α kinase inhibitor neflamapimod in patients with dementia with Lewy bodies (DLB)

Presenteur : James Galvin

James Galvin[1], John-Paul Taylor[2], Nathalie Adda[3], Amanda Gardner[3], Shannon Bradley[3], Kelly Blackburn[3], John J Alam[3]
[1]U. of Miami Miller School of Medicine, Boca Raton, United States, [2]Newcastle University, Newcastle Upon Tyne, United Kingdom, [3]CervoMed Inc, Boston, United States

P020 PRImus-AD: Safety data of the Phase 2b study treating early AD patients with the novel drug candidate PRI-002

Presenteur : Gerhard Tischler

Gerhard Tischler[1], Dagmar Jürgens[2], Alexander Brener[1], Tina Bartsch[1], Gunther Kauselmann[1], Knut Adermann[2], Kathrin Zeiger[2], Katja Linder[1], Julie-Anne Gabelich[1], Lorenzo Bulli[1], Julia Post-Schulz[1], Dieter Willbold[2], Oliver Peters[2]
[1]PRInnovation GmbH, Düsseldorf, Germany, [2]Priavoid GmbH, Düsseldorf, Germany

P021 PRImus-AD: Design, Recruitment and Baseline Data of the Phase 2 Study Treating Early AD Patients with the Novel Drug Candidate PRI-002

Presenteur : Dagmar Jürgens

Dagmar Jürgens[1, 2], Gerhard Tischler[2], Alexander Brener[2], Tina Bartsch[2], Gunther Kauselmann[1, 2], Knut Adermann[1, 2], Kathrin Zeiger[2], Katja Lindner[2], Julie-Anne Gabelich[2], Dieter Willbold[1, 3], Oliver Peters[1, 4]
[1]Priavoid GmbH, Düsseldorf, Germany, [2]PRInnovation GmbH, Düsseldorf, Germany, [3]Institut für Physikalische Biologie, Heinrich Heine University , Düsseldorf, Germany, [4]Department of Psychiatry and Neuroscience, Charité - Universitätsmedizin Berlin, Berlin, Germany

P022 Effect of the P. gingivalis (Pg) gingipain inhibitor atuzaginstat on neuropsychiatric symptoms in Pg-positive mild-moderate AD patients and distress in their caregivers: Analysis of the NPI-12 in the Phase 2/3 GAIN trial

Presenteur : Michael Detke

Michael Detke[1], Marwan Sabbagh[2], Joanna Bolger[1], Tyler Duke[3], Florian Ermini[1], Casey Lynch[1], Stephen Dominy[1]
[1]Lighthouse Pharma, Novato, United States, [2]Barrow Neurological Institute, Phoenix, United States, [3]Pentara Corp, Millcreek, United States

P023 ALTITUDE-AD: Qualitative interviews assessing treatment expectations and motivations for clinical trial participation in early Alzheimer's disease

Presenteur : Stephanie Cline

Elizabeth Merikle[1], Todd Feaster[2], Eric Siemers[2], Diana Kerwin[3], Stephanie Cline[2]
[1]Clinical Outcomes Assessment Consultant, Parksville, Bc, Canada, [2]Acumen Pharmaceuticals, Newton, Ma, United States, [3]Kerwin Medical Center, Dallas, Tx, United States

P024 Perspectives on the care experience in early Alzheimer's: Narratives from study partners in the ALTITUDE-AD clinical trial

Presenteur : Stephanie Cline

Elizabeth Merikle[1], Todd Feaster[2], Robyn Moxon[2], Eric Siemers[2], Dung Trinh[3], Stephanie Cline[2]
[1]Clinical Outcomes Assessment Consultant, Parksville, Bc, United States, [2]Acumen Pharmaceuticals, Newton, Ma, United States, [3]Healthy Brain Research, Long Beach, Ca, United States

P025 Clinical trial design and baseline characteristics of buntanetap's pivotal study in treating early Alzheimer's patients

Presenteur : Cheng Fang

Cheng Fang[1], Sarah Maccalum[1], Hui Liu[1], David Feng[2], Maria Maccecchini[1]
[1]Annovis Bio, Malvern, United States, [2]TCM, Princeton, United States

P026 C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 programme at Neuroclnx Glasgow.

Presenteur : Jennifer Lynch

Kanwal Aadil, Lewis Cowan, Jennifer Lynch, Fraser Inglis
Neuroclnx Glasgow, Motherwell, United Kingdom

P027 BenfoTeam Phase 2 RCT in Early Alzheimer's Disease: Report of Completed Enrollment and Recruitment

Presenteur : Howard Feldman

Andrea Lacroix[1], Howard Feldman[2, 3], José Luchsinger[4], Hyun Keun Cho[2, 3], Adam Tran[2, 3], Diane Jacobs[2, 3], David Salmon[2, 3], Donna Tan[2, 3], Andrew Mackelfresh[2, 3], Bryce Truver[2, 3], Jody-Lynn Lupo[2, 3], Carolyn Revta[2, 3], Gary Gibson[5]
[1]Division of Epidemiology, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, United States, [2]Department of Neurosciences, University of California San Diego, La Jolla, United States, [3]Alzheimer's Disease Cooperative Study, University of California San Diego, La Jolla, United States, [4]Departments of Medicine and Epidemiology, Columbia University Irving Medical Center, New York, United States, [5]Brain and Mind Research Institute, Weill Cornell Medicine, New York, United States

P029 Safety and Efficacy of Mevidalen in Alzheimer's Disease: A Phase 2, Randomized, Double-Blinded Trial

Presenteur : Adam Fleisher

Adam Fleisher[1], Nicole Mehdiyoun[1], Hu Haoyan[1], Tronchin Giulia[2], Hansson Oskar[3]
[1]Eli Lilly, Indianapolis, United States, [2]Eli Lilly, Cork, Ireland, [3]Eli Lilly, Boston, United States

P030 Brain–Gut Photobiomodulation in Mild-to-Moderate Alzheimer's Disease: Progress Update from the Light4Life Pivotal Trial

Presenteur : Guillaume Blivet

Julien Delrieu[1], Marie-Noëlle Cufi[2], Claire Paquet[3], Hermine Lenoir[4, 5], Louise Naccache[6], Antoine Garnier-Crussard[7, 8], Maud Jourdain[9], Mélodie Fouillen[10], Guillaume Blivet[11], Jacques Touchon[12]
[1]Toulouse University Hospital, Toulouse, France, [2]CHIC Castres-Mazamet, Castres, France, [3]Université Paris Cité, GHU APHP Nord, Hôpital Lariboisière, IHU ReConnect, Paris, France, [4]Services de gériatrie 1 & 2, Centre Mémoire de Ressources et de Recherche Île-de-France Sud - site Broca, AP-HP, Hôpital Broca, Paris, France, [5]Université Paris Cité, INSERM UMR-S 1144, Paris, France, [6]Lavaur Hospital, Lavaur, France, [7]Clinical Research Center Ageing-Brain-Frailty, Clinical and Research Memory Centre of Lyon, Lyon Institute For Aging, Charpennes Hospital, Hospices Civils de Lyon, Lyon, France, [8]Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, Bron, France, [9]Biofortis, Nantes, France, [10]RCTs, Lyon, France, [11]REGEnLIFE, Paris, France, [12]Montpellier University, Montpellier, France

P031 Episodic Memory Testing in TRAVELLER and TRONTIER: Evaluating the Relationship Between the International Shopping List Test (ISLT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

Presenteur : Ralph Lee

Yu-Jay Huoh[1], Ralph Lee[1], Elly Lee[1], Tara Parnitvithikul[1], T. Richard Parenteau[1], Dung Trinh[2], My-Linh Tong[1], Edward Zamrini[1], Maricor Grio[1]
[1]Irvine Clinical Research, Irvine, United States, [2]Healthy Brain Clinic, Long Beach, United States

P032 Oral Blarcamesine Clinical Effect In a Phase 2b/3 Early AD Population For SIGMAR1 And Col24a1 Genotypes

Presenteur : Marwan Sabbagh

Marwan Sabbagh[1], Audrey Gabelle[2], Timo Grimmer[3], Juan-Carlos Talavera[4], Jeffrey Edwards[4], Terrie Kellmeyer[4]
[1]Barrow Neurological Institute, Phoenix, United States, [2]University of Montpellier, Montpellier, France, [3]Technical University of Munich, Munich, Germany, [4]Anavex, New York, United States

P033 Masupirdine (a pure 5-HT6 receptor antagonist): Baseline demographic and clinical characteristics of the phase-3 clinical study targeting agitation in patients with dementia of Alzheimer's type

Presenteur : Pradeep Jayarajan

Ramakrishna Nirogi, Satish Jetta, Vinod Kumar Goyal, Vijay Benade, Anil Shinde, Santosh Kumar Pandey, Ramkumar Subramanian, Abdul Rasheed Mohammed, Dhanunjay Dogiparti, Pradeep Jayarajan, Venkat Jasti

Suven Life Sciences Ltd, Hyderabad, India

P034 Evaluation of Sex and APOE4-Related Differences in Baseline Characteristics and Disease Progression Among Placebo-Treated Patients in Anti-Amyloid Alzheimer's Clinical Trials

Presenteur : Kevin Krudys

Athanasios Chamzas, Gopichand Gottipati, Ananth Ram Nookala, Venkatesh Atul Bhattaram, Mehul Mehta, Ramana Uppoor, Kevin Krudys, Sreedharan Sabarinath

Center for Drug Evaluation and Research, FDA, Silver Spring, United States

P035 Evolution of Late-Stage Alzheimer's Disease Clinical Trial Design: Toward Biomarker-Driven, Precision Development

Presenteur : Laurentiu Gutiu

Laurentiu Gutiu[1], Abby Fuller[2], Todorova Antoniya[3]

[1]Fortrea Germany GmbH, Munich, Germany, [2]Fortrea Inc., Durham, United States, [3]Fortrea Belgium SRL, Brussels, Belgium

P036 Senolytic Therapy in Early Alzheimer's Disease: A Randomized Phase II Trial Suggests Effects on CSF Tau Biomarkers

Presenteur : Miranda Orr

Miranda Orr[1], Valentina Garbarino[2], Kristen Pitts[1], Shiva Kazempour[1], Natalia Mitin[3], Tiffany Kautz[2], Laura Ibanez[1], Suzanne Hendrix[4], Vijay Ramanan[5], Ronald Peteren[5], Tamara Tchkonia[6], James Kirkland[6], Nicolas Musi[6], Suzanne Craft[7], Mitzi Gonzales[6]

[1]Washington University, St Louis, United States, [2]UTHealth San Antonio, San Antoino, United States, [3]Sapre-Bio, , United States, [4]Pentara, , United States, [5]Mayo Clinic, Rochester, United States, [6]Cedars Sinai, Los Angeles, United States, [7]Wake Forest School of Medicine, Winston-Salem, United States

P037 A Phase 2 Randomized, Controlled Trial of MK-1167, a Positive Allosteric Modulator of the α7 nAChR, as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer's Disease Dementia

Presenteur : Eva Kohegyi

Eva Kohegyi, Beatriz Caballero, James Kost, Yi Mo, Yuki Mukai, Aristide Merola, Michael F. Egan

Merck & Co., Inc., Rahway, United States

P038 Repeated Theta Burst Stimulation to Brain Area 8AV Transiently Improves Memory Retention in Early-Stage Alzheimer's Disease

Presenteur : Michael Rosenbloom

Ian Coulter, Michael Rosenbloom, John Yi, Andrea Stocco

University of Washington, Seattle, United States

P039 A Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Phase Ia, First in Human Study of the Safety, Tolerability and Pharmacokinetics of OLX-07010, a Novel Tau Self-Association Inhibitor, in Healthy Adult and Older Volunteers.

Presenteur : William Erhardt

William Erhardt[1], John Ieni[1], Uma Kuruganti[1], Eliot Davidowitz[1], James Moe[1], Hakop Gevorkian[2]

[1]Oligomerix, Inc, Bronx, NY, United States, [2]California Clinical Trials Medical Group, Glendale, CA, United States

P040 Phase 1 Study Results of the Novel TREM2 Small Molecule Agonist MNA-001: Safety, Pharmacokinetics And Pharmacodynamics In Healthy Young And Elderly Volunteers

Presenteur : Niels Plath

Manuela Polydoro, Tamara Agajanov, Peter Flagstad, Angeliki Kallia Spentza, Laura Sans-Comerma, Jin Zheng, Ashley Comer, Ashley Lu, Joachim Vilstrup, Morten Andersen S, Ninna Frederiksen, Maria Dalby, Rita Balice-Gordon, David Howe, Niels Plath

Muna Therapeutics, Frederiksberg, Denmark

P041 Bilateral Pulvinar Transcranial Focused Ultrasound Stimulation in Mild Dementia With Lewy Bodies: A Randomized Triple-Blind Sham-Controlled Trial

Presenteur : Siyuan Xie

Siyuan Xie, Yi Xing, Yi Tang

Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China

P042 Five-year phase II BCG immunotherapy trial for Alzheimer's disease prevention in diabetes: Impact of APOE ε4 status on p-tau217 and Aβ42/40

Presenteur : Denise Faustman

Shiho Hashiguchi[1, 2], James Reilly[1], Nicholas Kartsounis[1], Emily Naughton[1], Thora McIsaac[1], Zachary Lucchini[1], Joan Braley[1], Hui Zheng[1], Willem Kühtreiber[1, 2], Denise Faustman[1, 2]

[1]Massachusetts General Hospital, Charlestown, United States, [2]Harvard Medical School, Boston, United States

P043 Effectiveness and safety of electroconvulsive therapy for severe, treatment-resistant agitation and aggression in dementia: Results from the ECT-AD study

Presenteur : Brent Forester

Brent Forester

Tufts Medical Center, Boston, United States

P044 A next-generation septin molecular glue, REM392, advancing to confirm proof of concept in mild-to-moderate Alzheimer's disease patients

Presenteur : Floor Stam

Floor Stam, Mieke Nuytten, Eveline Dubroux, Marieke Voets, Jessika Meuvis, Gerard Griffioen

remynd N.V., Leuven, Belgium

P045 Initial neurodegeneration biomarker results from a Phase 2a clinical trial of neflamapimod in patients with non-fluent variant primary progressive aphasia

Presenteur : Ian M Grant

Ian M Grant[1], Hugo Botha[2], Lawerance S Honig[3], Douglas W Scharre[4], Gardner Amanda[5], Kelly Blackburn[5], Bradley F Boeve[2], John J Alam[6], David J Irwin[7]

[1]Northwestern University, Chicago, United States, [2]Mayo Clinic, Rochester, United States, [3]Columbia University, New York, United States, [4]Ohio State University, Columbus, United States, [5]CervoMed, Boston, United States, [6]Mayo Clinic, Boston, United States, [7]University of Pennsylvania, Philadelphia, United States

P046 Safety, tolerability, pharmacokinetics and changes in CSF α-synuclein seeding activity and the CSF proteome in a first-in-patient trial of the oligomer modulator anle138b

Presenteur : Johannes Levin

Johannes Levin[1], Jonathan Evans[2], Nand Singh[3], Sue Melbourne[3], Amber Morgan[3], Camille Carroll[4], Olivia Wagemann[5], Matteo Vestrucci[6], Scott Berry[6], Sebastian Longen[7], Svenja Trossbach[1], Felix Schmidt[1], Daniel Weckbecker[1], Torsten Matthias[1], Armin Giese[1]

[1]MODAG GmbH, Wendelsheim, Germany, [2]Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, [3]Quotient Sciences, Nottingham, United Kingdom, [4]Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom, [5]Department of Neurology, Ludwig-Maximilians-University Munich, Munich, Germany, [6]Berry Consultants, Austin, United States, [7]AESKU.Diagnostics GmbH, Wendelsheim, Germany

P047 Interim Safety and Biomarker Analysis of PRECISE-AD

Presenteur : William Mantyh

William Mantyh[1], Wendy Luca[2], Misty Lamendola[2], Heidi Pavia[2], Lindsay Moody[2], Neil Warma[2], Max Milbury[2], Johanne Kaplan[2], Suzanne Hendrix[3], Neil Cashman[4, 2], Larry Altstiel[2]

[1]University of Minnesota, Minneapolis, United States, [2]ProMIS Neurosciences, Cambridge, MA, United States, [3]Pentara, Millcreek, United States, [4]University of British Columbia, Vancouver, Canada

P048 Phase 2a clinical trial of the oral p38α kinase inhibitor neflamapimod in patients with non-fluent variant primary progressive aphasia

Presenteur : Ian M. Grant

Ian M. Grant[1], Hugo Botha[2], Lawerance S. Honig[3], Douglas W. Scharre[4], Amanda Gardner[5], Kelly Blackburn[5], Bradley F. Boeve[2], John J. Alam[6], David J. Irwin[7]

[1]Northwestern University, Chicago, United States, [2]Mayo Clinic, Rochester, United States, [3]Columbia University, New York, United States, [4]Ohio State University, Columbus, United States, [5]CervoMed, Inc., Boston, United States, [6]CervoMed Inc., Boston, United States, [7]University of Pennsylvania, Philadelphia, United States

P049 Results from 2 phase 1 studies evaluating the dual FAAH/MAGL inhibitor irafamdastat in healthy adults (including Japanese and elderly)

Presenteur : Richard Hargreaves

Thomas Lodeweyckx[1], Jan De Hoon[1], Amina Haggag[2], Alice Wang[3], Min Chen[4], Kevin Dines[4], Joel Schwartz[4], Michael Thomas[4], Mark Thomas[4], Anthony Krakovich[4], Yanying Wang[4], Sumit Bansal[4], Richard Hargreaves[4], Marc Gleichmann[3]

[1]Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, Catholic University Leuven, Leuven, Belgium, [2]CenExel, Anaheim, United States, [3]Bristol Myers Squibb (affiliation at time of study), Princeton, United States, [4]Bristol Myers Squibb, Princeton, United States

P050 Safety and Modulation of ABCC9 pathways by nicorandil for the Treatment of Hippocampal Sclerosis of aging: The SMArT–HS Study primary outcome results

Presenteur : Gregory Jicha

Gregory Jicha, Erin Abner, Ahmed Bahrani, Maria Carrillo, Elif Coskun, Danica Coy, Alexandra Curtis, Brian Gold, Molly Harper, Emily Smith, Heather Snyder, Peter Nelson

University of Kentucky, Lexington, United States

P051 The ABCA1 agonist CS6253 in humans increases plasma apoE and amyloid in plasma and cerebrospinal fluid.

Presenteur : Jan Johansson

Jan Johansson[1], Bengt Winblad[2], Henrik Zetterberg[3], Jeffrey Cummings[4], Hussein Yassine[4]

[1]Artery Therapeutics, Inc., San Ramon, United States, [2]Karolinska Institute, Stockholm, Sweden, [3]Sahlgrenska, Gothenburg, Sweden, [4]UoNevada, Las Vegas, United States

P052 SAPHARY Phase 1b/2a study to investigate the safety, efficacy, and pharmacokinetics of GAL-101 salt as oral treatment for patients with mild to moderate Alzheimer's disease

Presenteur : Katrin Riemann

Katrin Riemann[1], Bernhard Katgely[1], Alexander Gebauer[1], Luciana Summo[1], John Harrison[2], Charlotte Teunissen[3], Willem De Haan[4], Andreas Busjahn[5], Manfred Windisch[6], Hermann Russ[1]

[1]Galimedix Therapeutics Inc., Kensington, United States, [2]Alzheimercentrum, AUmc, Amsterdam, The Netherlands, [3]Neurochemistry Laboratory, Alzheimer Center Amsterdam UMC, Amsterdam, The Netherlands, [4]Alzheimer Center, Department of Neurology, Amsterdam UMC, Amsterdam, The Netherlands, [5]HealthTwist GmbH, Berlin, Germany, [6]NeuroScios GmbH, St. Radegund/graz, Austria

P053 Low-dose levetiracetam to treat cortical hyperexcitability in early Alzheimer's disease: a randomized, double-blind phase 2a crossover trial

Presenteur : Stephanie Buss

Stephanie Buss, Brice Passera, Recep Ozdemir, Emma Ferry, Martina Upton, Carol Abedelnor, Grace Desmond, Brenna Hagan, Peter Fried, Tom Travison, Daniel Press, Mouhsin Shafi
Beth Israel Deaconess Medical Center, Boston, United States

P054 Baseline Characteristics of Participants Enrolled in a Multiple Ascending Dose Study of the C-Terminal Targeting Anti-Tau Antibody VY7523 in Early Alzheimer's Disease

Presenteur : Monroe Butler

Monroe Butler, Charlotte Chung, Joydeep Ghosh, Jennifer Morgan, Joydip Kundu, Krishanu Mathur, Vik Arora, Wencheng Liu, Craig Mallinckrodt, Maurice Emery, Tina Olsson, Dinah Sah, Alfred Sandrock, Raj Rajagovindan, Elena Ratti
Voyager Therapeutics, Lexington, United States

P055 First-in-Human Study Design of VY1706, a Systemically Administered Blood-Brain Barrier (BBB)-Penetrant Tau Lowering Gene Therapy in Early Alzheimer's Disease

Presenteur : Monroe Butler

Monroe Butler, Charlotte Chung, Joydeep Ghosh, Vik Arora, Wencheng Liu, Thrusha Chauhan, Ivan Nestorov, Tina Olsson, Craig Mallinckrodt, Rajeev Sivasankaran, Todd Carter, Dinah Sah, Alfred Sandrock, Raj Rajagovindan, Elena Ratti
Voyager Therapeutics, Lexington, United States

P056 Lithium Orotate for Early Stages of Alzheimer Disease and Related Dementias: Design and Methods of a Placebo-Controlled Dose-Ranging Pilot Trial

Presenteur : Olivia Okereke

Olivia Okereke[1], Joann Manson[2], Pamela Rist[2], Howard Sesso[2], Jennifer Gatchel[1], Chirag Vyas[1], David Mischoulon[1], David Bennett[3], Bruce Yankner[4]
[1]Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, United States, [2]Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States, [3]Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, United States, [4]Department of Genetics, Harvard Medical School,, Boston, United States

P057 Design of a Phase 2a Trial of LRRK2 Inhibitor HT-4253 in Pre-symptomatic APOE4 Carriers Identified via Population-Scale Genomics and Blood-Based Biomarkers

Presenteur : Jeremiah Bearss

Jeremiah Bearss[1], Nesrin Yasser[2], Ajisa Ali[3], John Kauwe[4], David Bearss[1]
[1]HALIA THERAPEUTICS, Utah, United States, [2]HALIA THERAPEUTICS, Dubai, United Arab Emirates, [3]HALIA THERAPEUTICS - Dubai (United Arab Emirates), Dubai, United Arab Emirates, [4]Brigham young university, Hawaii, United States

P058 NSC001 in Alzheimers's disease: Phase 2a proof of concept of the best in class biased selectove M1 muscarinic agonist

Presenteur : Manfred Windisch

Manfred Windisch[1], Abraham Fischer[2]
[1]NSC-Therapeutics GmbH, St. Radegund, Austria, [2]ADPD, Holon, Israel

P059 TREMHANCE: A Phase 2 study to evaluate the efficacy and safety of TREM2 agonist SAR448851 in early Alzheimer's disease

Presenteur : Jeffrey Cummings

Jeffrey Cummings[1], Catherine Mummery[2], David Watson[3], Christopher Rowe[4], Charlotte Teunissen[5], Sebastian Palmqvist[6], Jeffrey Norton[7], Sneha Narasimhan[8], Stephane Hourcade[9], Xiaodong Luo[10], Bing Zhu[10], Erik Wallstroem[10], Marco Colonna[11]
[1]University of Nevada Las Vegas, Las Vegas, Nevada, United States, [2]Dementia Research Centre, University College London, London, United Kingdom, [3]Alzheimer's Research and Treatment Center, Wellington, Florida, United States, [4]Austin Health, Heidelberg, Australia, [5]Amsterdam University Medical Center, Amsterdam, The Netherlands, [6]Lund University, Lund, Sweden, [7]Charter Research, The Villages, Florida, United States, [8]Sanofi, Morristown, New Jersey, United States, [9]Sanofi, Vitry-Sur-Seine, France, [10]Sanofi, Cambridge, Massachusetts, United States, [11]Washington University in St. Louis, St. Louis, Missouri, United States

P061 Caring for Behavioral Symptoms of Dementia (CBD): Pilot Trial of Cannabidiol for Anxiety in Patients with Mild Cognitive Impairment and Alzheimer's Dementia

Presenteur : Emily Kim

Rosemary Smith[1], Emily Kim[2], Kimaya Reddy[2], Edward De La Cruz[2], Rosain Ozonsi[2], Julia Merrill[2], Andre Nguyen[2], Regan Patrick[2, 3], David Harper[2, 3], Ipsit Vahia[2, 3], Brent Forester[4], Staci Gruber[1, 3]
[1]Marijuana Investigations for Neuroscientific Discovery (MIND) Program, McLean Hospital, Belmont, United States, [2]Geriatric Psychiatry Research Program (GPRP), McLean Hospital, Belmont, United States, [3]Department of Psychiatry, Harvard Medical School, Boston, United States, [4]Department of Psychiatry, Tufts Medical Center, Boston, United States

P062 Long-term Cognitive Benefit of troculeucel NK Cell Therapy in a Patient With Moderate Alzheimer's Disease: A Single-Subject Analysis

Presenteur : Paul Song

Paul Song[1], Hui Lucia[1], Hong Sean[1], Kang Yoonmi[1], Lee Hank[1], Mata Juan[1], Chung Harry[2], Carr Jesse[2], Betito Katia[2]
[1]NKGen Biotech, Santa Ana, United States, [2]Behavioral Research Specialists, LLC, Glendale, United States

P063 ADVANCE: A Randomised, Double-Blind, Placebo-Controlled Phase 2a Trial of ALZ-101 Active Immunotherapy in Early Alzheimer's Disease

Presenteur : Stefan Pierrou

Stefan Pierrou[1], Anders Sandberg[1], Arnesson Karin[1], Sjögren Niclas[2], Sabbagh Marwan[3]
[1]Alzinova AB, Mölndal, Sweden, [2]Cytel Inc., Stockholm, Sweden, [3]Barrow Neurological Institute, Phoenix, United States

P064 Phase 1b Proof-of-Mechanism Trial of EC5026, a Soluble Epoxide Hydrolase Inhibitor, in Biomarker-Confirmed Early Alzheimer's Disease

Presenteur : Myuri Ruthirakuhan

Myuri Ruthirakuhan[1], Cindy McReynolds[2], William Schmidt[2], Heather Hsu[2], Mario Masellis[1], Sandra Black[1], Walter Swardfager[1]
[1]Sunnybrook Research Institute, Toronto, On, Canada, [2]EicOsis Human Health Inc., Davis, Ca, United States

P065 Operational Strategies for Executing Complex, Dose-Escalation Phase 1 Alzheimer's Disease Clinical Trials

Presenteur : Bob Dagher

Bob Dagher
Clinilabs, Eatontown, United States

P066 First-in-Human Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator, in Healthy Human Subjects

Presenteur : Anil Shinde

Anil Shinde, Vinod Kumar Goyal, Veera Raghava Chowdary Palacharla, Ramkumar Subramanian, Satish Jetta, Pradeep Jayarajan, Vijay Benade, Santosh Kumar Pandey, Dhanunjay Dogiparti, Ilayaraja Kalaikadhiban, Abdul Rasheed Mohammed, Ramakrishna Nirogi, Venkat Jasti
Suven Life Sciences, Hyderabad, India

P067 THN391 – A First-In-Class Anti-fibrin Antibody for Treatment of Inflammation in Alzheimer's Disease: Update of an Ongoing Phase 1b Study for the Treatment of Early Alzheimer's Disease

Presenteur : Aaron B. Kantor

Nuno Mendonca[1], Aaron B. Kantor[1], Tanja A.M. Hoffman[1], Sarah Kavanagh[1], Henk J.M.M. Mutsaerts[2], Frederik Barkhof[2], Khalid Abd-Elaziz[3], E. Jort G.B. Vijverberg[2], Catherine Mummery[4], Craig Ritchie[5]
[1]Therini Bio, Sacrramento, Ca, United States, [2]Amsterdam UMC, Amsterdam, The Netherlands, [3]CTC Groningen, Groningen, The Netherlands, [4]University College London Hospitals, London, United Kingdom, [5]Scottish Brain Sciences, Edinburgh, United Kingdom

P068 Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): Update on progress in a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate

Presenteur : Linda Van Eldik

Linda Van Eldik[1], Wendy Ziai[2], Lauren Sansing[3], D. Martin Watterson[4], Saktimayee Roy[4], Daniel Hanley[2]
[1]University of Kentucky, Lexington, United States, [2]Johns Hopkins Univ, Baltimore, United States, [3]Yale University, New Haven, United States, [4]Northwestern University, Chicago, United States

P069 Global Exploratory Phase 2 Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of TML-6, a Synthetic Curcumin Analog Targeting the Autolysosomal Pathway in Early Alzheimer's Disease: Study Design and Rationale

Presenteur : Hiep Nguyen

Ih Jen Su[1, 2], Chien-Hong Lin[2], Chia-Yu Hsu[2], Hui-Chen Wang[2], Hiep Nguyen[3], Feng-Shiun Shie[4]
[1]Department of Biotechnology and Food Technology, Southern Taiwan University of Science and Technology, Tainan City, Taiwan, [2]Merry Life Biomedical Company, Tainan City, Taiwan, [3]Nguyen Scientific, Encinitas, United States, [4]Center for Neuropsychiatric ResearchNational Health Research Institutes, Zhunan Town, Taiwan

IMAGING (MRI & PET)

P070 Clinical And Biomarker Characteristics Of Persons With Atypical Tau PET Deposits: Comparison Of Patients Who Have Tau Deposits Consistent With AD

Presenteur : Lynne Hughes

Douglas Beauregard[1], Richard Mohs[1], Robin Wolz[2], Lynne Hughes[1], Amanda Ng[1], John Dwyer[1]
[1]Global Alzheimer's Platform Foundation, Washington, DC, United States, [2]IXICO, London, United Kingdom

P071 Baseline probable CAA phenotype, lobar microbleeds, and multispot white matter hyperintensities predict clinically consequential ARIA during anti-amyloid therapy

Presenteur : Wai-Ying Wendy Yau

Wai-Ying Wendy Yau[1], Elizabeth Moore[1], Era Laho[2], Ron Danziger[1], Bradford Dickerson[1], Sheena Baratono[1], Kirk Daffner[1], Teresa Gomez-Isla[1], Nathan Praschan[1], Sokratis Charisis[1], John Dickson[1], Michael Erkkinen[3], Mariel Kozberg[1], Liliana Ramirez-Gomez[1], Jeremy Ford[4]
[1]Mass General Brigham Department of Neurology, Harvard Medical School, BOSTON, United States, [2]Mass General Brigham Department of Neurology, BOSTON, United States, [3]Department of Neurology, University of California Davis, Sacramento, United States, [4]Mass General Brigham Department of Radiology, Harvard Medical School, BOSTON, United States

P072 Comparison of NeuroEXPLORER PET system and conventional PET/CT in measuring regional tau burden in Alzheimer's disease

Presenteur : Christopher van Dyck

Alexandra Difilippo, Ryan O'Dell, Daniel Camacho, William Wakefield, Katerina Allanson, Natalie Baer, Yannis Cavrel, Richard Carson, Adam Mecca, Christopher Van Dyck
Yale University, New Haven, United States

P073 Automated FLAIR volumetry of ARIA-E under lecanemab and donanemab: agreement with clinical grading, interval change, and an audit of the manual reference

Presenteur : Zahra Khodakarami

Zahra Khodakarami, Sandhitsu Das, David Wolk, Christopher Brown, Paul Yushkevich
University of Pennsylvania, Philadelphia, United States

P074 Laromestrocel preserves brain volume and cognitive function in Alzheimer's disease by inhibiting neuroinflammation

Presenteur : Brian Rash

Brian Rash[1], Sofya Levitina[1], Jeffrey Botbyl[2], Chris Conklin[3], Madhura Ingalhalikar[3], Joshua Hare[1]
[1]Longeveron Inc, Miami, United States, [2]Provonix Inc, Sewell, United States, [3]Clario Inc, Philadelphia, United States

P075 Nicotinamide Riboside Supplementation in Mild Cognitive Impairment and Mild Alzheimer's Disease: Target Engagement and Downstream Effects of Mitochondrial Function and Oxidative Stress

Presenteur : Fei Du

Fei Du[1], Chao Wang[1], Abigail Stein[1], Boyu Ren[1], Edward De La Cruz[1], Kimaya Alysa Reddy[1], Eilis Reardon[2], Regan Eric Partirck[1], Lpsit Vahia[1], Dost Öngür[1], Brent P. Forester[2]
[1]McLean Hospital, Mass-General Brigham Department of Psychiatry, Harvard Medical School, Belmont, United States, [2]Tufts Medical Center and Tufts University School of Medicine, Boston, United States

P076 Longitudinal amyloid-PET trajectories in subjects with early compared to late onset Alzheimer's disease: results from LEADS and ADNI study

Presenteur : Ganna Blazhenets

Ganna Blazhenets[1], Marlene Lin[1], Ani Eloyan[2], Kala Kirby[3], Maryanne Thangarajah[2], Dustin Hammers[3], Robert A Koeppe[4], David N Soleimani-Meigooni[1], Susan M Landau[5], William J Jagust[5], Maria C Carrillo[6], Bradford C Dickerson[7], Liana G Apostolova[3], Gil D Rabinovici[1], Renaud La Joie[1]
[1]Edward and Pearl Fein Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, United States, [2]Department of Biostatistics, Center for Biostatistics and Health Data Science, Brown University School of Public Health, Providence, United States, [3]Department of Neurology, Indiana University School of Medicine, Indianapolis, United States, [4]Department of Radiology, University of Michigan, Ann Arbor, United States, [5]Department of Neuroscience, University of California, Berkeley, United States, [6]Medical and Scientific Relations, Alzheimer's Association, Chicago, United States, [7]Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, United States

P077 Detection of tau pathology in patients with early Alzheimer's disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies

Presenteur : Christopher C. Rowe

Christopher C. Rowe[1], Serge Gauthier[2], Kenji Ishii[3], Keith Johnson[4], Sterling C. Johnson[5], Susan Landau[6], Eric Reiman[7], Koen Van Laere[8], Luca Passamonti[9], David Scott[10], Alison Long[11], Sulantha S. Mathotaarachchi[11], Hartmuth C. Kolb[11], Antoine Leuzy[11], Samantha Budd-Haeberlein[11]
[1]Austin Health, Melbourne, Australia, [2]McGill University, Montreal, Canada, [3]Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [4]Harvard Medical School, Boston, United States, [5]University of Wisconsin-Madison, Madison, United States, [6]University of California Wisconsin-Madison, Berkeley, United States, [7]Banner Alzheimer's Institute, Phoenix, United States, [8]University Hospitals Leuven, Leuven, Belgium, [9]Lantheus, Bedford, United States, [10]Clario, Philadelphia, United States, [11]Enigma Biomedical Group, Knoxville, United States

P078 Early Cerebrovascular MRI Abnormalities in Diabetes: Non-Amyloid Pathway to Cognitive Impairment

Presenteur : Maria Vassilaki

Maria Vassilaki[1], Ekaterina Hofrenning[1], Angela Fought[1], Clifford Jack JR.[1], David Knopman[1], Jonathan Graff-Radford[1], Ronald Petersen[1], Zoe Arvanitakis[2, 3], Prashanthi Vemuri[1]
[1]Mayo Clinic, Rochester, United States, [2]Rush Alzheimer's Disease Center, Chicago, United States, [3]Rush University Medical Center, Chicago, United States

P079 DELTA-SVD: A Diffusion MRI Framework for Cerebrovascular Injury Relevant to Alzheimer's Disease Clinical Trials

Presenteur : Marco Duering

Anna Dewenter[1], Benno Gesierich[2], Julie Rutten[3], Daniel Tozer[4], Pauline Maillard[5], Frank-Erik De Leeuw[6], Prashanthi Vemuri[7], Nicolai Franzmeier[1], Karl G. Helmer[8], Steven M. Greenberg[9], Anand Viswanathan[9], Saskia Lesnik Oberstein[3], Hugh S. Markus[4], Martin Dichgans[1], Marco Duering[2]
[1]Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany, [2]Antaros Medical AB, Mölndal, Sweden, [3]Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, [4]Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom, [5]Department of Neurology, University of California, Davis, Davis, United States, [6]Radboud University Medical Center, Department of Neurology; Research Institute for medical research and Innovation, Nijmegen, The Netherlands, [7]Department of Radiology, Mayo Clinic, Rochester, United States, [8]Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, United States, [9]Department of Neurology, J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, United States

P080 Robustness of Amyloid PET on a Brain-Dedicated PET Scanner in Real-World Neurology Practice: Quantification Stability and Visual-Read Agreement

Presenteur : Camilia Hoorvash

Camilia Hoorvash[1], Matthias Brendel[2], Dario Dhoqina[2], Johannes Sebastian Gnoerich[2], Alvaro Carpio Chicote[1], Jannis Fischer[1], Michael Shriver[3]
[1]Positrigo AG, Zurich, Switzerland, [2]Ludwig-Maximilians-Universität München, Germany, Munich, Germany, [3]Proscan Imaging, Naples, United States

P081 Association of Pretreatment Blood–Brain Barrier Water Exchange Rate With 6-Month Amyloid PET Change During Lecanemab Treatment in Alzheimer's disease

Presenteur : Lu Yuanyuan

Lu Yuanyuan, Wei Lijiang, Xing Yi, Tang Yi
Xuanwu Hospital, Capital Medical University, Beijing, China

P082 Minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging in the Alzheimer's disease spectrum

Presenteur : Gerard Nisal Bischof

Gerard Nisal Bischof[1, 2], Lukas Frontzkowski[3], Marianthi Zeinaki[3], Boris-Stephan Rauchmann[3], Johannes Gnörich[3], Dario Dhoqina[3], Günther Höglinger[4, 5, 6], Rudolf.A Werner[3], Gemma Salvado[7, 8], David Vallez-Garcia[7], Robert Perneczky[9, 10], Norman Koglin[11], Nicolai Franzmeier[12], Andrew Stephens[11], Matthias Brendel[13, 14, 15]
[1]Lantheus GmbH Germany, Berlin, Germany, [2]University Hospital Cologne, Germany, Cologne, Germany, [3]University Hospital, LMU Munich, Department of Nuclear Medicine, Munich, Germany, Munich, Germany, [4]German Center for Neurodegenerative Diseases, DZNE, Munich, Germany, Munich, Germany, [5]Munich Cluster for Systems Neurology, SyNergy, Munich, Germany, Munich, Germany, [6]University Hospital, LMU Munic Department of Neurology,, Munich, Germany, [7]Barcelona eta Brain Research Center (BBRC), Barcelona, Spain, [8]University Hospital, LMU Munich, Institute for Stroke and Dementia Research (ISD), Munich, Spain, [9]University Hospital, LMU Munich, Department of Psychiatry and Psychotherapy,, Munich, Germany, [10]Germany; German Center for Neurodegenerative Diseases, DZNE, Munich, Germany, Munich, Germany, [11]Lantheus Germany GmbH, Berlin, Germany, [12]Munich Cluster for Systems Neurology, SyNergy, Munich, Germany;, Munich, Germany, [13]University Hospital, LMU Munich, Department of Nuclear Medicine, Munich, Germany;, Munich, Germany, [14]German Center for Neurodegenerative Diseases, DZNE, Munich,, Munich, Germany, [15]Munich Cluster for Systems Neurology, SyNergy, Munich, Germany, Munich, Germany

P083 Spatial Heterogeneity of Amyloid- Clearance During Lecanemab Treatment: Associations With Pretreatment White-Matter Microstructure and Cognitive Change

Presenteur : Min Fang

Min Fang
Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

P084 Alzheimer disease in Down syndrome: A decade of biomarker discovery and a pathway to clinical trials.

Presenteur : Elizabeth Head

Elizabeth Head[1], Mark Mapstone[1], Bradley Christian[2], Benjamin Handen[3], Michael Rafii[4]
[1]University of California Irvine, Irvine, United States, [2]University of Wisconsin, Madison, Madison, United States, [3]University of Pittsburgh, Pittsburgh, United States, [4]University of Southern California, Los Angeles, United States

P085 Spatiotemporal Emergence and Longitudinal Progression of Tau-PET Pathology in Autosomal Dominant Alzheimer Disease: Implications for Prevention Trial Design

Presenteur : Savannah Tiemann Powles

Savannah Tiemann Powles[1], Nicole McKay[1], Shaney Flores[1], Julie Wisch[1], Edita Sabaredzovic[1], Sarah Keefe[1], Guoqiao Wang[1], Jalen Scott[1], T. Hunter Smith[1], Stephanie Doering[2], Eric McDade[1], Randall Bateman[1], Brian Gordon[1], . Dominantly Inherited Alzheimer Network*[3], Tammie Benzinger[1]
*[1]Washington University in St. Louis School of Medicine, St. Louis, United States, [2]Massachusetts General Hospital, Boston, United States, [3]*Observational Study and Trials Unit*

P086 Do superagers in various cognitive domains show resistance to imaging-based neuropathologies? The Lifeafter90 Study

Presenteur : Batool Rizvi

Batool Rizvi[1], Hilary Colbeth[1], Rifat Alam[1], Alexander Posis[1], Katherine Colcord[2], Charles Decarli[1], Dan Mungas[1], Paola Gilsanz[3], Maria Corrada[2], Rachel Whitmer[4]
[1]UC Davis, Davis, United States, [2]UC Irvine, Irvine, United States, [3]Kaiser Permanente Northern California Division of Research, Pleasanton, United States, [4]UC Davis, Irvine, United States

P087 Point-of-Care Low-Field MRI for Monitoring ARIA-E and Pseudoatrophy During Anti-Amyloid Therapy

Presenteur : Annabel Sorby-Adams

Annabel Sorby-Adams[1], Ava Farnan[1], Shenghua Zhu[1], John R. Dickson[1], Liliana Ramirez-Gomez[2], Alberto Serrano-Pozo[1], Arman Fesharaki-Zadeh[3], Matthew S. Rosen[4], Jeremy Ford[5], Kevin N. Sheth[3], Adam De Havenon[3], J. Eugenio Iglesias[4], Teresa Gomez-Isla[1], W. Taylor Kimberly[1]
[1]Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, United States, [2]Department of Neurology, Mass General Brigham and Harvard Medical School - Boston, Boston, United States, [3]Yale Center for Brain & Mind Health, Yale New Haven Hospital and Yale Medical School, New Haven, United States, [4]Athinoula A. Martinos Center for Biomedical Imaging, Mass General Brigham and Harvard Medical School, Boston, United States, [5]Department of Radiology, Mass General Brigham and Harvard Medical School, Boston, United States

P088 A practical correction for non-specific [18F]MK-6240 uptake to improve tau PET quantification for early detection

Presenteur : Praveen Honhar

Praveen Honhar[1], Jessie Fanglu Fu[1], Amal Tiss[2], Michael Properzi[3], Aaron Schultz[1], Julie Price[1], Keith Johnson[1]
[1]Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, United States, [2]Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, United States, [3]Massachusetts General Hospital, Boston, United States

P089 Tau PET spatial patterns for trial-relevant measurement of tau progression in preclinical AD: AHEAD-3/45 and HABS

Presenteur : Stephanie Doering

Jessie Fanglu Fu[1], Stephanie Doering[1], Praveen Honhar[1], Amal Tiss[1], Emma Thibault[1], Eva Pintucci[1], Elliott Slade[1], Alex Becker[1], Michelle Farrell[1], Michael Properzi[1], Aaron Schultz[1], Reisa Sperling[1], Julie Price[1], Keith Johnson[1], Actc Ahead 3-45 Study Team[2]
[1]Massachusetts General Hospital, Boston, United States, [2]Alzheimer Clinical Trials Consortium, , United States

P090 Predicting Amyloid PET Positivity from a Brief Digital Cognitive Assessment in Memory Clinic Patients

Presenteur : Ali Jannati

David Libon[1], Mitchel Kling[1], Ali Jannati[2], Kallie Sweetman[1], Jacqueline Nguyen[1], Ileana De Anda-Duran[3], Rod Swenson[4], Sean Tobyne[2], Alvaro Pascual-Leone[2, 5]
[1]Rowan University, Glassboro, United States, [2]Linus Health, Boston, United States, [3]Tulane University, New Orleans, United States, [4]University of North Dakota,, Grand Forks, United States, [5]2Hebrew SeniorLife - Harvard Medical School, Boston, United States

P091 Radiology Inferred CAA as a Potential Biomarker: Links to Pathology Timing, Cognition, and Proteomics

Presenteur : Julie Oomens

Julie Oomens[1], Ramiro Eduardo Rea Reyes[1], Leonardo Rivera-Rivera[1], Mai Abdelmoaty[2], Rachael Wilson[2], Sterling Johnson[1]
[1]Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States, [2]Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States

P092 AIND: A Validated AI-Derived Neurodegeneration Marker for Alzheimer's Disease Clinical Trials

Presenteur : David Vaillancourt

David Vaillancourt[1], Jesse Desimone[2], Robin Chen[1], Shannon Chiu[3], Wei-En Wang[1], Freydell Espinoza-Urbina[1], Angelos Barmpoutis[1]
[1]University of Florida, Gainesville, United States, [2]Neuropacs, Gainesville, United States, [3]Mayo Clinic, Phoenix, United States

P093 Baseline Radiologic Predictors of ARIA-E and ARIA-H: A Quantitative AI-Supported MRI Analysis of a US Real-World Cohort

Presenteur : Mark Pippenger

Mark Pippenger[1], Nuno Pedrosa De Barros[2], Dirk Smeets[2], Arno Liseune[2], Ricardo Magalhaes[2], Diana Sima[2], Thibo Billiet[2], Wim Van Hecke[2], Aaron Ritter[3], Bela Ajtai[4], Keith Schluterman[5], Kinyee Fong[6], Boyang Bian[6], Nick Belviso[6], Lydia Wood[6]
[1]Baptist Health Medical Center, North Little Rock, United States, [2]icometrix, Leuven, Belgium, [3]Hoag Medical Center, Newport Beach, United States, [4]DENT Neurologic Institute, Amherst, United States, [5]Conway Regional Neuroscience Center, Conway, United States, [6]Biogen, Cambridge, United States

P094 Incidence of A -PET-positivity and tau-PET-positivity in individuals without dementia

Presenteur : Emma Coomans

Emma Coomans[1, 2], Colin Groot[1, 2], Rik Ossenkoppele[1, 2]
[1]Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands, [2]Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands

P095 Sex, education and race/ethnicity have distinct effects on amyloid and tau-PET status

Presenteur : Colin Groot

Colin Groot, Emma Coomans, Rik Ossenkoppele
Amsterdam UMC, Amsterdam, The Netherlands

P096 Burden-dependent bias of cerebellar reference regions in amyloid PET monitoring of disease-modifying therapy: eroded white matter as a calibratable anchor

Presenteur : Sang Won Seo

Sang Won Seo[1], Soo Hyun Cho[2], Seongmi Kim[1], Duk L Na[3], Seongbeom Park[4], Kichang Kwak[4], Hee Jin Kim[1], Jun Pyo Kim[1], Seunghwan Moon[1]
[1]Samsung medical center, Seoul, Korea, Republic of, [2]Chonnam National University Hospital, Gwangju, Korea, Republic of, [3]Happymind Clinic, Seoul, Korea, Republic of, [4]BeauBrain Healthcare, Seoul, Korea, Republic of

P097 Amyloid load in the precuneus is associated with lack of response to anti-amyloid treatment in preclinical Alzheimer's disease.

Presenteur : Annalena Venneri

Annalena Venneri, Matilde Grilli, Riccardo Manca
University of Parma, Parma, Italy

P098 Outpatient Medications and Risk of Amyloid-Related Imaging Abnormalities in a Memory Clinic Population Receiving Anti-Amyloid Therapy

Presenteur : Sokratis Charisis

Sokratis Charisis, John Dickson, Yingnan He, Cinthya Aguero Murillo, Jeremy N Ford, Michael G Erkkinen, Liliana A Ramirez Gomez, Katelyn Mary Horan, Wedgina Norelus, Sheena R Baratono, Elmira Hassanzadeh, Nathan C Praschan, Sudeshna Das, Kirk R Daffner, Teresa Gomez-Isla
Mass General Brigham, Boston, United States

P099 Towards clinical CMB detection: a two-stage deep learning approach utilising synthetic data

Presenteur : Robin Wolz

Anita Karsa[1], Richard Joules[1], Jane Waugh[1], Luigi Lorenzini[2], Frederik Barkhof[2, 3], Robin Wolz[1]
[1]IXICO, London, United Kingdom, [2]Amsterdam UMC, Amsterdam, The Netherlands, [3]University College London, London, United Kingdom

P100 Integration of neuroimaging signatures of aging and Alzheimer's disease with plasma biomarkers for the detection and prediction of cognitive impairment

Presenteur : Mitzi Gonzales

Mitzi Gonzales[1], Ngoc Huynh Ho[2], David Wang[2], Sachintha Brandigampala[2], Tanweer Rashid[2], Mengjin Dong[2], Sokratis Charisis[2], Timothy Hohman[3], Sudha Seshadri[2], Christos Davatzikos[4], Kristine Yaffe[5], Jon Toledo[6], Mohamad Habes[2]
[1]Cedars-Sinai, Los Angeles, United States, [2]UT Health San Antonio, San Antonio, United States, [3]Vanderbilt, Nashville, United States, [4]University of Pennsylvania, Philadelphia, United States, [5]University of California San Francisco, San Francisco, United States, [6]Houston Methodist, Houston, United States

P101 Rapid tau proliferation at different amyloid stages based on initial tauopathy

Presenteur : Michelle Farrell

Michelle Farrell[1], Emma Thibault[1], Elliott Slade[1], Fanglu Fu[1], Julie Price[1], Brian Healy[1], Heidi Jacobs[1], Rachel Buckley[2], Reisa Sperling[2], Keith Johnson[2]
[1]Massachusetts General Hospital, Harvard Medical School, Boston, United States, [2]Massachusetts General Hospital, Brigham & Women's Hospital, Harvard Medical School, Boston, United States

P102 Regional Amyloid PET Quantification for Re-review of Global Centiloid-Negative Scans in ADNI and IDEAS

Presenteur : Regina Ey Kim

Yeong Sim Choe[1], Hyunjae Yu[1], Mijung Park[1], Renaud La Joie[2], Gil Rabinovici[2], Regina Ey Kim[1], Donghyeon Kim[1]
[1]Research Institute, Neurophet Inc, Seoul, Korea, Republic of, [2]Department of Neurology, Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, United States

P103 Predicting Regional Tau-PET SUVR using Plasma and Structural MRI Biomarkers

Presenteur : Thomas Kirk

Sofiia Tatosh[1], Armen Bodossian[1], Logan Zhang[1], Thomas Kirk[1], Martin Craig[1], Michael Chappell[1, 2]
[1]Quantified Imaging, London, United Kingdom, [2]School of Medicine, University of Nottingham, Nottingham, United Kingdom

P104 Sleep Quality and Precuneus Cerebral Blood Flow Predict Progression of Subjective Cognitive Decline: A Longitudinal Study

Presenteur : Li Wenyi

Li Wenyi
Beijing Tiantan hospital, Beijing, China

P105 Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium

Presenteur : Timothy Hohman

Timothy Hohman
Vanderbilt University Medical Center, Nashville, United States

P106 Regional cerebellar vulnerability associated with sleep phenotypes in the Alzheimer's disease spectrum

Presenteur : Yoo Hyun Um

Yoo Hyun Um, Suhyung Kim
Department of Psychiatry, St.Vincent's Hospital, Suwon, Korea, Republic of

P107 Predictors of longitudinal amyloid clearance due to lecanemab treatment: A preliminary report from a real-world clinical cohort

Presenteur : Yuta Katsumi

Yuta Katsumi[1], Neguine Rezaii[1], Kirk Daffner[2], John Dickson[1], Jeremy Ford[1], Seth Gale[2], Teresa Gomez-Isla[1], Gad Marshall[2], Liliana Ramirez Gomez[1], Dennis Selkoe[2], Hyun-Sik Yang[2], Wai-Ying Yau[1], Mark Eldaief[1], Scott McGinnis[2], Bradford Dickerson[1]
[1]Massachusetts General Hospital, Boston, United States, [2]Brigham and Women's Hospital, Boston, United States

P108 Predictors of ARIA-H in A4 Study: White matter hyperintensity and APOE ε4 selectively influence lobar microhemorrhages

Presenteur : Zahra Shirzadi

Zahra Shirzadi[1], Nazila Loghmani[2], Aaron Schultz[1], Wai-Ying Yau[1], Hyun-Sik Yang[1], Roy Yaari[3], Michael Properzi[1], Michael S. Rafii[4], Clifford R. Jack Jr[5], Steven M. Greenberg[1], Paul Aisen[4], Reisa A. Sperling[1], Jasmeer P. Chhatwal[1]
[1]Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, United States, [2]Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, , United States, [3]Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States, [4]Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [5]Mayo Clinic, Radiology, Rochester, United States

P109 Comparison of test-retest variability and longitudinal stability of total intracranial volume measurement between atlas-based and segmentation-based MRI methods

Presenteur : Luc Bracoud

Thomas Cajgfinger[1], Alessandro Delmonte[1], Madhura Ingalhalikar[2], Chris Conklin[2], Joel Schaerer[3], Meredith Burke[4], David Scott[4], Luc Bracoud[1]
[1]Clario, part of Thermo Fisher Scientific, Lyon, France, [2]Clario, part of Thermo Fisher Scientific, Philadelphia, United States minor outlying islands, [3]Clario, part of Thermo Fisher Scientific, Geneva, Switzerland, [4]Clario, part of Thermo Fisher Scientific, Philadelphia, United States

P110 Longitudinal evolution of enlarged perivascular spaces across the AD continuum

Presenteur : Luc Bracoud

Luc Bracoud[1], Alessandro Delmonte[1], Thomas Cajgfinger[1], Madhura Ingalhalikar[2], Chris Conklin[2], Joel Schaerer[3], Meredith Burke[2], David Scott[2]
[1]Clario, part of Thermo Fisher Scientific, Lyon, France, [2]Clario, part of Thermo Fisher Scientific, Philadelphia, United States, [3]Clario, part of Thermo Fisher Scientific, Geneva, Switzerland

P111 Retinal layer thickness predicts cerebral amyloid burden in preclinical Alzheimer's disease

Presenteur : Jordan Sergio

Jordan Sergio[1, 2, 3], Cyrus Raji[4], Ashley Bernardo[1, 2], Megan Stradtman[5], Savannah A. Doster[2, 3], Rachel Lacroix[3, 5], Emma T. Larracey[2, 3], Mahshid Naghashzadeh[4], Mobina Amanollahi[4], Soheil Mohammadi[4], Mona Mirbeyk[4], Mahsa Dolatshahi[4], Peter Snyder[1, 2, 6], Jessica Alber[1, 2, 3, 6]
[1]Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, United States, [2]Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, United States, [3]Butler Hospital Memory & Aging Program, Providence, United States, [4]Neuroimaging Labs Research Center at Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, United States, [5]Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, United States, [6]George & Anne Ryan Institute for Neuroscience, University of Rhode Island , Kingston, United States

P112 MRI-based enrichment for pathology-targeted progressive supranuclear palsy trials in non-fluent variant primary progressive aphasia

Presenteur : Jesús García-Castro

Jesús García-Castro[1], Maria Luisa Mandelli[2], Alexandre Bejanin[1], Oriol Dols-Icardo[1], Juan Fortea[1], Daniel Alcolea[1], Alberto Lleó[1], Kejal Kantarci[3], Hilary W. Heuer[2], Howard Rosen[2], Brad Boeve[3], Adam Boxer[2], Zachary Miller[2], Maria Luisa Gorno-Tempini[2], Ignacio Illán-Gala[1]
[1]Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, [2]Memory and Aging Center, UCSF, San Francisco, United States, [3]Mayo Clinic, Rochester, United States

P113 Evaluation of atrophy-defined subtypes in early symptomatic Alzheimer's disease

Presenteur : Vikas Kotari

Mintao Liu, Vikas Kotari, Jiaying Guo, Adam S. Fleisher, Rik Ossenkoppele, Sergey Shcherbinin
Eli Lilly and Company, , United States

P114 Distinct Associations Between Hippocampal Subfield Volumes and Episodic Memory in Alzheimer's Disease

Presenteur : Giulia Tronchin

Giulia Tronchin, Mintao Liu, Tina Wang, Alette Maria Wessels, Ming Lu, Vikas Kotari, Sergey Shcherbinin
Eli Lilly and Company, Indianapolis, United States

P115 Therapeutic Amyloid Reduction and Cortical Excitability in Alzheimer's Disease (TRACE-AD) Study Protocol and Early-Stage Findings.

Presenteur : Basma Gomaa

Basma Gomaa[1, 2], Stephanie Buss[1, 2]
[1]Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Boston, United States, [2]Department of Neurology, Harvard Medical School, Boston, United States

P116 Advanced Arterial Compliance Impairment Is Associated with Tau Accumulation and Progressive Neurodegeneration

Presenteur : Young Noh

Young Noh[1], Jaelim Cho[2], Yeo Jin Kim[3], Ha-Eun Seo[4], Daegyeom Kim[4], Jihyun Bae[4], Sang-Yoon Lee[5], Kee Hyung Park[6], Geert Jan Biessels[7], Jae-Hong Lee[8], Keun-Hwa Jung[9]
[1]Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea, Republic of, [2]Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of, [3]Department of Neurology, Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of, [4]Neuroscience Research Institute, Gachon University, Incheon, Korea, Republic of, [5]Department of Neuroscience, College of Medicine, Gachon University, Incheon, Korea, Republic of, [6]Department of Neurology, Gachon University Gil Medical Center, Incheon, Korea, Republic of, [7]Department of Neurology, UMC Utrecht, Utrecht, The Netherlands, [8]Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of, [9]8Department of Neurology, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of

P117 The Pronghorn Sign: Hunting for a Radiologic Biomarker in LBD

Presenteur : Preston Roche

Preston Roche[1], Samy Abdullah[1], James Rini[2], Leila Saadatpour[1, 3], Alicia Parker[1, 3], Tanvi Kosuri[1]
[1]UT San Antonio, San Antonio, United States, [2]OCHSNER Health, New Orleans, United States, [3]Biggs Institute, United States

P118 Tau PET signature of amyloid PET visual-positive/quantitative-negative discordance despite low global amyloid burden in ADNI

Presenteur : Saki Nakashima

Saki Nakashima[1], Kenichiro Sato[2], Yoshiki Niimi[2], Wataru Satake[1], Takeshi Iwatsubo[3]
[1]Department of Neurology, Graduate School of Medicine, The University of Tokyo - Tokyo (Japan), Tokyo, Japan, [2]Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, [3]National Center of Neurology and Psychiatry, Tokyo, Japan

ARTIFICIAL INTELLIGENCE–DRIVEN INNOVATION IN ALZHEIMER'S THERAPEUTICS

P119 Perturbation virtual cell models for causal discovery in Alzheimer's disease

Presenteur : Ravi Solanki

Ravi Solanki, Yash Shirsath, Anooj Patel, Jonathan Hoover
Prima Mente, San Francisco, United States

P120 Causal modeling using Gemini Digital Twins identifies SPI1 as a potential modifier of neurodegenerative disease progression

Presenteur : Apoorva Bharthur Sanjay

Apoorva Bharthur Sanjay, So-Youn Shin, Li Sun, Jean-Michel Gries, Jeanne Latourelle
Aitia, Cambridge, United States

P121 Predicting blood–brain barrier permeability of late-stage small-molecule drug candidates for Alzheimer's disease using artificial intelligence

Presenteur : Alexander Morin

Alexander Morin[1], Rick Fontenot[2], Panna Sharma[2], Maria Maccecchini[1]
[1]Annovis Bio, Malvern, United States, [2]Lantern Pharma, Dallas, United States

P122 Improved Performance and Fairness of Dementia Risk Stratification from Claims Data with Machine Learning

Presenteur : Daniel Schulman

Daniel Schulman[1], Ali Jannati[1, 2], Sean Tobyne[1]
[1]Linus Health Inc, Boston, MA, United States, [2]Harvard Medical School, Boston, MA, United States

P123 GPND-AI Treatment: A Trajectory Monitor for Treatment Responses

Presenteur : Ying Xu

Ying Xu[1], Rui Mu[1], Alex Roussak[1], Menghan Liu[1], Yike Chen[1], John Budde[1], Steven Funk[1], Tammie L. S. Benzinger[2], John C. Morris[3], David M. Holtzman[3], B Joy Snider[3], Randall J. Bateman[3], Suzanne E. Schindler[3], Carlos Cruchaga[1]
[1]Department of Psychiatry, Washington University School of Medicine, St Louis, United States, [2]Department of Radiology, Washington University School of Medicine, St Louis, United States, [3]Department of Neurology, Washington University School of Medicine, St Louis, United States

P124 FINGERS-7B: A Multi-Omic Foundation Model for Precision Biomarker Discovery

Presenteur : Arvid Gollwitzer

Arvid Gollwitzer[1, 2], Adrian Noriega De La Colina[1, 2, 3], Li-Huei Tsai[1, 4], Miia Kivipelto[5, 6], Giovanni Traverso[1, 2, 7]
[1]Broad Institute of MIT and Harvard, Cambridge, United States, [2]Massachusetts Institute of Technology, Cambridge, United States, [3]Brigham and Women's Hospital, Boston, United States, [4]The Picower Institute for Learning and Memory, Cambridge, United States, [5]FINGERS Brain Health Institute, Stockholm, Sweden, [6]Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, [7]Divison of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School , Boston, United States

P125 AI-based prognostic stratification accurately predicts future clinical decline and increases observed decline in symptomatic and preclinical AD placebo arms

Presenteur : Luca Villa

Luca Villa, Zi Hui Su, Ayoub Gueddou, Mathilde Borrot, Nicolas Guizard, Elizabeth Gordon
Qynapse, 2-10 rue d'Oradour-sur-Glane, 75015 Paris, France, Paris, France

P126 Characteristics, trajectories, and Alzheimer's disease biomarkers in subjective cognitive decline: a proposal for a management framework in clinical and research settings

Presenteur : Salvatore Mazzeo

Salvatore Mazzeo[1, 2], Michael Lassi[3], Sonia Padiglioni[4, 5], Alberto Arturo Vergani[3, 6], Valentina Moschini[4], Giulia Giacomucci[4], Carmen Morinelli[4], Silvia Bagnoli[7], Assunta Ingannato[7], Maria Salsone[1, 2], Massimo Filippi[8], Benedetta Nacmias[7, 9], Antonello Grippo[10, 9], Alberto Mazzoni[3], Valentina Bessi[10, 7]
[1]Neurology Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy, [2]Vita-Salute San Raffaele University,, Milan, Italy, [3]The BioRobotics Institute and Department of Excellence in Robotics and AI, Scuola Superiore Sant'Anna, Pisa, Italy, [4]SOD Neurologia, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, Florence, Italy, [5]Regional Referral Centre for Relational Criticalities - Tuscany Region, Florence, Italy, [6]Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy, [7]Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, [8]Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, «Vita-Salute» San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy, [9]IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy, [10]SODC Neurofisiopatologia, Azienda Ospedaliero-universitaria Careggi, Florence, Italy

P127 Artificial Intelligence–Guided Drug Repurposing for Alzheimer's Disease Based on the Unified Theory of Neurodegenerative, Metabolic, and Cardiovascular Diseases

Presenteur : Lloyd Tran

Lloyd Tran, Michael Willis, Zung Tran
Biomed AI, Inc., San Jose, United States

P128 AI-Enabled Analysis of Anti-Aβ Clinical Trial Outcomes Supports Investigation of the Neurogenesis-Based Therapeutic Candidate NA-831 for Alzheimer's Disease

Presenteur : Lloyd Tran

Lloyd Tran, Michael Willis, Zung Tran
Biomed AI, Inc., San Jose

P129 AI-designed disulfide-cyclized peptides targeting transferrin receptor 1: a computational-to-experimental pipeline for blood-brain barrier shuttle development

Presenteur : Weiwei Ma

Weiwei Ma[1], Dapeng Jiang[2], Bowen Gao[2], Yanyan Lan[2]
[1]Aipher (beijing) Technology, beijing, China, [2]Tsinghua Univ., beijing, China

P130 Feasibility of Automated ARIA-E Assessment on Data Collected From Portable MR Imaging Systems: A Case Series

Presenteur : Yoselyn Garcia

Yoselyn Garcia[1], Kayla Tran[1], Somphanh Khousakoun[1], Simon Eyndhoven[2], Rafay Khan[2]
[1]Tampa Bay Neurocognitive Institute, Clearwater, United States, [2]GE HealthCare, Leuven, Belgium

P131 Machine Learning Improves Error Detection for the CDR through Precision Endpoint Protection.

Presenteur : Selam Negash

Selam Negash, Matt Welch, Danielle Di Gregorio, Dorothee Schoemaker, Shelly Steele, Briana Webber-Lind, Barbara Echevarria, David Ju, Chris Randolph
Clario, part of Thermo Fisher Scientific, Philadelphia, United States

P132 Radiomics Classification of Amyloid Status on Florbetapir PET

Presenteur : Elif Sikoglu

Elham Yousef Kalafi[1], Samuel Lockhart[1, 2], Victoria Hegedus[1], Ryan Petrulli[1], David Cash[1, 3], Elif Sikoglu[1]
[1]Perceptive, Burlington, United States, [2]Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, United States, [3]UCL Queen Square Institute of Neurology, London, United Kingdom

P133 Automated visual assessment of amyloid PET images through deep-learning classification

Presenteur : Elif Sikoglu

Anand Kadumberi[1], Samuel Lockhart[1, 2], David Cash[1, 3], Elif Sikoglu[1]
[1]Perceptive, Burlington, United States, [2]Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, United States, [3]UCL Queen Square Institute of Neurology, London, United Kingdom

P134 Application of Data Mining and AI LLM Tools to enhance recruitment for an MCI clinical trial

Presenteur : Gloria Xie

Murali Doraiswamy, Gloria Xie
Duke University Medical Center, Durham, United States

P135 AI-Assisted Review Support Tool for Clinical Operations and Data Reconciliation in a Global Phase 3 Alzheimer's Disease Trial

Presenteur : Phil Kang

Phil Kang, Lisa Vaden, Ja Yeon Shin, Fred Kim, Jai Jun Choung
AriBio Co., Ltd., San Diego, United States

EPIDEMIOLOGY

P136 Cross-sectional and longitudinal factor analysis of everyday activity and cognition in cognitively unimpaired older adults: the Stanford Aging and Memory Study 7-Year Follow-Up

Presenteur : Irina Skylar-Scott

Olivia Lu[1], Kenyon Weis[1], Zihaui He[1], Valerie Carr[2], Alexandra Trelle[1], Christina Young[1], Joseph Winer[1], America Romero[1], Hillary Vossler[1], Jennifer Park[1], Sharon Sha[1], Deutch Gayle[1], Wilson Edward[1], Anthony Wagner[1], Irina Skylar-Scott[1]

[1]Stanford University, Palo Alto, United States, [2]San Jose State University, , United States

P137 Blood Pressure and Amyloid-Related Imaging Abnormalities During Anti-Amyloid Therapy: An Exploratory Meta-Analysis

Presenteur : Sarah Ackley

Sirui Zhang, Michelle Caunca, Michael Flanders, Kaleen Hayes, Sarah Ackley

Brown University, Providence, United States

P138 Frailty is associated with faster clinical progression in early symptomatic Alzheimer's disease: implications for anti-amyloid therapy

Presenteur : Nicholas Vogt

Nicholas Vogt[1, 2, 3], Heidi Jacobs[4, 5], Wai-Ying Wendy Yau[6, 7], Alvaro Pascual-Leone[1, 2, 7], Daniel Press[8, 3], Dae Hyun Kim[1, 9, 3]

[1]Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, United States, [2]Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States, [3]Department of Medicine, Harvard Medical School, Boston, United States, [4]Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, United States, [5]Department of Radiology, Harvard Medical School, Boston, United States, [6]Department of Neurology, Massachusetts General Hospital, Boston, United States, [7]Department of Neurology, Harvard Medical School, Boston, United States, [8]Beth Israel Deaconess Medical Center, Boston, United States, [9]Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States

P139 Variability in mild cognitive impairment incidence rates across study populations

Presenteur : Emmanuel Papadakis

Emmanuel Papadakis, Jeremiah Aakre, Jonathan Graff-Radford, Mary Machulda, Prashanthi Vemuri, Sophia Graff-Radford, Clifford Jack Jr, David Knopman, Maria Vassilaki, Ronald Petersen

Mayo Clinic, Rochester, United States

P140 Reciprocal Associations Between Alzheimer's Disease and Colorectal Cancer in Older Adults: A Real-World Cohort Analysis With Evaluation of Competing Mortality

Presenteur : Yuji Zhang

Yuji Zhang, Kathryn Barry, Sally Adebamovo, Michelle Shardell

University of Maryland Baltimore, Baltimore, United States

P141 Roles of coagulation factors targeted by existing or potential anticoagulants in Alzheimer's disease: Mendelian randomization study

Presenteur : Man Ki Kwok

Man Ki Kwok[1], Ian Chi Kei Wong[2], Stephen Burgess[3], Pak Chung Sham[2]

[1]Hong Kong Metropolitan University, , Hong Kong, [2]The University of Hong Kong, , Hong Kong, [3]University of Cambridge, , United Kingdom

P142 Physical Activity and Domain-Specific Cognitive Function in Older Adults by Hypertension Status: A Longitudinal Analysis of the Health and Retirement Study Harmonized Cognitive Assessment Protocol

Presenteur : Mohammad Moniruzzaman

Mohammad Moniruzzaman, Kelvin Choi

National Institute on Minority Health and Health Disparities, Bethesda, United States

P143 A Bayesian Data-Integration Framework for Estimating Diagnosed and Undiagnosed Dementia Burden at the County and State Level

Presenteur : Carolina Franco

Carolina Franco, Gianattasio Kan, Rein David

NORC at the University of Chicago, Dunkirk, United States

P144 Systemic inflammation and longitudinal trajectory of cognition and blood-based biomarkers of Alzheimer's Disease in a multiethnic community-based cohort

Presenteur : Yian Gu

Yian Gu, Lawarence Honig, Kang Min Suk, Sanchez Danurys, Reyes-Dumeyer Dolly, Manly Jennifer, Brickman Adam, Mayeux Richard

Columbia University, New York, United States

P145 Population-Adjusted Alzheimer's Clinical Trial Capacity in the United States: Reassessing the Perception of Site Saturation in High-Burden States

Presenteur : Sean Stanton

Sean Stanton, Sameer Saddiqui, Taylor Rice, Brandon Lenox, Craig Curtis
K2 Medical Research, Orlando, United States

P146 Pathology-Informed Polygenic Scores Identify Distinct Genetic Contributors to Alzheimer's and Non-Alzheimer's Dementia Across Ancestries

Presenteur : Yuexuan Xu

Yuexuan Xu[1], Tamil Gunasekaran[1], Yian Gu[1], Lawrence Honig[1], Jennifer Manly[1], Adam Brickman[1], Corinne Engelman[2], Sterling Johnson[2], Sid O'Bryant[3], Caghan Kizil[1], Badri Vardarajan[1], Richard Mayeux[1]
[1]Columbia University, New York, United States, [2]University of Wisconsin-Madison, Madison, United States, [3]University of North Texas Health Science Center, Fort Worth, United States

P147 The effect of herpes zoster vaccination on full-time care use in people with and without cognitive complaints: a causal inference study using Swedish record-linkage data

Presenteur : Pieter Van Der Veere

Pieter Van Der Veere[1], Emil Aho[1], Johansson Naimi[1], Lövheim Hugo[2], Jönsson Linus[1]
[1]Karolinska Institutet, Stockholm, Sweden, [2]Umeå University, Umeå, Sweden

P148 Characterization of Serious ARIA Events from Approved Amyloid Antibodies: Real World Analysis of Spontaneous Reports FDA Adverse Event Monitoring System (AEMS)

Presenteur : Soeren Mattke

Soeren Mattke[1], Tabasa Ozawa[1], Susan Abu-Shakra[2], John Hey[2]
[1]University of Southern California, , United States, [2]Alzheon, , United States

P149 Time Savings and Patient Preference for Subcutaneous Injection Versus Intravenous Infusion of Lecanemab

Presenteur : Cara Leahy

Cara Leahy[1], Victor Faradji[2], Lara Marcel[2], Feride Frech[3], Hideki Toyosaki[3], Dean Smith[4]
[1]Memorial Healthcare Institute for Neuroscience, Owosso, United States, [2]First Choice Neurology and Visionary Investigators Network (VIN), Miami, United States, [3]Eisai Inc., Nutley, United States, [4]School of Public Health, University of Michigan, Ann Arbor, United States

P150 Peri-infusion Blood Pressure Reactivity as a Non-Invasive Marker of Cerebrovascular Amyloid Burden during Lecanemab Treatment in Early Alzheimer's Disease

Presenteur : So Yeon Jeon

So Yeon Jeon[1], Byung-Hyug Choi[1], Jung Hwan Kim[2], Yu Kyeong Kim[1], Jun-Young Lee[1]
[1]SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of, [2]Seoul National University College of Medicine, Seoul, Korea, Republic of

P151 The population-level impact of herpes zoster vaccination on dementia-related and all-cause mortality: Evidence from country-wide death certificate data for England

Presenteur : Pascal Geldsetzer

Felix Michalik[1], Disser Michelle[1], Seunghun Chung[1], Min Xie[1], Markus Eyting[1], Mark Joy[2], Simon De Lusignan[2], Aziz Sheikh[2], Pascal Geldsetzer[1]
[1]Stanford University, Stanford, United States, [2]Oxford University, Oxford, United Kingdom

P152 Clinical Practice Outcomes with Lecanemab for Alzheimer's Disease

Presenteur : Andy Liu

Andy Liu
Duke University, Durham, North Carolina, United States

P153 Updated Results from a Post-Marketing Observational Study of Lecanemab in Japan

Presenteur : Atsushi Iwata

Atsushi Iwata[1], Sakata Yukinori[2], Koizumi Kinuyo[2], Kanekiyo Michio[3], Dhadda Shobha[3], Endo Akira[2], Kuang Weijie[2], Sakamoto Yusuke[2], Sumitomo Kenta[2], Ishii Mika[2], Iwatsubo Takeshi[4]
[1]Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [2]Eisai Co., Ltd., Tokyo, Japan, [3]Eisai Inc., New Jersey, United States, [4]National Center of Neurology and Psychiatry, The University of Tokyo Hospital, Tokyo, Japan

P154 Ambient fine particulate matter and the incidence of Alzheimer's disease dementia in a nationwide time-varying cohort of 150,836 Korean dementia care center registrants: the association reverses after adjustment for nitrogen dioxide

Presenteur : Sun Min Lee

Sun Min Lee[1, 2], Areum Kim[2], Gaeun Kim[2], Jiwon Ju[2], Im Seok Koh[1, 2]
[1]Department of Neurology, National Medical Center, Seoul, Korea, Republic of, [2]National Institute of Dementia, National Medical Center, Seoul, Korea, Republic of

P155 Burden Profiles by Caregiver Sex Among Hospice-Eligible Persons Living with Dementia: A Secondary Analysis of the LiBBY Phase II Trial

Presenteur : Leah Pulinat

Ava Wagner[1], Leah Pulinat[1], Brenda Armenta[2], Rema Raman[2], Kelly McCann[1], Jacobo Mintzer[3], Brigid Reynolds[1]
[1]Georgetown University, Washington, DC, United States, [2]University of Southern California, San Diego, United States, [3]The Medical University of South Carolina, Charleston, SC, United States

P156 Midlife alcohol intake and later-life amyloid burden according to APOE ε4 status

Presenteur : Manjae Kwon

Manjae Kwon[1, 2], Eosu Kim[2], John Gallacher[1], Sarah Bauermeister[1]
[1]Department of Psychiatry, University of Oxford, Oxford, United Kingdom, [2]Yonsei University College of Medicine, Seoul, Korea, Republic of

P157 Undetected Diabetes, Glycemic Status and Cognitive Outcomes in Hispanic/Latino Adults in Southern California: Baseline Findings from SERVE OC

Presenteur : Alissa Kurzman-Wecht

Alissa Kurzman-Wecht[1], Jeffrey Wing[2], Aryanna Chavez[1], Xueting Ding[1], Megan Castro[1], Desiree Gutierrez[1], Cassandra Cardenas[1], Stephania Tovar Vargas[1], Matthew Landry[3], Bernadette Boden-Albala[1, 4, 5]
[1]Department of Health, Society, and Behavior, Joe C. Wen School of Population & Public Health, University of California, Irvine, Irvine, United States, [2]Division of Epidemiology, College of Public Health, Ohio State University, Columbus, United States, [3]Department of Global Health and Biobehavioral Sciences, Joe C. Wen School of Population & Public Health, University of California, Irvine, Irvine, United States, [4]Department of Neurology, School of Medicine, University of California, Irvine, Irvine, United States, [5]Department of Epidemiology & Biostatistics, Joe C. Wen School of Population & Public Health, University of California, Irvine, Irvine, United States

P158 Limited social connection and dementia risk: candidate biological processes with therapeutic implications

Presenteur : Chao-Yi Wu

Chao-Yi Wu, Pia Kivisäkk, Hiroko Dodge, Steven Arnold
Massachusetts General Hospital, Harvard Medical School, Charlestown, United States

P159 Age-Specific Probabilities of Amyloid-PET Positivity Across Racial and Ethnic Groups: Results from HABS-HD

Presenteur : Michael Flanders

Michael Flanders[1], Michelle Caunca[2], Sarah Ackley[1]
[1]Brown University, Providence, United States, [2]UCSF, San Francisco, United States

P160 Combined slow gait and subjective cognitive decline and long-term adverse health outcomes in adults aged 66 years: A nationwide cohort study

Presenteur : Seon Young Ryu

Seon Young Ryu[1], Sojeong Park[2], Jiwoo Yun[2]
[1]The Catholic University of Korea, Daejeon St. Mary's Hospital, Daejeon, Korea, Republic of, [2]Hanmi Pharm. Co., Ltd, Seoul, Korea, Republic of

P161 Non-Melanoma Skin Cancer, but Not Systemic Cancer History, Is Associated with Faster Plasma P-tau217 Accumulation and Cognitive Decline in Cognitively Unimpaired Older Adults: A Longitudinal ADNI Analysis

Presenteur : Micah Tratt

Micah Tratt, Daniel Gillen, Joshua Grill
Institute for Memory Impairments and Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, Irvine, United States

P162 Stronger Association of PM2.5 Exposure with Early-Onset Alzheimer's Disease and Distinct Vulnerability Profiles: A Nationwide 16-Year Cohort Study with Supporting Evidence from iPSC-Derived Neurons

Presenteur : Hee Jin Kim

Daeun Shin[1], Suna Kang[2], Hyo Jin Son[1], Danbee Kang[1], Hee Jin Kim[1]
[1]Samsung Medical Center, Seoul, Korea, Republic of, [2]Korea Environment Institute, Sejong, Korea, Republic of

P163 From Diuresis to Dementia Prevention: How Carbonic Anhydrase Inhibitors May Modulate Dementia Risk in Glaucoma Patients

Presenteur : Rachel Dolan

Rachel Dolan[1], Reagan McGinley[2], Estevao Ribeiro[3], Andrew Melson[4], Claire Delpirou Nouh[5]

[1]University of Oklahoma College of Medicine, University of Oklahoma Health Campus, Oklahoma City, United States, [2]Baylor College of Medicine, Houston, United States, [3]Department of Neurology, University of Oklahoma Health Campus - Oklahoma City (United States), Oklahoma City, United States, [4]Dean McGee Department of Ophthalmology, University of Oklahoma Health Campus, Oklahoma City, United States, [5]Department of Neurology, University of Oklahoma Health Campus, Oklahoma City, United States

P164 Distinct Temporal Profiles of ARIA Subtypes During Donanemab Treatment: Real-World Experience from a Japanese Single-Center Cohort

Presenteur : Taro Bannai

Taro Bannai[1], Ryoko Ihara[1, 2], Masanori Kurihara[1, 2], Ryosuke Shimasaki[1, 2, 3], Keiko Hatano[1], Fumio Suzuki[4], Aya Midori Tokumaru[4], Toshiaki Akashi[4], Kenji Ishii[2, 5], Atsushi Iwata[1, 2]

[1]Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [2]Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [3]Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, [4]Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [5]Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P165 Sex-Divergent Plasma Proteomic Alterations and cognitive profiling in Bone-Related Pathways Across the Alzheimer's Disease

Presenteur : Vidyani Suryadevara

Vasudha Kannan[1], Rohit Suresh[2], Vidyani Suryadevara[3]
[1]Department of Biotechnology, Indian Institute of Technology Madras, Chennai, India, [2]All India Institute of Medical Sciences, Delhi, India, [3]Department of Genetics, Stanford University, Stanford, United States

P166 Sex matters in Alzheimer's disease: Gaps and recommendations for clinical trials

Presenteur : Gillian Coughlan

Gillian Coughlan[1, 2], Jill M. Goldstein[3, 4], Roberta D. Brinton[5], Kristine Yaffe[6], Emily G. Jacobs[7, 8], Roberta Marongiu[9], Kathryn G. Schubert[10], Heather Snyder[11], Jessica Z. K. Caldwell[12], Anna Chodos[6], Michelle Mielke[13], Lindsay R. Chura[14], Diana Slowiejko[15], Rachel Buckley[1, 2, 16]
[1]Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States, [2]Brigham and Women's Hospital, Boston, Massachusetts, United States, [3]Massachusetts General Hospital (MGH), Mass General Brigham Healthcare, and Harvard Medical School, Boston, Massachusetts, United States, [4]Innovation Center on Sex Differences in Medicine (ICON-X), Massachusetts General Hospital (MGH), Boston, Massachusetts, United States, [5]Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States, [6]University of California San Francisco, San Francisco, California, United States, [7]UC Santa Barbara, Santa Barbara, California, United States, [8]Ann S. Bowers Women's Brain Health Initiative, Santa Barbara, California, United States, [9]Weill Cornell Medicine, New York, New York, United States, [10]Society for Women's Health Research, Washington, Dc, United States, [11]Alzheimer's Association, Chicago, Illinois, United States, [12]University of Wisconsin-Madison, Madison, Wisconsin, United States, [13]Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States, [14]AARP, Washington, Dc, United States, [15]Genentech, Inc., South San Francisco, California, United States, [16]University of Melbourne, Melbourne, Victoria, Australia, Australia

P167 A common Alzheimer's disease-linked HLA-DRB1 genetic variant potentiates tau-associated microglial reactivity

Presenteur : João Pedro Ferrari-Souza

João Pedro Ferrari-Souza[1], Celia Bianco[1], Marco Antônio De Bastiani[2], Huan Li[1], Methasit Jaisa-aad[1], Giovanna Carello-Collar[2], Swarnali Dasgupta[1], Akhila Gundavelli[1], Srinija Alla[1], Jordan Marks[1], Bradley Hyman[1], Eduardo Zimmer[2], Sudeshna Das[1], Alberto Serrano-Pozo[1]
[1]Massachusetts General Hospital, Boston, United States, [2]Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

P168 APP-CTF accumulation: a key factor of APP dyshomeostasis in Alzheimer's disease

Presenteur : Alberto Lleo

Alberto Lleo, Sánchez-Aced Erika, Moya Borja, Sonia Siriri
Hospital Sant Pau, Barcelona, Spain

P169 Real-World Effects of Therapeutic Plasma Exchange With Albumin Replacement on Inflammatory Biomarkers Across the Alzheimer's Disease Continuum

Presenteur : Xavier Morato

Xavier Morato[1], Catherine Demos[2], Yahveth Cantero-Fortiz[1], Federico Casales[1], Emilio Alarcón-Martin[1], Oscar Bascuñana[1], Victoria Fernandez[1], Amanda Cano[1], Jordi Klamburg[1], Antonio Páez[3], Basilio Hernandez[3], Natalia Lopez Del Hoyo[3], Anu Mathew[3], Xavier Montalban[1], Mercè Boada[1]
[1]Ace Alzheimer Center Barcelona- Universitat Internacional de Catalunya (UIC), Barcelona, Spain, [2]Meso Scale Diagnostics, LLC., Rockville, United States, [3]Neuro-Innovation Hub, Grifols, Barcelona, Spain

P170 Computerized Olfactory Adaptive Training (COAT) Improves Hyperconnectivity in the Medial Temporal Lobe Networks in Patients with Mild Cognitive Impairments: a Randomized Clinical Trial

Presenteur : Evaristus A. Nwulia

Opeyemi Mercy Awofeso[1], Maria Hipolito[2], Ashley Vanmeter[3], Narayan Rai[2], Tamal Sadhukhan[2], Claudia Ivonne Mejía Mondragón[2], Haroon S Popal[1], Van Hecke Kinney[3], Rebecca Aitken[3], Adedoyin Kalejaiye[2], Vamsi Reddy[1], Jamal Monger[1], Charles Nwaokobia[1], Thomas Obisesan[2], Evaristus A. Nwulia[1]
[1]Evon Medics, Ellicott City, United States, [2]Howard University, Washington Dc, United States, [3]Georgetown University Medical CenterEvon Medics, Washington Dc, United States

P171 Topline results of a Phase IV trial of EGb761 in patients with Mild Cognitive Impairment: ACE-2020-EGb761

Presenteur : Xavier Morato Arus

Xavier Morato Arus[1], Marta Marquié[1], Juan Pablo Tartari[1], Asunción Lafuente[1], Marai Eugenia Sáez[2], Sara Jofresa[1], Laia Montoliu-Gayà[3], Marta Ibarria[4], Susana Diego[4], Mar Buendia[4], Nuria Aguilera[4], Natalia Tantinya[4], Laia Cañada[4], Pilar Sanz[4], Mercè Boada[4]
[1]Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain, [2]3CAEBI, Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain, [3]University of gothenburg, Mölndal, Sweden, [4]Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Sweden

P172 Modulation of Fibronectin-1 Restores Blood-Brain Barrier Integrity and Gliovascular Signaling in APOE 4-Associated Alzheimer's Disease

Presenteur : Caghan Kizil

Prabesh Bhattarai[1], Elanur Yilmaz[1], Tal Nuriel[2], Badri Vardarajan[1], Richard Mayeux[1], Caghan Kizil[1]
[1]Department of Neurology, Columbia University Irving Medical Center, New York City, United States, [2]Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York City, United States

P173 Neurogenesis Hypothesis: Evidence from Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease

Presenteur : Lloyd Tran

Lloyd Tran, Fern Vu, Zung Tran
Biomed Industries, Inc., San Jose, United States

P174 Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases: Clinical Evidence from NA-831 for Alzheimer's Disease, NA-931 for Obesity, and NA-911 for Ischemic Stroke

Presenteur : Lloyd Tran

Lloyd Tran, Fern Vu, Zung Tran
Biomed Industries, Inc., San Jose, United States

P175 Outpatient therapeutic plasma exchange with albumin replacement via peripheral access in Alzheimer's disease: real-world safety and feasibility in a single-center cohort from ACE Alzheimer Center Barcelona

Presenteur : Mercè Boada

Mercè Boada[1, 2], Yahveth Cantero-Fortiz[1, 2], Federico Casales[1], Sergi Valero[1], Genis Carrasco[1], Oscar Bascuñana[1], Berta Calm[1], Adrián Hinojosa[1], Emilio Alarcón-Martín[1], Amanda Cano[1], Victoria Fernández[1], Xavier Morató[1], Antonio Paéz[3], Basilio Hernández[3], Xavier Montalban[1, 4]
[1]Ace Alzheimer Center Barcelona- Universitat Internacional de Catalunya (UIC), Barcelona, Spain, [2]Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III,, Madrid, Spain, [3]Neuro-Innovation Hub, Grifols, Barcelona, Spain, [4]Universitat de Vic-central de Catalunya (UVic-UCC)4, Barcelona, Spain

P176 Therapeutic plasma exchange with albumin replacement via peripheral access in Alzheimer's disease: real-world evidence on cognitive outcomes in a single-center cohort from ACE Alzheimer Center Barcelona

Presenteur : Mercè Boada

Mercè Boada[1, 2], Yahveth Cantero-Fortiz[1, 3], Federico Casales[1], Sergi Valero[1], Genis Carrasco[1], Oscar Bascuñana[1], Berta Calm[1], Adrián Hinojosa[1], Emilio Alarcón-Martín[1], Amanda Cano[1], Victoria Fernández[1], Xavier Morató[1], Antonio Paéz[4], Natalia Lopéz Del Hoyo[1], Xavier Montalban[1, 5]
[1]Ace Alzheimer Center Barcelona- Universitat Internacional de Catalunya (UIC), Barcelona, Spain, [2]Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III,, Madrid, Spain, [3]Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, [4]Neuro-Innovation Hub, Grifols, Barcelona, Spain., Barcelona, Spain, [5]Universitat de Vic-central de Catalunya (UVic-UCC), Barcelona, Spain

P177 Concept for a Trial of Immunomodulatory Therapy with BCG to Prevent Progression of Preclinical Alzheimer's Disease

Presenteur : Pierre Tariot

Pierre Tariot[1], Inga Antonsdottir[2], Steven Arnold[3], Nicholas Ashton[4], William Bishai[2], Corey Casper[5], Marisa Denkinger[6], Denise Faustman[3], Pascal Geldsetzer[7], Tiffany Hensley-Mcbain[8], Joe Jiang[9], Jennifer Knox[1], Donald Lamm[10], Jeremy Pruzin[1]
[1]Banner Alzheimer's Institute, Phoenix, United States, [2]Johns Hopkins Medicine, Baltimore, United States, [3]Mass General Brigham, Boston, United States, [4]Banner Sun Health Research Institute, Phoenix, United States, [5]Banner Health, Phoenix, United States, [6]Banner Sun Health Research Instituter's Institute, Phoenix, United States, [7]Stanford Medicine, Palo Alto, United States, [8]McLaughlin Research Institute, Great Falls, United States, [9]DFnet, Seattle, United States, [10]University of Arizona, Phoenix, United States

P178 Dissociated MAS1 Receptor and Effector Expression Identifies a Failed Compensatory State in Human Vascular Cognitive Impairment: Implications for Therapeutic Strategy

Presenteur : Meredith Hay

Meredith Hay
University of Arziona, Tucson, United States

P179 Site Engagement Within a Centralized Recruitment, Engagement, and Retention Framework: The Alzheimer's Clinical Trials Consortium Experience

Presenteur : Taylor Clanton

Taylor Clanton[1], Marina Ritchie[1], Doris Molina-Henry[1], Crystal Glover[2], Paul Aisen[1], Reisa Sperling[3, 4], Joshua Grill[2], Rema Raman[1]
[1]Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [2]University of California, Irvine, Irvine, United States, [3]Department of Neurology, Harvard Medical School, Boston, United States, [4]Brigham and Women's Hospital, Boston, United States

P180 Feasibility of a multidomain intervention combining Reduced carbohydrate intake, Omega-3 fatty acids, MCT supplementation, and EXercise in older adults at risk of Alzheimer's disease: the ROMEX-AD trial.

Presenteur : Melanie Fortier

Melanie Fortier[1], Christian Bocti[1], Mark Espeland[2], Matthew Phillips[3], Karl Fernandes[1], Stephen Cunnane[1]
[1]Research Center on Aging and Department of Medicine, Université de Sherbrooke, Sherbrooke, Canada, [2]Wake Forest University School of Medicine, Winston-Salem, United States, [3]Department of Neurology, Waikato Hospital, Hamilton, New Zealand

P181 Prevention of Alzheimer's Disease with a novel class of CNS-penetrant anti-inflammatory drugs

Presenteur : Victor Shifrin

Victor Shifrin[1], Linda Van Eldik[2]
[1]ImmunoChem Therapeutics, LLC, Newton, MA, USA; [2]University of Kentucky, Lexington, KY, USA

P182 Phase 1 Clinical Development Strategy for PNA5 in VCID: Translational Biomarkers, Neurovascular Mechanisms, and SAD/MAD Design

Presenteur : Meredith Hay

Meredith Hay, Tamara Crockett
ProNeurogen, Inc, Tucson, United States

P183 Is cerebral Aβ42-amyloidosis (CAB42-A) a more appropriate labelling for asymptomatic patients than Alzheimer's disease?

Presenteur : Michaela Defrancesco

Michaela Defrancesco
Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria, Innsbruck, Austria

P184 Treatment of age-related upstream bioenergetic and redox impairment promotes clearance of A and tau aggregates, lowers oxidative nitration and promotes synapse formation in isolated neurons from AD mouse models

Presenteur : Gregory Brewer

Gregory Brewer[1], Svara Shah[1], Ricardo Santana[2]
[1]UC Irvine, Irvine, United States, [2]UNAM, Mexico City, Mexico

P185 Pipeline Diversification and Emerging Therapeutic Hypotheses in Alzheimer's Disease

Presenteur : Laurentiu Gutiu

Laurentiu Gutiu[1], Abby Fuller[2], Antoniya Todorova[3]
[1]Fortrea Germany GmbH, Munich, Germany, [2]Fortrea Inc., Durham, United States, [3]Fortrea Belgium SRL, Brussels, Belgium

NON-PHARMACOLOGIC INTERVENTIONS

P186 Cognitive Benefits of a Multidomain Lifestyle Intervention Across Baseline Physical Function Levels in Older Adults with Mild Cognitive Impairment: A Secondary Analysis of the SUPERBRAIN-MEET Randomized Controlled Trial

Presenteur : So Young Moon

So Young Moon[1], Da Ae Kim[1], Seong Hye Choi[2]

[1]Ajou university school of medicine, Suwon, Korea, Republic of, [2]Inha University Hospital, Incheon, Korea, Republic of

P187 Personalized digital intervention is associated with greater adherence to brain-healthy lifestyle recommendations, with additional benefit from motivational coaching

Presenteur : Javier Solana-Sánchez

Javier Solana-Sánchez[1], Maria Ortuño-Saavedra[1], Simon Fankhauser[1], David Bartrés-Faz[2], Paloma Chausa[3], Diego Moreno-Blanco[3], Gemma Albi-Villuendas[1], Marta Alvarez-Ambrosio[3], Ignacio Oropesa[3], Patricia Sánchez-González[3], Enrique Gómez[3], Gabriele Cattaneo[1]

[1]Guttmann Hospital de Neurorehabilitació, Institut Universitari adscrit a la UAB, Barcelona, Spain, [2]Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain, [3]Biomedical Engineering and Telemedicine Centre, ETSI Telecomunicación, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain

P188 Primary endpoint evaluation of ultra-high frequency visual stimulation intervention on episodic memory impairment in Alzheimer's disease

Presenteur : Julian Keil

Julian Keil[1], Maria Buthut[2], Ravit Hadar[1], Jana Fass[3], Liam Doherty[1], Jakob Litsch[1], Victor Hernandez-Urbina[1], Fabian Queisner[1], Markus Müschenich[1], Surjo Soekadar[2]

[1]Nuuron GmbH, Berlin, Germany, [2]Charité – Universitätsmedizin Berlin, Berlin, Germany, [3]Medical School Berlin, Berlin, Germany

P189 Lifestyle change and relationship of modifiable factors with cognition in women at risk for Alzheimer's disease

Presenteur : Jessica Kirkland Caldwell

Jessica Kirkland Caldwell[1], Taylor Levine[2], Nikki Kaplan[2], Emily Post[2], Zhi Baker[2], Sandra Darling[3], Shehroo Pudumjee[2]

[1]University of Wisconsin Madison, Madison, United States, [2]Cleveland Clinic Nevada, Las Vegas, United States, [3]Cleveland Clinic, Cleveland, United States

P190 Mind-Body Interventions for Individuals with Subjective Cognitive Decline: Feasibility, Acceptability, and Preliminary Effects on Blood Based Biomarkers of Amyloid and Tau Pathology

Presenteur : Ruchika Prakash

Ruchika Prakash[1], Quinn Meyerson[1], Madhura Phansikar[1, 2], Elise Grant[1, 3], Megan Fisher[1, 4], A. Cordova[1], Sarah Dove[1], Rond Malhas[5], James Teng[1], Nevyana Todorova[1], Ninette Simonian[1], Elizabeth Head[5], Rebecca Andridge[1], Kathy Wright[1], Doug Scharre[1]

[1]The Ohio State University, Columbus, United States, [2]Eastern Illinois University, Charleston, United States, [3]Ohio University, Athens, United States, [4]University of California at Los Angeles, Los Angeles, United States, [5]University of California at Irvine, Irvine, United States

P191 Adherence as a Moderator of Cognitive Benefit in a Digital, Person-Centred Multidomain Lifestyle Intervention Trial

Presenteur : Yen Ying Lim

Catherine Robb[1], Emily Rosenich[1], Paul Maruff[2], Yen Ying Lim[1]

[1]Monash University, Melbourne, Australia, [2]Cogstate Ltd, Melbourne, Australia

P192 Digital Cognitive Behavioral Therapy for Insomnia in Older Adults with Mild Cognitive Impairment: Results from the SHUTi MIND Phase IIb Randomized Controlled Trial

Presenteur : Meghan Mattos

Meghan Mattos[1], Wen You[1], Carol Manning[1], Jennifer Lingler[2], Kirsten Macdonnell[1], Naveen Abedin[1], Lee Ritterband[1]

[1]University of Virginia, Charlottesville, United States, [2]University of California- Davis, Sacramento, United States

P193 Psychosocial outcomes after learning APOE and pTau-217 results: Findings from the eSMARTER trial

Presenteur : Claire Erickson

Claire Erickson[1], Angela Bradbury[2], Brian Egleston[3], Carolyn Langlois[1], Elisabeth McCarty Wood[2], Kristin Harkins[2], Emily Largent[2], J. Scott Roberts[4], Eric Reiman[1], Marisa Denkinger[1], Nicholas Ashton[1], Jason Karlawish[2], Jessica Langbaum[1]

[1]BAI, Phoenix, United States, [2]UPenn, Philadelphia, United States, [3]Temple, Philadelphia, United States, [4]UMich, Ann Arbor, United States

P194 Plasma Proteomics Identifies a Two-Signal Synaptic Preservation Signature Associated with Cognitive Benefit in the FINGER Trial

Presenteur : Adrian Noriega De La Colina

Adrian Noriega De La Colina[1, 2, 3], Arvid Gollwitzer[1, 4], Anna Matton[5], Francesca Mangialasche[5], Li-Huei Tsai[6], Alina Salomon[5, 7, 8], Tiia Ngandu[5, 7], Giovanni Traverso[9, 2, 10, 11], Miia Kivipelto[12, 13]

[1]Broad Institute of MIT and Harvard, Cambridge, United States, [2]Massachusetts Institute of Technology, Cambridge, United States, [3]Brigham and Women's Hospital, Boston, United States, [4]Massachusetts Institute of Tecnology, Cambridge, United States, [5]Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden, [6]The Picower Institute for Learning and Memory, MIT, Camridge, United States, [7]Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland, [8]FINGERS Brain Health Institute,, Stockholm, Sweden, [9]Broad Institute of MIT and Harvard, Solna, Sweden, [10]Divison of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School , Cambridge, United States, [11]Koch Institute for Integrative Cancer Research, MIT, Cambirdge, United States, [12]Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden, [13]FINGERS Brain Health Institute, Stockholm, United States

P195 BRIGHT-Mind Study: A Prospective, Randomized Trial of Digital Cognitive Training Effects on Cognitive, Functional and Imaging Outcomes

Presenteur : Robert John Schafer

Robert John Schafer[1], Kevin Madore[1], Kelly Hennigan Macniven[2], John G. Nadra[3], Preston P. Thakral[4], P. Murali Doraiswamy[5]

[1]Lumos Labs, Inc., San Francisco, United States, [2]Independent, San Francisco, United States, [3]Michigan State University, East Lansing, United States, [4]Department of Psychology, Smith College, Northampton, United States, [5]Duke University School of Medicine, Durham, United States

P196 Non-Pharmacological Interventions for Dementia Prevention in Cognitively Unimpaired Adults at Elevated Risk: A Scoping Review

Presenteur : Julie Oomens

Julie Oomens[1], Dandi Chen[1], Samira Maboudian[1], Mai Abdelmoaty[2], Joyce Chong[1], Jessica Kirkland Caldwell[1]

[1]Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States, [2]Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States

P197 Mood and Cognitive Outcomes of a Mindfulness Based Intervention in Veterans with Mild Cognitive Impairment: A Pilot Randomized Trial

Presenteur : Heera Kamaraj

Heera Kamaraj[1, 2], Kathy Xie[1, 2], Sarah Harer[1, 2], Brenna Hagan[2], Meltem Karaca[3], Sofia Angelini[1], Brandon Frank[1, 4], Andrew Budson[1, 4], Katherine Turk[1, 4]

[1]Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, United States, [2]Alzheimer's Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, United States, [3]Assumption University, Worcester, United States, [4]lzheimer's Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, United States

P198 Faster is Better: Modifiable Risk Factors for Alzheimer's Disease & Dementia in the ACTIVE Study

Presenteur : Hyunkyu Lee

Hyunkyu Lee[1], Karlene Ball[2], Henry Mahncke[1]

[1]Posit Science, [2]UNIVERSITY OF ALABAMA AT BIRMINGHAM

P199 Early Detection of cognitive Decline and Dementia prevention in women: the 3D study protocol

Presenteur : Salvatore Mazzeo

Salvatore Mazzeo[1, 2], Federico Emanuele Pozzi[1], Elisa Bortolin[1, 2], Giulia Bruschi[1, 2], Arianna Frijo[1], Alessandro Bombaci[1, 2], Gianni Cutillo[1, 2], Eleonora Ferrante[1], Laura Renna[3], Rosanna Cardani[3], Massimo Filippi[4], Maria Salsone[1, 2]

[1]Neurology Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy, [2]Vita-Salute San Raffaele University,, Milan, Italy, [3]BioCor Biobank, IRCCS Policlinico San Donato, San Donato Milanese, Italy, [4]Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy

P200 PodCaring: Investigating the Feasibility and Efficacy of the Dementia Untangled Podcast for Caregivers and Patients with Early-Stage Cognitive Impairment

Presenteur : Jasmine Zhang

Jasmine Zhang[1], Heather L. Mulder[2], Nellie M. High[2], Robert J. Bauer[2], Jennifer C. Knox[2], Yinghua Chen[2], Lori Nisson[2], Jessica B. Langbaum[2], Amber D. Ayers[3], Matthew J. Huentelman[4], David Coon[5], Jeremy J. Pruzin[2]

[1]University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, United States, [2]Banner Alzheimer's Institute, Phoenix, Arizona, United States, [3]Banner Alzheimer's Institute, Tucson, Arizona, United States, [4]Translational Genomics Research Institute, Phoenix, Arizona, United States, [5]Arizona State University Edson College of Nursing and Health Innovation, Phoenix, Arizona, United States

P201 VR&R Trial: Interim Results on the Use of Virtual Reality to Support Caregiver Respite in Dementia Care

Presenteur : Sahil Patel

Vanessa Geitz[1], Samantha Lewis-Fung[1], Sahil Patel[2], Mattaya Pallett[1, 3], Essete Tesfaye[1], Lora Appel[1, 2]

[1]University Health Network, Toronto, Canada, [2]York University, Toronto, Canada, [3]Humber Polytechnic, Toronto, Canada

P202 Can Menopausal Status Moderate the Effects of Aerobic Exercise on Executive Functions? Evidence from a Randomized Controlled Trial

Presenteur : Michal S. Beeri

Sharon Sanz Simon[1], Maya Gal[2], Seonjoo Lee[3], Marcella D. Walker[3], Michal S. Beeri[1], Gloria Bachman[1], Vincenzo Lauriola[3], Richard Sloan[3], Yunglin Gazes[4]

[1]Rutgers University, New Jersey, United States, [2]Albert Einstein College of Medicine,, New York, United States, [3]Columbia University, New York, United States, [4]The Nathan Kline Institute for Psychiatric Research, New York, United States

P203 A Care Coach protocol for caregivers of persons with dementia (PWD) to help manage behavioral and psychological symptoms of dementia (BPSD).

Presenteur : Miriam Jocelyn Rodriguez

Miriam Jocelyn Rodriguez, Jacqueline Burnell, Sonia Cerezo, Vanessa Kercher, Jordan Hill, Richard Holden, Malaz Boustani

Indiana University, Bloomington, United States

P204 Factors contributing to retention in a mobile telehealth intervention trial for dementia caregivers.

Presenteur : Miriam Jocelyn Rodriguez

Miriam Jocelyn Rodriguez[1], Jordan Hill[1], Mariana Stavig[1], Roger Zoh[1], Anna Macagno[1], Agnis Duah[1], Malaz Boustani[2], Richard Holden[1]

[1]Indiana University, Bloomington, United States, [2]Indiana University, Indianapolis, United States

P205 Cognitive Effects, Adherence, and Acceptability of a 12-Week Mobile Cognitive Training Program in Mild Cognitive Impairment

Presenteur : Seungwon Chung

Seungwon Chung[1], Bori R. Kim[2], Geonha Kim[1]

[1]Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea, Republic of, [2]Ewha Medical Research Institute, Ewha Womans University, Seoul, Korea, Republic of

P206 Perceived Usefulness Mediates the Association Between Concern About Brain Health and Engagement in Brain Health Activities

Presenteur : Raymond L Ownby

Raymond L Ownby[1], Joshua Caballero[2]

[1]Nova Southeastern University, Fort Lauderdale, FL, United States, [2]University of Georgia, Athens, GA, United States

P207 Individualized LC-DLPFC Connectivity-Guided iTBS Improves Cognition in MCI: A Pilot Study

Presenteur : Gong Liang

Gong Liang

Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu, China

P208 Social Isolation as a modifiable determinant of physiological decline in midlife women: Translational implications for intrinsic capacity and healthspan

Presenteur : Christine Gierke

Christine Gierke[1, 2, 3, 4], Walthers Diaz-Gierke[5, 6], Carlos F. Navarro[7, 6], Paula Muñoz[8, 2], Montserrat Fernandez[9, 6], Nicolas Ferrer[10, 6], Martina Morales[6], Andrea Acevedo[6, 11], Alejandra Muñoz[6, 12], Gabriela Gutierrez[6], Valentina Jara[6, 13], Francisca Castillo[6, 14]

[1]Servicio de Neurología y Neurocirugía, Hospital Clinico Universidad de Chile (HCUCH), Santiago, Chile, [2]Social Isolation Research Center (SIRC) Chile, Santiago , Chile, [3]Escuela de Psicología, Universidad Diego Portales (UDP), Santiago , Chile, [4]Escuela de Psicología, Universidad San Sebastián (USS), Santiago, Chile, [5]Escuela de Psicología, Universidad Adolfo Ibañez (UAI), Santiago, Chile, [6]Social Isolation Research Center (SIRC) Chile, Santiago, Chile, [7]Depto. Ingeniería Electrica, Facultad de Ingeniería Universidad de Chile, Santiago, Chile, [8]Escuela de Psicologia, Universidad Academia de Humanismo Cristiano (UAHC), Santiago, Chile, [9]Centro Medico GLANDORF, Chihuahua, Mexico, [10]Escuela de Psicologia, Universidad de las Americas (UDLA), Santiago, Chile, [11]Escuela de Psicología, Universidad Autónoma de Chile, Santiago , Chile, [12]Escuela de Psicología, Universidad Santiago de Chile (USACH), Santiago, Chile, [13]FACSO, Universidad de Chile, Santiago , Chile, [14]FACSO, Universidad de Chile, Santiago, Chile

P209 Augmented Exercise Interventions: Optimizing Response to Exercise Modalities for Cognitive Enhancement in Early AD

Presenteur : Krista Lanctot

Krista Lanctot[1], Julian Schecter[1], Yejin Kang[1], Sandra Black[1], Nathan Herrmann[2], Sara Mitchell[1], Susan Marzolini[3], Paul Oh[3], Jennifer Rabin[1], Tarek Rajji[4], Mark Rapoport[1], Walter Swardfager[1], Mehreen Siddiqui[1], Kate Survilla[1], Damien Gallagher[1]

[1]Sunnybrook Research Institute, Toronto, Canada, [2]Department of Psychiatry, University of Toronto, Toronto, Canada, [3]KITE Research Institute, Toronto Rehabilitation Institute – University Health Network, Toronto, Canada, [4]Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, United States

P210 Neural substrates generating a gamma frequency response to 40Hz GENUS light and sound stimulation

Presenteur : Diane Chan

Diane Chan[1, 2], Ute Geigenmuller[1], Monica Zheng[1], Andrew Becker[1], Erika Ruiz[1], Remi Philips[1], Natalie Hahn[1], Aaron Boes[3, 4], Matthew Howard[3, 4], Eleonora Marcantoni[5], Simon Hanslmayr[5], Diego Vidaurre Henche[6, 7, 8], Emery Brown[1, 9], Edward Boyden[1], Li-Huei Tsai[1]

[1]MIT, Cambridge, United States, [2]AInylam, Cambridge, United States, [3]University of Iowa, Iowa City, United States, [4]Iowa Neuroscience Institute, Iowa City, United States, [5]Centre for Neurotechnology, Glasgow, United Kingdom, [6]Centre de Recerca Matematica, Barcelona, Spain, [7]University of Oxford, Oxford, United Kingdom, [8]Aarhus University, Aarhus, Denmark, [9]Massachusetts General Hospital, Boston, United States

P211 Differential Cognitive Responses to Active and Sham rTMS Combined with Cognitive Training in Early Alzheimer's Disease

Presenteur : Juyoun Lee

Juyoun Lee[1], Inho Lee[2], Kun Ho Kim[3], Ae Young Lee[1]

[1]Department of Neurology, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of, [2]Department of Radiology, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of, [3]Department of Nuclear Medicine, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of

P212 Impact of a Multidomain Lifestyle Intervention on Gut Microbiota: An Exploratory Sub-study of the SUPERBRAIN Trial

Presenteur : Seong Hye Choi

Seong Hye Choi[1], Jee Hyang Jeong[2], Yangki Minn[3], Woorim Kang[4], So Young Moon[5], Yoo Kyoung Park[6]

[1]Inha University College of Medicine, Incheon, Korea, Republic of, [2]Ewha Womans University School of Medicine, Seoul, Korea, Republic of, [3]Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea, Republic of, [4]Kangwon National University, Chuncheon, Korea, Republic of, [5]Ajou University School of Medicine, Suwon, Korea, Republic of, [6]Graduate School of East-West Medical Nutrition, Kyung Hee University, Yongin, Korea, Republic of

BIOMARKERS (CSF & PLASMA)

P213 An ultrasensitive immunoassay for cryptic HDGFL2 expression in CSF as a biomarker for TDP-43 nuclear loss of function

Presenteur : Sarah Shahub

Sarah Shahub[1], Alpana Singh[1], Marisa Denkinger[1], Antonia Demleitner[2], Laura Tzeplaeff[2], Kathryn Citrano[3], Vidhya Bharathi Maheswari Jawahar[4], Kari Dieckhoff[1], James Liu[1], Taina Marques[1], Kathryn Ghisays[1], Paul Lingor[2], Leonard Petrucelli[4], Nicholas Ashton[1]
[1]Banner Sun Health Research Institute, Sun City, United States, [2]Technical University of Munich, Munich, Germany, [3]Mayo Clinic, Jacksonville, United States, [4]University of Miami Miller School of Medicine, Miami, United States

P214 Quantitative Predicted Effects of Chronic Kidney Disease on Alzheimer's Disease Plasma Biomarkers and Biomarker Ratios

Presenteur : Joshua Bornhorst

Joshua Bornhorst[1], Chelsea Swartchick[1], Daniel Figdore[1], Susan Ashrafzadeh-Kian[1], Prashanthi Vemuri[1], Jonathan Graff-Radford[1], David Knopman[1], Micheal Griswold[2], Petrice Cogswell[1], Jack Jr CLIFFORD.[1], Ronald Petersen[1], Stephen Weigand[1], Alicia Algeciras-Schimnich[1]
[1]Mayo Clinic, Rochester, United States, [2]University of Mississippi Medical Center, Jackson, United States

P215 Clinical Verification of the Lumipulse Phosphorylated Tau 217/Amyloid Beta 42 Ratio Assay

Presenteur : Anna Mammel

Anna Mammel[1], Kelsey Hallett[1], Donald Biehl[1], Hans Frykman[1, 2, 3]
[1]Neurocode USA Inc., Bellingham, United States, [2]BC Neuroimmunology, Vancouver, Canada, [3]University of British Columbia, Vancouver, Canada

P216 Glycocalyx Blood Markers Predict and Monitor ARIA in Anti-Amyloid-Treated Patients: Convergent Evidence from BBB Imaging and Clinical Data

Presenteur : Brian DellaValle

Brian Dellavalle[1, 2, 3], Jeremy Ford[4], Mathias Lindh Jørgensen[1, 3], Luisa Knecht[1, 3], Rikke Brønnum Nielsen[1, 5], Tove Persson[1, 3], Richard Frank[6], Behnaz Khazai[4], Vlad V Senatorov Jr[7], Aaron R Friedman[7], Nicholas Schwartz[8, 9], Sarah Kremen[10], Oleg Yerstein[11, 12, 13], Lawren Vandevrede[9], Andreas Jeromin[6]
[1]GLX Analytix ApS, Copenhagen, Denmark, [2]GLX Analytix , Menlo Park, United States, [3]Copenhagen Center for Translational Research, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, [4]Mass General Brigham, Harvard Medical School, Boston, United States, [5]Copenhagen Center for Translational Research, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, [6]GLX Analytix, Menlo Park, United States, [7]Reservoir Neuroscience, Emeryville, United States, [8]University of Maryland Baltimore, Baltimore, United States, [9]Memory and Aging Center, Department of Neurology, University of California, San Francisco, United States, [10]Goldrich Center for Alzheimer's and Memory Disorders, Department of Neurology, Cedars-Sinai Health Sciences University, Los Angeles, United States, [11]Synapticure, Chicago, United States, [12]UMass Chan Medical School, Worcester, United States, [13]Tufts University School of Medicine, Boston, United States

P217 Age, APOE Status, Renal Function, Glycemia, and Prior Ischemic Stroke Associate With Baseline Plasma p-tau217 in BROADWAY.

Presenteur : Akash Patel

Akash Patel[1], Andrew Hsieh[2], Adam Johnson[2], Michael Davidson[2]
[1]University of Chicago, , United States, [2]NewAmsterdam Pharma, , United States

P218 Plasma Proteomics in APOE 4 Homozygotes Identifies a Central Role of the Immune System in Resilience and Susceptibility to Alzheimer's Disease

Presenteur : Erik Johnson

Eric Dammer, Shiva Afshar, Isabel Petrescu, Allan Levey, Erik Johnson
Emory University, Atlanta, United States

P219 Plasma p-tau217 above and below validated Alzheimer cutoffs in cardiovascular disease: between-range versus within-range determinants in BROADWAY.

Presenteur : Akash Patel

Akash Patel[1], Andrew Hsieh[2], Adam Johnson[2], Michael Davidson[2]
[1]University of Chicago, , United States, [2]NewAmsterdam Pharma, , United States

P220 Brain-Derived Plasma p-tau217 Lacks the HbA1c Association Observed With Conventional p-tau217 in American Indian Tribal Elders

Presenteur : William Mantyh

Rene Labounek[1], Matti Matheson[1], Annamarie Hill[1], Adam Block[1], Ashley Petersen[1], Adam Hansen[1], Meghan Kremer[1], Annie Roberston[1], Breton Asken[2], Danni Li[1], Igor Nestrasil[1], Christophe Lenglet[1], Corey Strong[3], Joseph Henderson[4], William Mantyh[1]
[1]University of Minnesota, Minneapolis, United States, [2]University of Florida, Gainsville, United States, [3]Bois Forte Band of Chippewa Health Services, Nett Lake, United States, [4]University of Minnesota Duluth, Duluth, United States

P221 Selective detection of BD-tau species improves the specificity of blood AD biomarkers and reduces confounding from peripheral tau sources

Presenteur : Markus Otto

Samir Abu-Rumeileh[1], Henning Grosskopf[1], Arthur Guthknecht[1], Alexander Mensch[1], Patrick Oeckl[2], Hans Klafki[3], Jens Wiltfang[3], Lutz Froelich[4], Lucrezia Hausner[4], Vincenzo Silani[5], Dietmar Thal[6], Jochen Weishaupt[2], Ingolf Lachmann[7], Federico Verde[5], Markus Otto[1]
[1]Martin Luther University, Department of Neurology, Halle (Saale), Germany, [2]University of Ulm, Ulm, Germany, [3]University of Goettingen, Goettingen, Germany, [4]ZI Mannheim, Mannheim, Germany, [5]IRCCS Istituto Auxologico Italiano, Milano, Italy, [6]Laboratory for Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, Leuven, Belgium, [7]Roboscreen, Leipzig, Germany

P222 NPTX2-Centered Interaction-State Proteomics in Cerebrospinal Fluid and Plasma Reveals Biofluid-Specific Signatures of Alzheimer's Disease

Presenteur : Paul Worley

Paul Worley[1], Chan Hyun Na[1], Kyungdo Kim[1], Meifang Xiao[1], Taekyung Ryu[1], Carol Barnes[2], Douglas Galasko[3], Jin Hyeok Kim[1]
[1]Johns Hopkins, Baltimore, United States, [2]University of Arizona, Tucson, United States, [3]UCSD, San Diego, United States

P223 Spectris treatment is associated with a coordinated plasma proteomic response: Module-level analysis from the OVERTURE feasibility study in mild-to-moderate Alzheimer's disease

Presenteur : Mihály Hajós

Mihály Hajós[1, 2], Saima Rathore[3], Allan Levey[3], Nicholas Seyfried[3], Duc Duong[3, 4], Anantharaman Shantaraman[3], Brennan Jackson[1], Miguel Hernandez[1], Nina Khera[1], Evan Hempel[1], Chandran Seshagiri1[1], Ralph Kern[1]
[1]Cognito Therapeutics Inc., Cambridge, United States, [2]Yale University Medical School, New Haven, CT, USA, New Haven, United States, [3]Emory University, Atlanta, United States, [4]Emtherapro Inc, Systems Biology, Atlanta, United States

P224 BEACON: A Future-Proof Neuropathological Validation Platform for Emerging Biomarkers of Proteinopathy

Presenteur : Colin Groot

Colin Groot, Ilse Bader, Rik Ossenkoppele, Coomans Emma
Amsterdam UMC, Amsterdam, The Netherlands

P225 Multimodal evaluation of a 5-plex blood-based biomarker panel for Alzheimer's disease

Presenteur : Andrea L. Benedet

Burak Arslan[1], Tevy Chan[2], Kubra Tan[1], Nesrine Rahmouni[2], Joseph Therriault[2], Tharick A. Pascoal[3], Nicholas J. Ashton[4], Henrik Zetterberg[1], Pedro Rosa-Neto[5], Andrea L. Benedet[1]
[1]University of Gothenburg, Gothenburg, Sweden, [2]McGill University, Montreal, Canada, [3]University of Pittsburgh, Pittsburgh, United States, [4]Banner Health Institute, Phoenix, United States, [5]UT Southwestern, Texas, United States

P226 — Remote Diagnostic accuracy of the automated Elecsys CSF A 42/A 40 ratio and A 42 in a population reflective of clinical practice

Presenteur : Myrto Andreadou

Myrto Andreadou[1], Cornelia Fuetterer[2], David Caley[3], Marc Suárez-Calvet[4, 5], Mercè Boada[6, 7], Kristian Steen Frederiksen[8, 9], David Watson[10]
[1]Roche Diagnostics International Ltd, Rotkreuz, Switzerland, [2]Roche Diagnostics GmbH, Penzberg, Germany, [3]Roche Diagnostics Ltd, Burgess Hill, United Kingdom, [4]Barcelona eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, [5]Servei de Neurologia, Hospital del Mar, Barcelona, Spain, [6]Ace Alzheimer Center Barcelona, International University of Catalunya, Barcelona, Spain, [7]Center for Biomedical Research Network on Neurodegenerative Diseases (CIBERNED), Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain, [8]Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark, [9]Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, [10]Alzheimer's Research and Treatment Center, Wellington, Fl, United States

P227 Temporal plasma proteomic responses to lecanemab and their associations with amyloid clearance and cognitive change: a multicentre, real-world cohort study

Presenteur : Sang Won Seo

Jun Pyo Kim[1], Bo Hyun Kim[1], Jungah Lee[1], Hee Jin Kim[1], Eun-Joo Kim[2], Henrik Zetterberg[3], Sang Won Seo[1]
[1]Samsung Medical Center, Seoul, Korea, Republic of, [2]Pusan National University Hospital, Busan, Korea, Republic of, [3]University of Gothenburg, Mölndal, Sweden

P228 Comparator Choice and Handling of Indeterminate Results in Reported Agreement and Confirmatory Testing for Plasma Amyloid Biomarkers: A Paired PET–CSF Study with PET-Anchored Thresholds

Presenteur : Khushboo Verma

Khushboo Verma[1], Satwant Kumar[2]
[1]University of Texas at Tyler, TYLER, United States, [2]Alzheimer Alliance of Smith County, TYLER, United States

P229 SLIM (Single-Arm Lead-In with Multiple Assessments): Optimizing Repeated Biomarker Assessments to Improve Statistical Power in Clinical Trials

Presenteur : Hiroko Dodge

Hiroko Dodge[1], Liu Chen[1], Chao-Yi Wu[1], Yan Gao[1], Gene Bowman[2], Howard Feldman[3], Steven Arnold[1]
[1]Department of Neurology, Interdisciplinary Brain Center, Massachusetts General Brigham, Harvard Medical School, Boston, United States, [2]Department of Neurology, McCance Center for Brain Health, Massachusetts General Brigham, Harvard Medical School, Somerville, United States, [3]San Diego School of Medicine, Alzheimer's Disease Cooperative Study at the University of California, La Jolla, United States

P230 Nasal Fluid Biomarkers from the Brain-Nose Interface as a Novel Minimally Invasive Tool for Alzheimer's Disease Research and Diagnosis

Presenteur : Matthias Langhorst

Xiao Feng[1], Mohammad Bashiri[1], Philipp E. Geyer[2], Sebastian Virreira Winter[2], Oliver Peters[3], Lutz Froelich[4], Jens Wiltfang[5], Timo J. Oberstein[6], Stefan Kotschote[1], Maria Babu[1], Marion San Nicoló[1], Matthias Langhorst[1], Sabine Mertzig[1], Mareike Albert[1]

[1]Noselab GmbH, Widenmayerstrasse 27, 80538, Munich, Germany, [2]ions.bio GmbH, Am Klopferspitz 19, 82152, Planegg, Germany, [3]Charité-Universitätsmedizin Berlin, Department of Psychiatry, Berlin, Germany, [4]Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, [5]Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August University, Von-Siebold Strasse 5, 37075, Goettingen, Germany, [6]Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany

P231 Treatment response biomarkers in early Alzheimer's disease: longitudinal trajectories, sample size estimates, and the impact of progression variability

Presenteur : Charlotte Teunissen

Marlies Oosthoek[1], Alida Leistra[1], Yanaika Hok-A-Hin[1], Michael Tanck[1], Tomohiro Okuda[2], Lisanne In 'T Veld[1], Azzam Aladdin[1], Pieter Van Bokhoven[1], Betty Tijms[1], Roos Jutten[1], Philip Scheltens[3], Everard Vijverberg[1], Charlotte Teunissen[1], Lisa Vermunt[1]

[1]Amsterdam UMC, Amsterdam, The Netherlands, [2]Toyama, Tokyo, Japan, [3]EQT Life Sciences, Amsterdam, The Netherlands

P232 Native cfDNA Methylation Profiling Identifies Cortical Neuron-Associated Signals in Alzheimer's Disease and Mild Cognitive Impairment

Presenteur : Isaac Stirland

Isaac Stirland

Renew Biotechnologies, Pleasant Grove, United States

P233 Minimizing false positive and indeterminate plasma pTau-217 results caused by impaired renal clearance with myelin oligodendrocyte glycoprotein

Presenteur : Hyun Kook Lim

Hyun Kook Lim[1], Yoo Hyun Um[1], Li Wang[2], Adheesha Danthanarayana[2], Sasi Mudumba[2], Henry Huang[2], Irene B Meier[3], Vaibhav A Narayan[3], Menghan Liu[4], Carlos Cruchaga[4], Sterling Johnson[5], Henrik Zetterberg[5], Steve Williams[2], Yuling Luo[2], Xiao-Jun Ma[2]

[1]The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of, [2]Alamar Biosciences,, Fremont, United States, [3]Davos Alzheimer's Collaborative, Geneva, Switzerland, [4]Washington University, St. Louis, United States, [5]The University of Wisconsin, Madison, United States

P234 Head-to-Head Comparison of Plasma pTau217 and pTau217/A 42 Across Key Immunoassay platforms in an Asian Cohort with High Cerebrovascular Disease Burden

Presenteur : Joyce Ruifen Chong

Joyce Ruifen Chong[1], Amelia Ting Yu Yam[2], Anqi Toh[2], Ng Chiew Yong[2], Gandan Jiang[3], Temmei Ito[3], Chizuru Kobayashi[3], Amitabh Dash[4], Pallavi Sachdev[5], Christopher Chen[2], Mitchell Kim Peng Lai[2]

[1]Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Wisconsin, United States, [2]Memory, Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, [3]Eisai Co. Ltd., Tokyo, Japan, [4]Eisai (Singapore) Pte Ltd., Singapore, Singapore, [5]Eisai Inc., New Jersey, United States

P235 Clinical performance and biomarker-specific confounding of plasma Alzheimer's disease biomarkers in a real-world memory clinic cohort

Presenteur : Yinuo Lei

Yinuo Lei, Xinyi Xia, Qi Qin, Yi Tang

Xuanwu Hospital Capital Medical University, Beijing, China

P236 Neuron-Derived Extracellular Vesicles from Plasma Stratify APOE ε4 Carriers with TBI History

Presenteur : Michaela Cullum-Doyle

Michaela Cullum-Doyle[1, 2], Matthew S. Panizzon[1], Victoria B. Risbrough[1], Robert A. Rissman[2]

[1]University of California San Diego, La Jolla, United States, [2]Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States

P238 VeraBIND Tau, a Novel Plasma Assay Reflecting Pathological Tau Binding Activity, Predicts Longitudinal Cognitive Decline Independently of Plasma pTau217

Presenteur : Bernard Hanseeuw

Bernard Hanseeuw[1], Lisa Quenon[2], Jean-Louis Bayart[2], Winnie Pak[3], Josh Soldo[3], Khalid Iqbal[4]

[1]Cliniques Universitaires Saint-Luc, Brussels, Belgium, [2]UCLouvain, Brussels, Belgium, [3]Veravas, Austin, United States, [4]New York State Institute for Basic Research, New York, United States

P239 Influence of Pre-analytical Transport Conditions, Routine Blood Biomarkers, and Comorbidities on the performance of Elecsys plasma p-Tau181 (TAPOREWORLD study)

Presenteur : Peter Körtvelyessy

Peter Körtvelyessy[1, 2, 3], Falko Böhringer[4], Luca Keller[4], Julie Bitzer[4], Ersin Ersözlü[5], Julian Hellmann-Regen[5], Laura Göschel[1]
[1]Charité – Universitätsmedizin Berlin, Department of Neurology, Berlin, Germany, [2]Labor Berlin, Divisions Innovation and Neurodegeneration, , Berlin, Germany, [3]German Center for Neurodegenerative Diseases (DZNE), , Magdeburg, Germany, [4]Labor Berlin, Division Studies and Cooperation, Berlin, Germany, [5]Charité-Universitätsmedizin Berlin, Department of Psychiatry, Berlin, Germany

P240 Clinical Impact of Introducing Blood-Based pTau217 Testing in Canadian Alzheimer's Disease Diagnostic Pathways: Initial Results from a Localized Clinical Simulation Model

Presenteur : Alonso Montoya

Sophie Roth[1], Alonso Montoya[2], Aleina Spigelman[2], Ronald A. Booth[3], Sharon Cohen[4], Andrew Frank[5], Linda Lee[6]
[1]Roche Diagnostics International Ltd., Rotkreuz, Switzerland, [2]Roche Diagnostics, Laval, Qc, Canada, [3]University of Ottawa, Ottawa Hospital & Eastern Ontario Regional Laboratory Association (EORLA), Ottawa, On, Canada, [4]Toronto Memory Program, Toronto, On, Canada, [5]Bruyère Health Research Institute, Ottawa, On, Canada, [6]McMaster University, Hamilton, Schlegel-UW Research Institute for Aging, Hamilton, Waterloo, On, Canada

P241 Convergent Central and Peripheral Immune Remodeling After 6 Months of Lecanemab Treatment in Early Alzheimer's Disease: Longitudinal TSPO PET and Plasma Multi-Omics

Presenteur : Lu Shen

Yiliang Liu, Haokun Liu, Keying Fang, Weiwei Zhang, Ling Xiao, Yongxiang Tang, Shuo Hu, Bin Jiao, Lu Shen
Xiangya Hospital, Central South University, Changsha, China

P242 Plasma Interleukin-6 Is Associated With Cognitive Impairment Independent of Ethnoracial Group in a Diverse Cohort of Older Adults

Presenteur : Maria Misiura

Maria Misiura[1], Tammy Joseph[2], Jessica Cooper[3], Gabi Champion[2], Alex Bartlett[2], Jennalyn Burnette[2], Kyle Thatcher[2], Nadine Ciera Austin[2], Vonetta M. Dotson[2]
[1]Center for Translational Research in Neuroimaging & Data Science | Georgia State University, Atlanta, United States, [2]Georgia State University, Atlanta, United States, [3]Emory University, Atlanta, United States

P243 pTau-217 in Clinical Practice: Utilization Patterns and APOE-Driven Variability in Real-World Data

Presenteur : David Alfego

David Alfego[1], Joseph Volpe[2]
[1]Labcorp, San Diego, United States, [2]Labcorp, Durham, United States

P244 Ratio-Based Plasma p-Tau217 Biomarkers Outperform Single Measures for Detecting Early Amyloid Pathology in Preclinical AD

Presenteur : James D Doecke

James D Doecke[1, 2], Azadeh Feizpour[3, 4], Rodrigo Canovas[1], Christopher J Fowler[3], Simon Laws[2], Larry Ward[3], Colin L Masters[5], Ruth Pfeiffer[6], Corey Carlson[6], Jeremiah S Hinson[7], Charbel Abou-Diwan[6], Ruth Pfeiffer[6], Christopher C Rowe[3, 4], Vincent Dore[8, 4]
[1]Australian E-Health Research Centre, CSIRO, Herston, Australia, [2]Centre for Precision Health, Edith Cowan University, Joondalup, Australia, [3]The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, [4]Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Australia, [5]Alzheimer's Research Australia, University of Western Australia, Nedlands, Australia, [6]Beckman Coulter Diagnostics, Brea, United States, [7]Danaher Diagnostics, Washington, United States, [8]Australian E-Health Research Centre, CSIRO, Parkville, Australia

P245 Not a Substitute for Confirmation: The Performance of Commercial Plasma Biomarkers in a Real-World Anti-Amyloid Treatment Pathway

Presenteur : Aaron Ritter

Aaron Ritter[1], Stephanie Martins[1], Erica Welch[1], Junko Hara[1], Jefferson Kinney[2]
[1]Hoag Neuroscience Institute, Newport Beach, United States, [2]UNLV, Las Vegas, United States

P246 Foundation model-enabled multi-omic profiling for differential diagnosis of Alzheimer's disease and related dementias: discovery across AD, FTD and LBD with validation in a real-world NHS memory clinic cohort

Presenteur : Hayley Holt

Hayley Holt[1], Carolina Machado[1], Anjeet Jhutty[1], Christoforos Nalmpantis[1], Pouya Niki[1], Ravi Solanki[2], Georgia Ross[1], Ivan Koychev[1]
[1]Prima Mente, London, United Kingdom, [2]Prima Mente, San Francisco, United States

P247 BD-p-Tau217/BD-p-Tau181 Tasso+ Capillary Plasma Ratio Best Correlates with Venous Plasma p-Tau217

Presenteur : Taraneh Atri

Taraneh Atri[1], Marisa N. Denkinger[1], James Liu[1], Alpana Singh[1], Michelle Surdyn[1], Victoria Brown[1], Guadalupe Martinez[1], Angela Kuramoto[1], Taina M. Marques[1], Jessica B. Langbaum[2], Alireza Atri[1], Nicholas J. Ashton[1]
[1]Banner Sun Health Research Institute, Sun City, United States, [2]Banner Alzheimer's Institute, Phoenix, United States

P248 Impact of Blood-Based Biomarkers (BBMs) on Time to Treatment Initiation with Anti-Amyloid Therapies (AATs): A Retrospective Analysis Using the Optum Market Clarity Alzheimer's Enriched Data

Presenteur : Rifky Tkatch

Rifky Tkatch[1], Courtney Adams[1], Bryan Cobb[1], Feride Frech[1], Bonnie Bui[2], Jamie Tucker[2], Brady Dehart[2], Julia Certa[2], Hideki Toyosaki[2], Yosuke Nakamura[2], Rhonna Shatz[3]
[1]Eisai Inc., Nutley, United States, [2]Optum Life Science, Eden Prairie, United States, [3]University of Cincinnati, Cincinnati, United States

P249 Brain Mass Spectrometry-Guided Development of Novel Plasma Immunoassays for Early Tau Pathology

Presenteur : Xuemei Zeng

Xuemei Zeng[1], Marissa Farinas[1], Lamia T Choity[1], Eric E Abrahamson[1], Milos D Ikonomovic[1], Alexandra J Gilsrud[1], Monika R Sanotra[1], Julia K Kofler[1], Beth E Snitz[1], Annie D Cohen[1], Oscar L Lopez[1], Lei Liu[2], Jasmeer P Chhatwal[2], Thomas K Karikari[1]
[1]University of Pittsburgh, Pittsburgh, Pa, United States, [2]Harvard University, Cambridge, Ma, United States

P250 Plasma and Tau-PET Reflect Distinct Biological Processes Underlying Cognitive Decline in Alzheimer's Disease

Presenteur : James D Doecke

James D Doecke[1, 2], Azadeh Feizpour[3, 4], Rodrigo Canovas[5], Christopher J Fowler[3], Jurgen Fripp[1], Simon Laws[2, 6], Larry Ward[3], Colin L Masters[7], Paul Maruff[8], Corey M Carlson[9], Jeremiah S Hinson[10], Charbel Abou-Diwan[9], Ruth Pfeiffer[9], Christopher C Rowe[3, 4], Vincent Dore[5]
[1]The Australian e-Health Research Centre, CSIRO, Herston, Australia, [2]Centre for Precision Health, Edith Cowan University, Joondalup, Australia, [3]The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, [4]Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Australia, [5]The Australian e-Health Research Centre, CSIRO, Parkville, Australia, [6]Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, [7]Alzheimer's Research Australia, University of Western Australia, Nedlands, Australia, [8]Cogstate, Ltd, Parkville, Australia, [9]Beckman Coulter Diagnostics, Chaska, United States, [10]Danaher Diagnostics, Washington, United States

P251 From Bench to Bedside: Presynaptic Complexins as Synaptic Endpoints for Alzheimer's Disease Trials

Presenteur : Ted Wilson

Justin H. Mendiola[1], Sophie Jones[1], Masood Manoochehri[1], Bess Frost[1], Edward Huey[2], Ted Wilson[1]
[1]Brown University, Providence, United States, [2]Butler Hospital, Providence, United States

P252 Performance of Plasma and CSF biomarkers for tauPET staging in Alzheimer's Disease: evidence from mass spectrometry and immunoassays in Autonomy

Presenteur : Shannon Leslie

Tina Wang[1], Shannon Leslie[1], Setareh Moughadam[1], Fatma Ayhan[2], Stephanie Slania[2], Kristof Van Kolen[3], Ziad Saad[1], Gallen Triana-Baltzer[1]
[1]Johnson & Johnson, San Diego, United States, [2]Johnson & Johnson, Springhouse, United States, [3]Johnson & Johnson, Beerse, Belgium

P253 Apolipoprotein E4 quantification by NULISA in cognitively unimpaired cohorts for screening for APOE 4 carriership and homozygosity

Presenteur : Ashvini Keshavan

Ashvini Keshavan[1, 2], Katharine Wiltshire[1, 2], Amanda Heslegrave[2], Henrik Zetterberg[2, 3], Jonathan Schott[1, 2]
[1]Dementia Resarch Centre, UCL Queen Square Institute of Neurology, London, United Kingdom, [2]UK Dementia Research Institute at University College London, London, United Kingdom, [3]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

P254 A Clinically Tractable Five-protein Plasma Panel Improves Alzheimer's Disease Diagnosis Beyond p-Tau217

Presenteur : Johannes Eichner

Johannes Eichner[1], Scott Levin[2], Muhammad Ali[3], Carlos Cruchaga[3], Timo Wittenberger[1], Jeremiah Hinson[2]
[1]Genedata, Basel, Switzerland, [2]Danaher Diagnostics, Washington, Dc, United States, [3]Washington University, Saint Louis, Mo, United States

P255 Plasma brain-derived p-tau217/total-tau ratio outperforms plasma p-tau217 for detecting autopsy-confirmed Alzheimer's neuropathology, including in early-disease and mixed-pathology cases

Presenteur : Denis Smirnov

Denis Smirnov[1, 2], Xuemei Zeng[3], Marissa Farinas[3], Michel Nafash[3], Victor Villemagne[3], Sarah Berman[3], Henrik Zetterberg[4], Tharick Pascoal[3], Beth Snitz[3], Ann Cohen[3], Oscar Lopez[3], M. Ilyas Kamboh[3], Milos Ikonomovic[3], Julia Kofler[3], Thomas Karikari[3]
[1]Mass General Brigham, Boston, United States, [2]Harvard Medical School, Boston, United States, [3]University of Pittsburgh, Pittsburgh, United States, [4]University College London, London, United States

P256 Blood-Based and Digital Biomarker Strategies Are Reshaping Alzheimer's Clinical Trial Recruitment, Cohort Readiness, and Site Operations

Presenteur : Sean Stanton

Sean Stanton, Candice Espinoza, Sameer Siddiqui, Taylor Rice, Brandon Lenox, Briana Stanton
K2 Medical Research, Maitland, Fl, United States

P257 Quantum Capacitance Electrochemical Biosensor for the Rapid and Ultrasensitive Detection of p-tau217 and MTBR-tau243

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra[1], Keyao Song[1], Spondita Goswami[2], Rajan K. Chakrabarty[1]
[1]Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, United States, [2]Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, United States

P258 Single-aggregate detection of misfolded neurodegenerative disease proteins

Presenteur : Andrew Stern

Andrew Stern[1], Chungmin Han[2], Borberg Ella[2], Lily Wickland Shearer[1], Tal Gilboa[2], Zoe Swank[2], Arek Melkonian[2], Justin Rolando[2], David Walt[2]
[1]Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Department of Neurology, Boston, United States, [2]Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, United States

P259 US Real-World Patterns of Amyloid Testing and Anti-Amyloid Therapy Initiation in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI)

Presenteur : Kinyee Fong

Kinyee Fong[1], Ameur M. Manceur[2], Nick Belviso[1], Eli Shobin[1], Boyang Bian[1], Akash Bhushan[3], Lisa Leung[3], Adyasha Das[3], Sonick Suri[3], Vamsi Chandra Kasivajjala[3], Lydia Wood[1]
[1]Biogen MA Inc., Cambridge, United States, [2]Cytel, Cambridge, United States, [3]NeuroDiscovery AI, Alpharetta, United States

P260 Needle-free biomarker detection platform using the olfactory neuroepithelium: superiority to blood-based assays in Alzheimer's disease

Presenteur : Koko Ishizuka

Koko Ishizuka, Guanqun Shang, Akira Sawa
Johns Hopkins University, Baltimore, United States

P261 Validation of Elecsys pTau217 plasma assay cutoffs for detection of amyloid pathology across care settings

Presenteur : Annunziata Di Domenico

Annunziata Di Domenico[1], Sayuri Hortsch[2], David Caley[3], Niels Borlinghaus[2], Kaj Blennow[4, 5], Oskar Hansson[5, 6], Marc Suárez-Calvet[7, 8], Craig Ritchie[9], Nicholas Ashton[10, 11], Marisa Denkinger[11], Christopher Rowe[12, 13], Ming Lu[14], Sameera Wijayawardana[15], Sebastian Palmqvist[6, 16]
[1]Roche Diagnostics International Ltd, Rotkreuz, Switzerland, [2]Roche Diagnostics GmbH, Penzberg, Germany, [3]Roche Diagnostics Ltd, Burgess Hill, United Kingdom, [4]Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, [5]Eli Lilly and Company, Stockholm, Sweden, [6]Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, [7]Barcelona eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, [8]Servei de Neurologia, Hospital del Mar, Barcelona, Spain, [9]Scottish Brain Sciences, Edinburgh, United Kingdom, [10]Banner Alzheimer's Institute and University of Arizona, Phoenix, United States, [11]Banner Sun Health Research Institute, Sun City, United States, [12]Australian Dementia Network Ltd, Melbourne, Australia, [13]University of Melbourne, Melbourne, Australia, [14]Eli Lilly and Company, Philadelphia, United States, [15]Eli Lilly and Company, Indianapolis, United States, [16]Memory Clinic, Skåne University Hospital, Malmö, Sweden

P262 Mitigating amyloid endpoint heterogeneity to establish robust cutoffs and clinical performance of Elecsys pTau217 and pTau181 plasma immunoassays

Presenteur : Sayuri Hortsch

Sayuri Hortsch[1], Annunziata Di Domenico[2], Myrto Andreadou[2], Imke Kirste[3], Michael Weiner[4], Christopher Rowe[5, 6], James Doecke[7, 8], Niklas Mattsson-Carlgren[9, 10], Sebastian Palmqvist[9, 10], Gregory Klein[11], Tobias Bittner[11, 12]
[1]Roche Diagnostics GmbH, Penzberg, Germany, [2]Roche Diagnostics International Ltd, Rotkreuz, Switzerland, [3]Roche Molecular Systems Inc, Tucson, United States, [4]University of California San Francisco, San Francisco, United States, [5]Australian Dementia Network, University of Melbourne, Melbourne, Australia, [6]Austin Health, Melbourne, Australia, [7]Australian E-Health Research Centre, CSIRO, Brisbane, Australia, [8]Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, [9]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, [10]Memory Clinic, Skåne University Hospital, Malmö, Sweden, [11]F. Hoffmann-La Roche Ltd, Basel, Switzerland, [12]Genentech, Inc., San Francisco, United States

P263 The associations between plasma-based synaptic, neurodegeneration, vascular, and inflammatory biomarkers with synaptic density in neurodegeneration measured using [18F]SynVesT-1 PET.

Presenteur : Koen Poesen

Koen Poesen[1], Soha Alali[1], Charles Carron[1], Amir Ghodrati[1], Susanne Schmidt[2], Koen Van Laere[1]
[1]KU Leuven, Leuven, Belgium, [2]UBonn, Bonn, Germany

P264 Inflammatory Biomarkers in Alzheimer's Disease Immunomodulatory Trials: A Systematic Review of Biomarker–Clinical Concordance and Translational Context-of-Use

Presenteur : Myuri Ruthirakuhan

Myuri Ruthirakuhan[1], Nicole Owsicki[1], Sofia Perfetto[1], Kiran Shocker[1], Amanda Leisgang Osse[2], Yadi Zhou[3], Min Su Kang[1], Feixiong Cheng[3], Walter Swardfager[1], Jeffrey Cummings[2], Julie Ottoy[1, 4]
[1]Sunnybrook Research Institute, Toronto, On, Canada, [2]Department of Brain Health, University of Nevada Las Vegas, Las Vegas, United States, [3]Cleveland Clinic, Las Vegas, United States, [4]Department of Medicine (Neurology), University of Toronto, Toronto, On, Canada

P265 Diagnostic accuracy of Elecsys pTau181 and pTau217 plasma assays using global cutoffs in an Asian cohort: Results from the K-ROAD registry

Presenteur : Jun Pyo Kim

Jun Pyo Kim[1], Gwendlyn Kollmorgen[2], Christian Kuffer[2], Annunziata Di Domenico[3], Myrto Andreadou[3], Tobias Bittner[4, 5], Sayuri Hortsch[2], Sang Won Seo[1]

[1]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, [2]Roche Diagnostics GmbH, Penzberg, Germany, [3]Roche Diagnostics International Ltd, Rotkreuz, Switzerland, [4]F. Hoffmann-La Roche Ltd, Basel, Switzerland, [5]Genentech, Inc., South San Francisco, United States

P266 Inflection-based ordering of plasma and PET biomarkers along an Alzheimer's disease progression axis in two independent cohorts

Presenteur : Jeon So Yeon

Lee Kyungsung[1], Yi Dahyun[2], Ham Hyunsun[3], Byun Min Soo[4, 5], Kim Yu Kyeong[6, 7], Lee Jun-Young[3, 4], Lee Dong Young[4, 5], Jeon So Yeon[3, 4]

[1]Emocog, Seoul, Korea, Republic of, [2]Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea, Republic of, [3]Department of Psychiatry, Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, Korea, Republic of, [4]Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea, Republic of, [5]Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea, Republic of, [6]Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of, [7]Department of Nuclear Medicine, Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, Korea, Republic of

P267 From Stackers to Streamliners: Alzheimer's Disease Work-up Archetypes and the Impact of AD BBM Ratio Test Results on Diagnostic Escalation

Presenteur : Trever Burgon

Trever Burgon[1], David Paculdo[1], Lopamudra Das[2]

[1]QURE Healthcare, St. Louis, United States, [2]Beckman Coulter Diagnostics, Brea, United States

P268 A Novel Plasma Biomarker Panel Assessed by NULISA Improves Amyloid Positivity Diagnosis Beyond pTau-217 for Clinical Trial Enrichment

Presenteur : Ser Mien Chia

Ser Mien Chia[1], Yumi Kawamura[1], Geetha Chilla[1], Nicholas Ho[1], Charlene Ong[1], Matthew Choo[1], Ryan Clark[2], Dean Lee[1], Asad Abu Bakar Ali[1], Matthew Kennedy[2]

[1]Quantitative Biosciences, MSD International GmbH, Singapore, Singapore, Singapore, [2]Discovery Neuroscience, Merck & Co., Inc., Boston, MA, USA, Boston, United States

P269 A 5-Plex Plasma Biomarker Panel for Amyloid PET Status Classification Beyond pTau-217 Alone: A Pilot Study

Presenteur : Noah Elder

Noah Elder, Hien Nguyen, Jason Wan, Robert Lin

Taudia, Inc., San Carlos, United States

P270 Development of a plasma biomarker signature for Alzheimer's disease using the Roche NTK; what do we gain by adding to pTau217?

Presenteur : James D. Doecke

Rodrigo Canovás[1], Azadeh Feizpour[2, 3], Christopher J. Fowler[2], Vincent Dóre[1, 3], Gwendlyn Kollmorgen[4], Clara Quijano-Rubio[5], Christopher M. Rank[4], Simon M. Laws[6, 7, 8], Larry Ward[2], Colin L. Masters[9], Christopher C. Rowe[2, 3], James D. Doecke[6, 10]

[1]The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia, [2]The Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Melbourne, Victoria, Australia, [3]Department of Molecular Imaging & Therapy, Austin Health,, Melbourne, Victoria, Australia, [4]Roche Diagnostics GmbH, Penzberg, Germany, [5]Roche Diagnostics International Ltd, Rotkreuz, Switzerland, [6]Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia, [7]Collaborative Genomics and Translation Group, Edith Cowan University, Joondalup, Western Australia, Australia, [8]Curtin Medical School, Curtin University, Bentley, Western Australia, Australia, [9]Alzheimer's Research Australia, The University of Western Australia, Western Australia, Australia, [10]The Australian e-Health Research Centre, CSIRO, Brisbane, Australia

P271 Use of the VeraBIND Tau Functional Plasma Assay to Detect Active Tau Pathology in Preclinical Mouse Models

Presenteur : Nicole M Maphis

Nicole M Maphis[1, 2], Joshua Soldo[3], Kavya Shamsundar[3], Winnie Pak[3], Khalid Iqbal[4, 5], Ali Riazi[2], Kiran Bhaskar[1, 2]

[1]Department of Molecular Genetics & Microbiology/Neurology, University of New Mexico, Albuquerque, United States, [2]TheraVac Biologics, Albuquerque, United States, [3]Veravas, Inc, Austin, United States, [4]New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States, [5]Phanes Biotech, Inc, Malvern, United States

P272 Real-World Plasma Alzheimer Biomarkers, Amyloid PET, and Functional–Cognitive Burden in an Underrepresented Multimorbid Gulf/MENA Memory-Clinic Cohort

Presenteur : Hanan Sheikh Ibrahim,md,facp

Hanan Sheikh Ibrahim, Md, Facp

[1] Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates [2] Center for Continuing Medical Learning (CCLM), Case Western Reserve University School of Medicine, Cleveland, Ohio, USA, Abu Dhabi, United Arab Emirates

P273 Toward an inflammation axis for the ATN(V)I framework in dementia: CSF outperforms plasma and MRI biomarkers using the albumin index as a standard for inflammation

Presenteur : Gary Rosenberg

Azadeh Golduzian, Erik Erhardt, Atvind Caprihan, John Adair, Jsnice Knoefel, Jill Prestopnick, Sasha Hobson, Gary Rosenberg

University of New Mexico, Albuquerque, United States

P274 Brain-enriched Circular RNAs as blood-based biomarkers for detection of Alzheimer's disease-related biology across the disease continuum

Presenteur : Nikolaos Mellios

Nikolaos Mellios[1], Bridget Phillips[2], Jessie Sanford[2], Vaibhav Janve[3], Nikolaos Mellios[1], Grigorios Papageorgiou[1], John Morris[2], Joel Perlmutter[2], Paul Kotzbauer[2], Richard Perrin[2], Timothy Hohman[3], Laura Ibanez[2], Carlos Cruchaga[2]
[1]Circular Genomics, San Diego, United States, [2]Washington University School of Medicine,, St Louis, United States, [3]Vanderbilt University Medical Center, Nashville, United States

P276 Cognitive Reserve and the Clinical Expression of Alzheimer's Disease Plasma Biomarkers in Subjective Cognitive Decline and Mild Cognitive Impairment

Presenteur : Giovanna Pinto Coelho Nuti

Giovanna Pinto Coelho Nuti
University of Campinas (UNICAMP), Campinas, Brazil

P277 Elecsys pTau217 plasma assay cutoff determination and validation for the detection of amyloid pathology in a Chinese population

Presenteur : Jiawei Xin

Jiawei Xin[1], Yuyuan Huang[2], Xuhui Chen[3], Ming Guan[2], Chuantao Zuo[2], Yingping Cao[1], Zhongyou Ji[1], Mengjie Dong[3], Jun Hu[3], Guoyu Lan[4], Qiman Yin[5], Yim Yung[5], Xiaochun Chen[1], Jintai Yu[2], Tengfei Guo[4]
[1]Fujian Medical University Union Hospital, Fuzhou, Fujian, China, [2]Huashan Hospital affiliated to Fudan University, Shanghai, China, [3]Peking University Shenzhen Hospital, Shenzhen, Guangdong, China, [4]Shenzhen Bay Laboratory, Shenzhen, Guangdong, China, [5]Roche Diagnostics (Shanghai) Ltd, Beijing, China

P278 Evaluation of Alzheimer's Blood Based Biomarkers in Race, Sex, Education, FAST and APOE 4 Carrier Status Evaluation of Alzheimer's Blood based biomarkers in race, sex, education, FAST and APOE 4 Carrier Status

Presenteur : Ruhaan Shah

Maya Ibrahim[1], Ruhaan Shah[2], Ira Katigbak[2], Lee Watson[2], Omar Almashharawi[2], Isabella Principe[2], Eduardo Chacon[2], Kevin Aimua[2], Rory Roberts[2], Monica Crane[2]
[1]Tennessee Memory Disorders Foundation, Knoxville, United States, [2]Tennessee Memory Disorders Foundation - Knoxville (United States), Knoxville, United States

P279 Comparative and Incremental Value of Plasma p-tau217, GFAP, NfL, and A 42/40 Across Amyloid, Tau, and Clinical Progression

Presenteur : Sunghwan (Andy) Kim

Sunghwan (Andy) Kim[1], Jun-Young Lee[2, 3], So Yeon Jeon[4], Jeong-Mi Moon[1]
[1]Emocog Inc., Gwacheon, Korea, Republic of, [2]Seou National University, Gwacheon, Korea, Republic of, [3]Emocog Inc. - Seoul (Korea, Republic of), Seoul, Korea, Republic of, [4]Seou National University, Seoul, Korea, Republic of

P280 Short-term reproducibility and clinical risk categorization of commercial plasma biomarkers for Alzheimer's disease in a real-world US hospital setting

Presenteur : Liqhwa Ncube

Liqhwa Ncube, Joseph Morales, Briella Smaw, Elita Farahdel, Tafadzwa Nyikadzino, Danielle Jacobstein, Claudia Kunney, Anna Torten Rabinowitz, Ophir Keret, George Naasan, Fanny Elahi
Icahn School of Medicine at Mount Sinai, New York, United States

P281 Plasma Phosphorylated Tau in Alzheimer's Disease: The Translational Shift Toward Scalable Early Detection

Presenteur : Princess Obazee

Princess Obazee[1], Harita Dilip[2], Pranjal Arekar[3], Alexander Nguyen[4], Amelia Schenk[5], Grace Lee[6], Shreeya Kerthipati[7], Shefali Bandla[8], Saanvi Jain[9], Sahana Saravana Kumar[10], Aanya Veeranagoudar[11], Abel Biju[12], Peter Kucharczyk[13]
[1]ThinkNeuro, Columbia, United States, [2]ThinkNeuro, Cary, United States, [3]ThinkNeuro, little Rock, United States, [4]ThinkNeuro, Houston, United States, [5]ThinkNeuro, Bridgewater Township, United States, [6]ThinkNeuro, Austin, United States, [7]ThinkNeuro, Coppell, United States, [8]ThinkNeuro, Denton, United States, [9]ThinkNeuro, Livingston, United States, [10]ThinkNeuro, Frisco, United States, [11]ThinkNeuro, Louisville, United States, [12]ThinkNeuro, Toronto, Canada, [13]ThinkNeuro, New York, United States

P282 AI-Based Retinal Hyperspectral Imaging for Detection of Brain Amyloid Pathology: Cohort Characterization and Blinded Validation Framework from the Bio-Hermes-002 Study

Presenteur : Eliav Shaked

Anthony Rinaldi[1], Justin Digregorio[1], Yanir Levy[1], Jared Westreich[1], Bar Mayo[1], Ahmad Omar Ahsan[1], Maïlis Bietenhader[1], Rozana Naureen[1], Eliav Shaked[1], Doug Beauregard[2]
[1]RetiSpec, Toronto, Canada, [2]Global Alzheimer's Platform Foundation, Washington, United States

P283 Cost and Time Impact of LucentAD Complete as a Blood-Based Diagnostic Aid for Alzheimer's Disease: A Model-Based Analysis

Presenteur : Sam Dickson

Caleb Dayley[1], Lindsey Mette[2], David Wilson[2], Prince Agyapong[1], Mitch Wassom[1], Sam Dickson[1]
[1]Pentara Corporation, Salt Lake City, United States, [2]Quanterix Corporation, Billerica, United States

P284 Utility of plasma pTau217 for cohort enrichment and outcome measurement in prevention trials

Presenteur : Pia Kivisäkk

Pia Kivisäkk, Hadia Fatima, Chao-Yi Wu, Hiroko H Dodge, David H Salat, Steven E Arnold
Massachusetts General Hospital, Harvard Medical School, Boston, United States

P285 Macrostructural brain changes associated with baseline Alzheimer's disease pathology: A longitudinal MRI study with CSF biomarkers from BIOCARD

Presenteur : Dishaa Sinha

Dishaa Sinha[1], Ishan Durve[2], Harshita Sinha[3], Ahmet Begde[1], Yi Yang[1], Elijah Mak[4], Nemanja Vaci[5], Vanessa Raymont[1], Alejo Nevado-Holgado[1], Ivan Koychev[6]
[1]University of Oxford, Oxford, United Kingdom, [2]Independent Researcher, Mumbai, India, [3]Queen Mary University of London, London, United Kingdom, [4]Mayo Clinic, Rochester, United States, [5]University of Sheffield, Sheffield, United Kingdom, [6]Imperial College London, London, United Kingdom

P286 Racial and Ethnic Differences in Blood-Based Biomarkers of Alzheimer's Disease Risk

Presenteur : Alexis Cieluch

Alexis Cieluch, Mark Rapp, Avigayil Rapp, Thomas Fomin
Basil Clinical, Queens, United States

P287 Predicting Progression to Mild Cognitive Impairment Using a Machine Learning Model

Presenteur : Alexa Pichet Binette

Sebastian Rodriguez Marquez[1], Yara Yakoub[2], Jany Lehouillier[1], Clémence Peyrot[1], Alexa Pichet Binette[1]
[1]Université de Montréal, Montreal, Canada, [2]Douglas Mental Health University Institute, Montreal, Canada

P288 Development and Analytical Validation of a High-Sensitivity Automated Immunoassay for p-tau205

Presenteur : Masashi Mori

Hiromi Miyazaki[1], Masashi Mori[1], Nanako Doi[1], Yuta Imai[2], Aoi Tanaka[2], Kengo Ishiki[2], Mayu Fujita[1], Yoshifumi Shima[1], Masahiro Miura[2], Shinichiro Oguni[1]
[1]Reagent Development Division, Sysmex Corporation, Kobe, Japan, [2]Central Research Laboratories, Sysmex Corporation, Kobe, Japan

P289 Therapeutic antibody interference with CSF tau assays in a gosuranemab basket trial across four primary tauopathies

Presenteur : Connor Dietz

Connor Dietz[1, 2], Molly Olzinski[2], Yann Cobigo[2], Amy Wolf[2], Argentina Lario Lago[2], Nicholas Ashton[3, 4], Rowan Saloner[2], Howie Rosen[2], Richard Tsai[2, 5], Julio Rojas[2], Lawren Vandevrede[2], Danielle Graham[6], Tien Dam[7], Peter Ljubenkov[2], Adam Boxer[2]
[1]Department of Medicine (Neurology), University of British Columbia, Vancouver, Canada, [2]Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, United States, [3]Banner Alzheimer's Institute and University of Arizona, Arizona, United States, [4]Banner Sun Health Research Institute, Sun City, United States, [5]Denali Therapeutics, South San Francisco, United States, [6]Biogen, Cambridge, United States, [7]Brenig Therapeutics, Somerville, United States

P290 Plasma Biomarkers of ARIA identified through NULISAseq Multiplex Profiling

Presenteur : Gloria Xie

Murali Doraiswamy, Laura Wang, Amber Navarra, Gloria Xie, Jeffrey Petrella, Andy Liu
Duke University, Durham, United States

P291 — Remote Re-evaluating TDP-43 assays: Hemolysis interference limits clinical utility

Presenteur : Myrto Andreadou

Myrto Andreadou[1], Anna Bayfield[2], Laura Effert[2], Nicholas J. Ashton[3], Sterling Johnson[4]
[1]Roche Diagnostics International Ltd, Rotkreuz, Switzerland, [2]Roche Diagnostics GmbH, Penzberg, Germany, [3]Banner Sun Health Research Institute, Sun City, Az, United States, [4]University of Wisconsin School of Medicine and Public Health, University of Wisconsin–Madison, Madison, Wi, United States

P292 Optimizing the Alzheimer's disease diagnostic pathway: An economic evaluation of a pTau217 blood-based biomarker in primary and specialist care in the US

Presenteur : Matthew De Nave

Sophie Roth[1], Matthew De Nave[2], Jared R. Brosch[3], Jeffrey M. Burns[4], Soeren Mattke[5], Lawren Vande Vrede[6], Maria-Magdalena Patru[2]
[1]Roche Diagnostics International Ltd, Rotkreuz, Switzerland, [2]Roche Diagnostics Corporation, Indianapolis, United States, [3]Indiana University School of Medicine, Indianapolis, United States, [4]University of Kansas Medical Center, Kansas City, United States, [5]University of Southern California, Los Angeles, United States, [6]University of California, San Francisco, United States

P293 Novel High-Throughput, Fully Automated Immunoassay for Cerebrospinal Fluid Phosphorylated Tau-205

Presenteur : Ben Schlichtmann

Ben Schlichtmann[1], Laia Montoliu-Gaya[2], Andrew Becker[1], Miklos Szabo[1], Juan Lantero-Rodriguez[2], Marnie Wallin[1], Jean-Sebastien Blanchet[3], Henrik Zetterberg[2], Mikaela Nichkova-Doseva[1]
[1]Beckman Coulter, Inc., Chaska, Minnesota, United States, [2]University of Gothenburg, Gothenburg, Sweden, [3]Beckman Coulter, Inc., Villepinte, France

P294 Preferences and access considerations for clinical adoption of blood-based biomarker tests to confirm amyloid- pathology in early Alzheimer's disease: a 12-country survey

Presenteur : Amitabh Dash

Amitabh Dash[1], Temmei Ito[2], Gandan Jiang[2]
[1]Eisai (Singapore) Pte Ltd., Singapore, Singapore, [2]Eisai Co. Ltd., Tokyo, Japan

P295 Development and Analytical Validation of APOE Genotyping with Dried Blood Spots on FTA cards

Presenteur : Kumar Gyanendra

Emily Bogden, Ablordeppey Kenny, Alidad Mireskandari, Finkelstein Sydney, Kumar Gyanendra
Diamir BioSciences, New Haven, United States

P296 BD pTau-217 and eMTBR-tau243 plasma biomarkers for Amyloid and Tau PET Classification in Alzheimer's Disease

Presenteur : Noah Elder

Noah Elder, Hien Nguyen, Robert Lin, Jason Wan
Taudia, Inc., San Carlos, United States

P297 Association of CSF p-tau217 with PET-Derived Individualized Amyloid Chronicity in PSEN1-E280A Mutation Carriers

Presenteur : V Ghisays

V Ghisays[1], Y Su[2], L Shan[2], M.N Denkinger[1], H.D Protas[2], D Aguillon[3], T Bittner[4], J.B Langbaum[2], P.N Tariot[2], S.C Johnson[5], E.M Reiman[2], R.C Alexander[2], N.J Ashton[1]
[1]Banner Sun Health Research Institute, Sun City, United States, [2]Banner Alzheimer's Institute, Phoenix, United States, [3]Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellin, Colombia, [4]F. Hoffmann-LaRoche Ltd, Basel Switzerland and Genentech Inc. a member of the Roche Group, South San Francisco, United States, [5]University of Wisconsin School of Medicine and Public Health, Madison, United States

P298 Identifying circulating biomarkers for amyloid conversion and early cognitive decline in matched CSF and plasma through unbiased proteomics

Presenteur : Matthijs De Geus

Matthijs De Geus[1], Shichkova Polina[2], Jan Muntel[1], Aida Kamalian[3], Alan Shomo[1], Nicole Barlow[1], Yuehan Feng[2], Abhay Moghekar[3]
[1]Biognosys Inc., Boston, United States, [2]Biognosys AG, Schlieren, Switzerland, [3]Johns Hopkins University, Baltimore, United States

P299 Baseline CSF p-tau181/Ab42 ratio predicts ARIA risk in lecanemab patients

Presenteur : Bethany Curd

Bethany Curd, Lin-Na Chou, Camilla Zubrick, Christine Cliatt Brown, Michelle Sorweid, Yoshimi Anzai, Satoshi Minoshima, Nicholas Frost
University of Utah, Salt Lake City, United States

P300 Astroglial Activation and Neurodegeneration as Kinetic Switches for p-Tau 217 Progression: A Longitudinal Multi-Analyte Stratification Analysis

Presenteur : David Wilson

David Wilson, Lindsey Mette, Meenakshi Khare, Matt Polack, Jorge Marques
Quanterix, Billerica, United States

P301 Establishing a Biobank Registry for Limbic-predominant Age-related TDP-43 Encephalopathy at Sutter Health

Presenteur : Shawn Kile

Shawn Kile, Armen Moughamian, Kimberly Christensen, Tammy Donnel, Sarah Robinson, Katherine Gillespie, Gregory Tranah
Sutter Health Research Institute, San Francisco, United States

P302 Analytical Validation of a novel liquid chromatography–tandem mass spectrometry (LC-MS/MS) multiplexed method measuring three phosphorylated forms of tau protein in plasma for Research Use

Presenteur : Venky Venkatesh

Matthew Meyer, Xinping Liu, Faith Irvin, Mark Adams, Tim West, Venky Venkatesh, John Bui, Justine Coppinger, Philip Verghese
C2N Diganostics, LLC, Saint Louis, United States

P303 Distribution of Biomarkers Among Patients Meeting Clinical Criteria for Alzheimer's Disease Psychosis Who Are Biomarker Negative for Amyloid Proteinopathy and p-Tau217

Presenteur : Samantha Friend

Samantha Friend[1], Bryan Dirks[2], Becky Howell[2], Xiaoshu Feng[2], Sanjeev Pathak[2]
[1]Acadia Pharmaceuticals Inc., San Diego, United States, [2]Acadia Pharmaceuticals Inc., Princeton, United States

P304 A Novel 5-Plex SPEAR Assay Targeting BD-pTau 217, eMTBR-Tau, BD-Tau, NF-L and GFAP Enables Comprehensive Assessment of Alzheimer's Disease Pathology and Neurodegeneration

Presenteur : Tracy Liu

Ahsan Ausaf Ali, Jiachong Chu, Pengyu Hao, Xi Chen, Arian Pushka, Chi Tang, Zidong Wang, Tracy Liu, Feng Xuan
Spear Bio, Woburn, United States

P305 Improved Stratification of Parkinson's Disease Using a Novel Ratio Analysis of Total and pS129- -Synuclein Enabled by the SPEAR Platform

Presenteur : Tracy Liu

Jeremy Tan, Emma Tordoff, Erden Eren, Tucker Fontana, Tsz Wing Fan, Tracy Liu, Xue Feng
Spear Bio, Woburn, United States

P306 Enhanced Discrimination of Parkinson's Disease Using a Novel -Synuclein Signature Assay on the SPEAR Platform

Presenteur : Tracy Liu

Erden Eren, Jeremy Tan, Emma Tordoff, Tucker Fontana, Tsz Wing Fan, Feng Xuan, Tracy Liu
Spear Bio, Woburn, United States

P307 Longitudinal Analysis of Circulating microRNA Expression Patterns During Alzheimer's Disease Progression in the 3xTg-AD Mouse Model

Presenteur : Simran Yadav

Simran Yadav[1], Aida Muntsant-Soria[2], Lydia Giménez-Llort[2], Urszula Wojda[1]
[1]Laboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland, Warszawa, Poland, [2]Institut de Neurociències, Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain., Spain, Poland

P308 Comparing results from three Alzheimer's Disease plasma biomarker tests in a prescreen study in healthy elderly participants

Presenteur : Lydia Morris

Lydia Morris[1], Lev Gertsik[1], Svetlana Semenova[2], Gary Walker[3], Aaron Koenig[3]
[1]California Clinical Trials Medical Group, Glendale, United States, [2]Parexel International, Glendale, United States, [3]Syndeio Biosciences, Indianapolis, United States

P309 Development and Analytical Validation of a Plasma ELISA for Glial Fibrillary Acidic Protein (GFAP) and Exploratory Analysis in a Clinical Cohort of Patients with Alzheimer's disease

Presenteur : María Pascual-Lucas

Noelia Fandos[1], Raquel Rodríguez[1], Judith Romero[1], María Pascual-Lucas[1], José Antonio Allué[1], Leticia Sarasa[1], Jesús Canudas[1], Ignacio Martínez[1], María Montañés[1], Jose Terencio[2, 1], Jorge Loscos[1]
[1]Araclon Biotech, Zaragoza, Spain, [2]Grifols, Sant Cugat Del Vallès, Barcelona, Spain

P310 Blood CD8 T cell recognition of APP and derivative non-Aβ peptides as screenable biomarkers for Alzheimer's and related MCI

Presenteur : Christopher Wheeler

Christopher Wheeler[1, 2, 3, 4], Pénélope Bourgoin[5], Debby Van Dam[6, 7], Yannick Vermeiren[8, 9], Hans De Reu[9], Peter Paul De Deyn[6, 7], Jean-Marc Busnel[5]
[1]T-NeuroDx; Ortega NeuroTherapeutics, Albuquerque, Aptos, United States, [2]Society for Brain Mapping & Therapeutics, World Brain Mapping Foundation,, Los Angeles, United States, [3]StemVax LLC, a wholly owned subsidiary of NovAccess Global, Cleveland, United States, [4]Dept of Chemistry & Biochemistry, University of California, Santa Cruz, Santa Cruz, United States, [5]Beckman-Coulter Life Sciences, Marseille, France, [6]Dept of Biomedical Sciences, Institute Born-Bunge, Laboratory of Neurochemistry and Behavior, University of Antwerp, Antwerp, Belgium, [7]Dept of Neurology and Alzheimer Research Center, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands, [8]Department of Biomedical Sciences, Institute Born-Bunge, Laboratory of Neurochemistry and Behavior, University of Antwerp, Antwerp, Belgium, [9]Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium

P311 Blood-Based Circular RNA Biomarkers for Alzheimer's Disease: Analytical Performance Using circRNA-specific quantitative and digital droplet PCR

Presenteur : Nikolaos Mellios

Grigorios Papageorgiou[1], Bridget Phillips[2], Carlos Cruchaga[2], Nikolaos Mellios[1]
[1]Circular Genomics, San Diego, United States, [2]Washington University School of Medicine, St. Louis, United States

P312 Circular RNA Biomarkers for Alzheimer's Disease are Associated with Multi-Lineage Pathological Pathways and significantly enriched in the brain

Presenteur : Nikolaos Mellios

Grigorios Papageorgiou[1], Bridget Phillips[2], Carlos Cruchaga[2], Nikolaos Mellios[1]
[1]Circular Genomics, San Diego, United States, [2]Washington University School of Medicine, St. Louis, United States

P313 Alzheimer's Disease specificity and consistent performance of a Circular RNA Blood-Based Biomarker Model Across Diverse Populations

Presenteur : Jessica Dehart

Bridget Phillips[1], Jessie Sanford[1], Vaibhav Janve[2], Nikolaos Mellios[3], Grigorios Papageorgiou[3], Jessica Dehart[3], John Morris[1], Joel Perlmutter[1], Paul Kotzbauer[1], Richard Perrin[1], Timothy Hohman[2], Laura Ibanez[1], Carlos Cruchaga[1]
[1]Washington University School of Medicine, St. Louis, United States, [2]Vanderbilt University Medical Center, Nashville, United States, [3]Circular Genomics, San Diego, United States

P314 Circular RNA Blood-Based Biomarkers Reliably Predict Progression of Asymptomatic Individuals to Alzheimer's Disease: ADRC and A4/LEARN Cohort Replication

Presenteur : Jessica Dehart

Bridget Phillips[1], Jessie Sanford[1], Vaibhav Janve[2], Nikolaos Mellios[3], Grigorios Papageorgiou[3], Jessica Dehart[3], John Morris[1], Joel Perlmutter[1], Paul Kotzbauer[1], Richard Perrin[1], Timothy Hohman[2], Laura Ibanez[1], Carlos Cruchaga[1]
[1]Washington University School of Medicine, St. Louis, United States, [2]Vanderbilt University Medical Center, Nashville, United States, [3]Circular Genomics, San Diego, United States

P315 Domain-Specific CSF Proteomic Signatures of Cognitive Function in the ALBION Cohort

Presenteur : Sokratis Charisis

Vasiliki Amaryllis Skyfa[1, 2], Christopher Papandreou[1], Martina Samiotaki[3], Georgios Hadjigeorgiou[4], Efthimios Dardiotis[5], Mary H. Kosmidis[6], Mary Yannakoulia[7], Paraskevi Sakka[8], Archontoula Drouka[7], Dora Brikou[7], Eirini Mamalaki[7], Eva Ntanasi[2], Nikolaos Scarmeas[2], Sokratis Charisis[9], George Manias[10]
[1]Department of Nutrition and Dietetics, School of Health Sciences, Hellenic Mediterranean University, Crete, Greece, [2]First Department of Neurology, Aiginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, [3]Institute for Bioinnovation, Biomedical Sciences Research Center «Alexander Fleming», Vari, Greece, [4]Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus, [5]Departement of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece, [6]Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece, [7]Department of Nutrition and Dietetics, Harokopio University, Athens, Greece, [8]Athens Association of Alzheimer's Disease and Related Disorders, Athens, Greece, [9]Harvard Medical School & Massachusetts General Hospital, Boston, United States, [10]Department of Digital Systems, University of Piraeus, Piraeus, Greece

P316 Amyloid Pathology Modulates the Proteomic Architecture of Global Cognition

Presenteur : Sokratis Charisis

Vasiliki Amaryllis Skyfa[1, 2], Christopher Papandreou[1], Martina Samiotaki[3], Georgios Hadjigeorgiou[4], Efthimios Dardiotis[5], Mary H. Kosmidis[6], Mary Yannakoulia[7], Paraskevi Sakka[8], Archontoula Drouka[7], Dora Brikou[7], Eirini Mamalaki[7], Eva Ntanasi[2], Nikolaos Scarmeas[2], Sokratis Charisis[9], Athos Antoniades[10]
[1]Department of Nutrition and Dietetics, School of Health Sciences, Hellenic Mediterranean University, Crete, Greece, [2]First Department of Neurology, Aiginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, [3]Institute for Bioinnovation, Biomedical Sciences Research Center «Alexander Fleming», Vari, Greece, [4]Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus, [5]Departement of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece, [6]Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece, [7]Department of Nutrition and Dietetics, Harokopio University, Athens, Greece, [8]Athens Association of Alzheimer's Disease and Related Disorders, Athens, Greece, [9]Harvard Medical School & Massachusetts General Hospital, Boston, United States, [10]Stremble Ventures LTD, Limassol, Cyprus

P317 Reducing the P-tau217 Diagnostic Grey Zone Through Multimarker and Sequential Strategies Incorporating Plasma Aβ in Mild Cognitive Impairment

Presenteur : María Pascual-Lucas

María Pascual-Lucas[1], Leticia Sarasa[1], Noelia Fandos[1], Jorge Loscos[1], Judith Romero[1], Adrián Sánchez[1], Jose Terencio[2, 1], Isabel Ortega-Madueño[3], María Cruz Cárdenas[3], Fernando Cava-Valenciano[3], María José Gil-Moreno[4], Jordi A Matías-Guiu[4], Jose Antonio Allué[1]
[1]Araclon Biotech-Grifols, Zaragoza, Spain, [2]Grifols, Barcelona, Spain, [3]Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain, [4]Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain

P318 Factors influencing longitudinal plasma phospho-tau 217 and 181 changes in Alzheimer's dementia – a memory clinic follow-up study.

Presenteur : Michaela Defrancesco

Michaela Defrancesco, Christian Humpel
Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria, Innsbruck, Austria

P319 Estimating the durability of residual effects on biomarkers after discontinuation of lecanemab

Presenteur : Jie Janice Pan

Simon Rothwell[1], Jie Janice Pan[2], Daniela Rossi[1], Jo Vandercappellen[3], Cianne Park[4], Indeg Sly[4]
[1]Eisai Europe LTD, Hatfield, United Kingdom, [2]Eisai Inc, Nutley, New Jersey, United States, [3]Eisai Pharma AG, Zurich, Switzerland, [4]Acumetis, London, United Kingdom

P320 Real-World Plasma Neurofilament Light Chain, Functional Staging Severity, and Amyloid PET Non-Concordance in an Underrepresented Multimorbid Gulf/MENA Memory-Clinic Cohort

Presenteur : Hanan Sheikh Ibrahim,md,facp

Hanan Sheikh Ibrahim, Md, Facp
Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates [2] Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA, Abu Dhabi, United Arab Emirates

P321 Healthcare Provider Perspectives and Confidence in Using Alzheimer's Blood Biomarkers in Clinical Practice

Presenteur : Amy Deckert

Monica Zigman Suchsland, Karen Weyrauch, Katherine Selzler, Tim Macleod, Alissa Kurzman, Amy Deckert
Davos Alzheimer's Collaborative, Wayne, United States

P322 Baseline Biomarker Profiles in the Diverse Vascular Contributions to Cognitive Impairment and Dementia (DVCID) Study

Presenteur : Sitong (Agnes) Zhou

Sitong (Agnes) Zhou[1], Jacopo Di Lucente[1], Jacob Conston[1], Danielle Harvey[1], Myriam Fornage[2], Charles Decarli[1], Lee-Way Jin[1]
[1]University of California, Davis, Sacramento, United States, [2]UTHealth Houston School of Public Health, Houston, United States

P323 Optimization of a Rapid, Cost-Effective qPCR Assay for Apolipoprotein E Genotyping

Presenteur : Lauren Johnson

Lauren Johnson[1], Sarah Auguste McCaulley[1], Isabelle Philipp[1], Zuguang Wang[1], Matthew Sticco[2], Logan Vero[2], Kavita Jain[2], Ganesan Anthony[2], Arejas Uzgiris[1]
[1]Siemens Healthcare Diagnostics, East Walpole, United States, [2]Siemens Healthcare Diagnostics, Tarrytown, United States

P324 Real-World Adoption of Blood Biomarkers to Support Timely Diagnosis of Alzheimer's Disease: Ongoing Multinational Implementation Study

Presenteur : Amy Deckert

Monica Zigman Suchsland, Karen Weyrauch, Tim Macleod, Katherine J. Selzler, Alissa Kurzman, Amy Deckert
Davos Alzheimer's Collaborative, Wayne, United States

P325 Association of HDL Cholesterol With Longitudinal Brain Tau Deposition: A Cross-Ethnic Cohort Study

Presenteur : Jee Wook Kim

Jee Wook Kim[1], Hye Ji I Cho[1], Shin Gyeom Kim[2], Dong Young Lee[3]
[1]Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of, [2]Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of, [3]Seoul National University Hospital, Seoul, Korea, Republic of

P326 Temporal and Dose-Dependent Modulation of the Endocannabinoid System by Dual FAAH/MAGL Inhibition in Humans: Implications for Alzheimer's Disease

Presenteur : Jie Li

Jie Li[1], Sumit Bansal[2], Rui Zhao[2], Joel Schwartz[2], Rosa Miceli[2], Marc Gleichmann[2], Yongjun Xue[2], Mary Coffey[2], Yi Luo[2], Sarah Harris[2]
[1]BMS, San Diego, United States, [2]BMS, Princeton, United States

PRE-CLINICAL, EARLY DISCOVERY AND MECHANISTIC RESEARCH

P327 Latent Cognitive Processes Exhibit Compensatory Behavior for Neurodegeneration

Presenteur : Jason Bock

Jason Bock[1, 2], Jared Roach[3], Joseph Kemnitz[4], Christopher Logan[1], John Alden[1], William Shankle[1]
[1]Shankle Clinic for Memory and Cognition, Newport Beach, United States, [2]Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States, [3]Institute for Systems Biology, Seattle, United States, [4]University of Wisconsin–Madison, Madison, United States

P328 STX-03, an Orally Bioavailable Small-Molecule Tau Aggregation Disruptor, Reduces Pathological Tau in the rTg4510 Mouse Model

Presenteur : Per Nilsson

Per Nilsson[1], Lovisa Johansson[1], Paul Tempest[2], Laurent Martarello[2], Evgenia Krekoukia[1], Nicki Jennings[2], Nancy Stratman[2], Vasco Sousa[3], Martins Katkevics[4], Wen-Chieh Wang[5], Thierry Bussiere[2], Karl Schmidt[2], John Beaver[2]
[1]Karolinska Institutet, Dept of Neurobiology, Care, Stockholm, Sweden, [2]Sentonix, Arlington, United States, [3]Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden, [4]Latvian Institute of Organic Synthesis, Riga, Latvia, [5]National Health Research Institute, Taipei, Taiwan

P329 Blocking C1q binding to murine anti-amyloid antibody, 3D6, strongly reduces complement activation, BBB leakage, microhemorrhages in amyloid mice

Presenteur : Cynthia Lemere

Cynthia Lemere[1], Praveen Bathini[1], Brianna Colletti[1], Mathias Schenk[2], Jens-Ulrich Rahfeld[2], David Holtzman[3], Stephan Schilling[3]
[1]Brigham and Women's Hospital; Harvard Medical School, Boston, United States, [2]Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany, [3]Washington University School of Medicine St. Louis, St. Louis, United States

P330 Impact of epitope location on Tau antibody efficacy in inhibiting Tau-seeded aggregation

Presenteur : Bruno Vasconcelos

Bruno Vasconcelos[1], Bart Hermans[1], Wim Van Der Elst[2], Matthias Bruckner[2], Bianca Van Broeck[1], Clara Theunis[1], Kristof Van Kolen[1]
[1]Neuroscience Department, Johnson & Johnson, Beerse, Belgium, [2]Discovery Statistics, Johnson & Johnson, Beerse, Belgium

P332 Neuroprotective Effects of Pan-Neuronal Hsp104 Co-Expression in Suppressing Amyloid-Aggregation and Toxicity

Presenteur : Samad Udaipurwala

Samad Udaipurwala[1, 2]
[1]UMass Chan Medical School, Worcester, Massachusetts, United States, [2]Shrewsbury High School, Shrewsbury, Massachusetts, United States

P333 An 'all-human' monoclonal screen for neutralizing tau neuritic dystrophy in human neurons exposed to diffusible oligomers from AD cortex yields B28, a next-gen anti-A antibody

Presenteur : Dennis J. Selkoe

Dennis J. Selkoe[1], Yi Ran Xu[1], Shaomin Li[1], Jean-Pierre Bellier[1], Youqi Tao[1], Anna E. Francis[1], Andrew M. Stern[1], Shanxue Jin[1], Beth L. Ostaszewski[1], Trebor L. Lawton[2], Laurent Pradier[3], David Reczek[4], Cynthia A. Lemere[1], Dominic M. Walsh[1], Ting Yang[1]
[1]Brigham and Women's Hospital, Boston, United States, [2]Abyssinia Biologics, Inc., Boston, United States, [3]Sanofi, Chilly Mazarin, France, [4]Sanofi, Cambridge, United States

P334 ALC919 employs neurotrophic, glymphatic and anti-inflammatory mechanisms to arrest amyloid-oligomer toxicity and restore brain mitochondrial complex I function

Presenteur : Sam Gandy

Sam Gandy[1], Mary Sano[1], Keiko Honda[2], Yuhki Saito[2], Haruka Saito[2], Koichi Kinoshita[2], Ayano Kimura[2], Ruriko Abe[2], Koichi Moteki[2], Takashi Sato[3], Takaomi Saido[4], Yasuomi Ouchi[5], Saori Hata[6], Kanae Ando[3], Toshiharu Suzuki[3]
[1]Icahn School of Medicine at Mount Sinai, New York, United States, [2]Hokkaido University, Sapporo, Japan, [3]Tokyo Metropolitan University, Tokyo, Japan, [4]RIKEN Center for Brain Sciences, Wako, Japan, [5]Hamamatsu University, Hamamatsu, Japan, [6]Natl Institute of Advanced Industrial Science and Technology, Sapporo, Japan

P335 Exclusive Detection of U-p53AZ in Alzheimer's Disease Compared to Other Neurodegenerative Diseases

Presenteur : David Lynch

David Lynch[1, 2], Sam Agus[3], Rakez Kayed[1, 2], Madison Samples[1, 2], Yu-Hsiu Wang[4], Rasche Michael[3], Kinnon Paul[3], Simona Piccirella[5]
[1]Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, United States, [2]Department of Neurology and Neurobiology, University of Texas Medical Branch, [3]Diadem Inc, Palo Alto, United States, [4]Department of Biochemistry and Molecular Biology, UTMB, Galveston, United States, [5]Diadem SpA, Milano, Italy

P336 MPS-AD: Human iPSC-Derived Microphysiological Systems Capture Molecular Heterogeneity and Enable Therapeutic Screening in Alzheimer's Disease

Presenteur : Annabel Curle

Annabel Curle[1, 2], Anna Cramer[1], Kellianne Alexander[1], Fasih Ahsan[1], Garrett Fogo[1], Courtney Benoit[1], Richard Pearse[1], Christina Muratore[1], Duc Duong[3], Nicholas Seyfried[3], David Bennett[4], Tracy Young-Pearse[4]
[1]Mass General Brigham, Boston, United States, [2]Harvard Medical School, Boston, United States, [3]Emory School of Medicine, Atlanta, United States, [4]Rush University Medical Center, Chicago, United States

P337 AI-guided protein design combined with multiplexed in vivo screening identifies novel shuttles that efficiently deliver Alzheimer's therapeutics into the CNS with improved pharmacokinetics, biodistribution and target engagement

Presenteur : Kimberly Scearce-Levie

Kimberly Scearce-Levie, Alvaro Garcia, Isabel Albuja, Alex Gerew, John Avera, Glenn Hauk, Noa Liberman-Isakov, Marshall Case, Sharon McGonigle, Brianna Unda, Fabliha Anam, Hala Haddad, Gleb Kuznetsov, Pierce Ogden
Manifold Bio, Boston, United States

P338 Design and characterization of KRSA-028, a novel bispecific antibody targeting amyloid beta and transferrin receptor with selective effector function modulation

Presenteur : Maribel Reyes

Maribel Reyes[1], Bernard Liu[2], Melissa Conerly[2], Kevin J. Kramer[2], Kalyan Pande[2], Erin Clark[3], Alexander A. Mitkas[2], Russell Sanderson[3], Joana Vidal[2], Byron H. Kwan[2], Ghassan N. Fayad[2], Jennifer Sager[1], Jason Oh[2], Michael Meehl[2], Angela She[1]
[1]Korsana Biosciences, Waltham, Ma, United States, [2]Paragon Therapeutics, Waltham, Ma, United States, [3]Formerly of Paragon Therapeutics, Waltham, Ma, United States

P339 Next-generation tau immunotherapy: NIDB-3101 biparatopic antibody PK, PD and tolerability data in NHP

Presenteur : Sylvain Lehmann

Sylvain Lehmann[1], Nicolas Pradeilles[1], Nadia Anceriz[2], Bruno Daubeuf[2], Pauline Lloveras[2], Laurence Chatel[2], Alizée Viandier[2], Adeline Lesnier[2], Eric Hatterer[2], Roman Rösemann[3], Oleg Demin Jr[4], Dmitry Shchelokov[4], Galina Saynukova[4], Jean-Philippe Courade[5]
[1]Laboratoire de Biochimie Protéomique Clinique CHU Montpellier, Hôpital St Eloi, IRMB, Montpellier, France, Montpellier, France, [2]Light Chain Bioscience - Novimmune SA, Geneva, Switzerland, Geneva, Switzerland, [3]Granzer Regulatory Consulting & Services, Muenchen, Germany, Muenchen, Germany, [4]InSysBio CY, Paphos, Cyprus, Paphos, Cyprus, [5]Discoveric bio alpha Ltd., Pfäffikon, Schwyz, Switzerland, Schwyz, Switzerland

P340 Exercise Training-Mediated Mitochondrial Modulation in the Alzheimer's Disease Hippocampus

Presenteur : Sean Kao

Sean Kao[1, 2], Farhan Yousaf[3], Shahid Ishaq[3], Iqbal-Ali Shah[3], Bor-Tsang Wu[4], Shin-Da Lee[3]
[1]Boston Medical Center, Boston, United States, [2]Johns Hopkins University, Baltimore, United States, [3]China Medical University, Taichung, Taiwan, [4]National Taichung University of Science and Technology, Taichung, Taiwan

P341 Alzheimer's Disease Patient Biology in a Dish

Presenteur : Marama Diaz-Asper

Tetsuya Tanaka, Yasaman Anzabi, Marama Diaz-Asper
Ricoh Biosciences, Baltimore, United States

P342 Translating single-cell multi-omics discoveries into APOE-targeted epigenome therapy for Alzheimer's Disease

Presenteur : Ornit Chiba-Falek

Bernadette O'Donovan[1], Keats Shwab[1], Boris Kantor[2], Ornit Chiba-Falek[1]
[1]Duke University, Durham, United States, [2]FSU, Durham, United States

P343 A postmortem whole human brain platform for Alzheimer's disease drug discovery

Presenteur : Paul Wes

Paul Wes, Nghia Nguyen, Congwei Wang, Scott Pope, Josip Butkovic, Ivan Mumlek, Chunmin Ge, Leah Rosales, Lindsay Slupczewski, Lucija Barisic, Brad Parry, Sean Murphy, Zvonimir Vrselja
Bexorg, New Haven, United States

P344 Systemic administration of a cell-internalizing CYTOPE® targeting phospho-TDP-43 achieves higher brain drug levels than parent pTDP-43 mAb and reduces CNS intraneuronal pathology in a mouse model of TDP-43 proteinopathy

Presenteur : Philip Dolan

Stephen Tam, Ian Gallager, Lauri Li, Kimberly Thomas, Heather Prill, Gang Zhang, Joshua Salmans, Erich Goldbach, Leeann Louie, Robert Brendza, Tarlochan Nijjar, Brian Campbell, Wagner Zago, Philip Dolan
Prothena Biosciences, Brisbane, United States

P345 Translational Efficacy, Vascular Safety, and IND-Enabling Development of GAIA-Aβ, a TAM Receptor-Engaging Amyloid-Beta Therapeutic

Presenteur : Jin Kyung Lee

Jin Kyung Lee[1], Soo Min Ji[1], Chanhyuk Kim[2], Wonsuk Chung[3], Sanghoon Park[1]
[1]Illimis Therapeutics., Inc., Seoul, Korea, Republic of, [2]Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea, Republic of, [3]Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea, Republic of

P346 Mechanistic and Therapeutic Evaluation of Small Molecule Tau Disaggregases as a treatment for Alzheimer's Disease

Presenteur : Nader Mostowfi

Nader Mostowfi, Foreman Ryan, Paul Seidler, Syed Ahmed, Michael Jakowec, Giselle Petzinger
University of Southern California, Los Angeles, United States

P347 Caspase-1 inhibitor VX-765 restores cognition across early, intermediate, and advanced stages of Alzheimer disease pathology in the J20 APPSwe/Ind mouse model

Presenteur : Andrea Leblanc

Andrea Leblanc[1], Joseph Flores[2], Anastasia Noel[2], Marie-Lyne Fillion[3]
[1]Casp-Aid Inc., Montreal, Canada, [2]McGill U, Montreal, Canada, [3]Lady Davis Institute, Montreal, Canada

P348 Cognitive-Metabolic Decoupling: A Quantitative Trait of Cognitive Resilience for Predicting MCI-to-Dementia Conversion in Alzheimer's Disease

Presenteur : Dany Mukesha

Dany Mukesha
Université Côte d'Azur, Colmar, France

P349 Trends in Episodic Memory and Cognitive Symptoms in Cognitively Normal APOE2 Homozygotes

Presenteur : Aimen Vanood

Aimen Vanood, Meredith Wicklund, Donna Locke, Blake Langlais, Richard Caselli, Bryan Woodruff
Mayo Clinic, Scottsdale, United States

P350 Binding profile of lecanemab in brain of patients with early Alzheimer's disease

Presenteur : Linda Söderberg

Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou, Karolina Minta, Olof Zachrisson, Gunilla Osswald, Lars Lannfelt, Christer Möller
BioArctic AB, Stockholm, Sweden

P351 Clearing Tau from the Inside Out: TRIM21-Mediated Immunotherapy Against Intracellular Tau Pathology

Presenteur : Nemil Bhatt,

Nemil Bhatt, Nikita Shchankin, Twisha Chatterjee, Jia Yi Liew, Balci Ahmet, Dhvani Pansuriya, Rakez Kayed
University of Texas Medical Branch, Galveston, United States

P352 Neural crest-derived nasal turbinate stem cells enhance the therapeutic efficacy of FDA-approved anti-A immunotherapy in patient-derived Alzheimer's disease cerebral organoids

Presenteur : Sung Won Kim

Jung Yeon Lim[1], Jung Eun Lee[2], Seung Ho Yang[2], Hyun Kook Lim[3], Sung Won Kim[1]
[1]Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of, [2]Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of, [3]Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of

P353 Preclinical Validation of VGF-Derived Peptide TLQP-21 as an Intranasal Therapeutic in the 5xFAD Mouse Model of Alzheimer's Disease

Presenteur : Meenakshi Bose

Meenakshi Bose[1], Allen Pan[1], Gabriela Farias-Quipildor[2, 3], Yong Huang[1, 3], Minghui Wang[4], Michelle Ehrlich[3], Stephen Salton[1]
[1]Nash Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, United States, [2]Nash Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, New York, United States, [3]Departments of Neurology, Genetics and Genomic Sciences, and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, United States, [4]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

P354 HET3 mice are a model of brain aging: evidence for dendritic spine loss, proteome perturbations, and spatial learning deficits during aging.

Presenteur : Josh Krivinko

Josh Krivinko[1], Susan Erickson[1], Akayla Lewin[1], Jiaqian Liu[2], Matthew Macdonald[1], Jason Newman[1], Stacey Rizzo[3], Robert Sweet[1, 4]
[1]Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States, [2]Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, United States, [3]Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, United States, [4]Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh

P355 Preclinical Evaluation of CATA-002, a Novel Aβ/TfR Bispecific Brain-Shuttled Catalytic Antibody for Enhanced Brain Penetration and Enzymatic Aβ Degradation in Alzheimer's Disease

Presenteur : Yue Liu

Wang Bo, Hoag Mattew, Shan Yuxi, Dong Jianbo, Fay Nathan, Spadoni Nicholas, Putrevu Saroja, Titong Allison, Yue Liu
Ab Studio Inc., Hayward, Ca, United States

P356 QSP platform of Alzheimer's Disease for exploring efficacy of anti-tau immunotherapy bepranemab

Presenteur : Tatiana Karelina

Tatiana Karelina, Dmitry Gordeev, Olga Ivanova, Polina Maliukova
InSysBio, Paphos, Cyprus

P357 next-generation tau immunotherapy: NIDB-3101 biparatopic antibody PK, PD and tolerability data in NHP

Presenteur : Jean-Philippe Courade

Jean-Philippe Courade[1], Nadia Anceriz[2], Roman Rösemann[3], Pauline Lloveras[2], Laurence Chatel[2], Bruno Daubeuf[2], Alizée Viandier[2], Adeline Lesnier[2], Eric Hatterer[2], Oleg Demin Jr[4], Dmitry Shchelokov[4], Galina Saynukova[4], Nicolas Pradeilles[5], Sylvain Lehmann[5]
[1]Discoveric Bio Alpha, Pfäffikon, Switzerland, [2]Light Chain Biosciences, Plan Les Ouates, Switzerland, [3]Granzer, Muenchen, Germany, [4]Insysbio, Paphos, Cyprus, [5]Laboratoire de Biochimie Protéomique Clinique CHU Montpelier, Montpelier, France

P358 Polygenic risk score–based frailty index predicts conversion to tau-positivity in Alzheimer's disease

Presenteur : Mi-Young Oh

Mi-Young Oh[1], Sang-Hyuk Jung[2]
[1]Department of Neurology, Sejong General Hospital, Bucheon-Si, Korea, Republic of, [2]Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Korea, Republic of

P359 How Re:Cognition Health (RCH) has Fast Tracked Patients to Receive Amyloid Targeted Treatment (ATT)

Presenteur : Emer MacSweeney

George Robinson[1, 2], Penny Muir[1], Emer Macsweeney[1]
[1]Cognition Health, London, United Kingdom, [2]Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

P360 Synergistic Effects of Mild Behavioral Impairment and APOE 4 on Cognitive Function in a Community-Based Middle-Aged and Older Population

Presenteur : Cheng-Sheng Chen

Cheng-Sheng Chen, Yi-Chun Yeh, Hsiu-Fen Lin
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

TRIAL DESIGN, STATISTICAL INNOVATION, AND ANALYTICAL FRAMEWORKS

P361 A harmonized multi-trial resource for understanding Alzheimer's disease progression, heterogeneity, and sex differences

Presenteur : Caitlin McHugh

Caitlin McHugh[1], Matthew Clement[1], Niranjan Bose[1], Caleb Daley[2], Suzanne Hendrix[2], Julie Wood[3]
[1]Alzheimer's Disease Data Initiative, Kirkland, United States, [2]Pentara, Millcreek, United States, [3]Vivli, Cambridge, United States

P362 Design-Induced Circularity in Alzheimer's Biomarker Trials and Trial-Ready Cohorts: Enrichment, Data-Driven Selection, and Estimand Mismatch

Presenteur : Khushboo Verma

Khushboo Verma, Satwant Kumar
University of Texas at Tyler, TYLER, United States

P363 Disaggregating Asian Populations in a Global Preclinical Alzheimer's Disease Trial: Recruitment, Screening and Randomization in the AHEAD 3-45 Study

Presenteur : Marina Ritchie

Marina Ritchie[1], Kedir Hussen[1], Oliver Langford[1], Maddox S. Bray[2], Shobha Dhadda[3], Michael Irizarry[3], Yasumi Kitahara[4], Reisa A. Sperling[5], Joshua D. Grill[6], Rema Raman[1]
[1]Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [2]University of California, Santa Barbara, Santa Barbara, United States, [3]Eisai Inc., Nutley, United States, [4]Eisai Co., Ltd., Tokyo, Japan, [5]Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, United States, [6]University of California, Irvine, Irvine, United States

P364 Assessing Efficiency in Adaptive ADRD Trial Frameworks: A Systematic Comparison of Group Sequential and Promising Zone Designs

Presenteur : Sarah Schlund

Sarah Schlund[1], Joshua Grill[2, 3, 4, 5], Daniel Gillen[1, 2]
[1]Department of Statistics, University of California, Irvine, Irvine, United States, [2]University of California, Irvine Institute for Memory Impairments and Neurological Disorders, Irvine, United States, [3]Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States, [4]Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, United States, [5]Institute for Clinical and Translational Science, University of California Irvine, Irvine, United States

P365 Plasma p-tau217 In Early Alzheimer's Disease Trial Screening: Insights from START

Presenteur : Marina Ritchie

Marina Ritchie[1], Oliver Langford[1], Yixuan Liang[1], Daniel Burns[2], Charlene Flournoy[1], Joshua D. Grill[3], Anthony Caggiano[4], Michael Grundman[5], Robert A. Rissman[1], Paul Aisen[1], Christopher H. Van Dyck[6], Rema Raman[1]
[1]Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [2]The University of Kansas, Lawrence, United States, [3]University of California, Irvine, Irvine, United States, [4]Cognition Therapeutics, Inc., Purchase, United States, [5]Global R&D Partners, LLC, San Diego, United States, [6]Yale School of Medicine, New Haven, United States

P366 Digital Informed Consent Process for Older Adults with Cognitive Impairments

Presenteur : Fuad Abujarad

Fuad Abujarad, Chelsea Edwards
Yale School of Medicine, New Haven, United States

P367 A Shiny-based Clinical Trial Power Simulator Leveraging 20+ Years of the ADNI as a Longitudinal Biomarker and Comorbidity Data

Presenteur : Isabella Hausle

Isabella Hausle
Northern California Institute for Research and Education, Los Angeles, United States

P368 Biological heterogeneity at clinical conversion to mild cognitive impairment: Implications for Alzheimer's disease clinical trials

Presenteur : Alison Myoraku

Alison Myoraku, Marta Mila-Aloma, Isabella Hausle, Pamela Thropp, Duygu Tosun
NCIRE/UCSF, San Francisco, United States

P369 Association of Within-Domain Outcome Measure Multiplicity with Statistically Significant Treatment Benefits in Alzheimer's Disease Drug Trials

Presenteur : Can Li

Can Li[1], Mengyuan Fu[1, 2], Karina Berg[3], Luwen Shi[1], Joseph Ross[2], Xiaodong Guan[1]
[1]Peking University, Beijing, China, [2]Yale School of Medicine, New Haven, United States, [3]University of Connecticut School of Medicine, Farmington, United States

P370 Clinical Trials Should Run Multi-Omic Foundation Models in the Loop

Presenteur : Arvid Gollwitzer

Arvid Gollwitzer[1, 2], Adrian Noriega De La Colina[1, 2, 3], Li-Huei Tsai[1, 4], Miia Kivipelto[5, 6], Giovanni Traverso[1, 2, 7]
[1]Broad Institute of MIT and Harvard, Cambridge, United States, [2]Massachusetts Institute of Technology, Cambridge, United States, [3]Brigham and Women's Hospital, Boston, United States, [4]The Picower Institute for Learning and Memory, Cambridge, United States, [5]FINGERS Brain Health Institute, Stockholm, Sweden, [6]Karolinska Institutet and Karolinska University Hospital,, Stockholm, Sweden, [7]Divison of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, United States

P371 Leveraging the NACC Data Platform and ADRC Network Infrastructure to Operationalize CLARiTI: A Model for Multimodal Data Coordination in AD/ADRD Research

Presenteur : Heather O'connell

Heather O'Connell[1], Erin Chin[2], Shilpa Allimatti[1], Hannah Koenig[1], Laura McLeod[1], Christine Mac Donald[1], Lindsay Clark[2], Tatiana Foroud[3], Gil Rabinovici[4], Elizabeth Mormino[5], Sterling Johnson[2], Walter Kukull[6], Sarah Biber[6, 7]
[1]National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, United States, [2]Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States, [3]Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States, [4]Fein Memory & Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, California, United States, [5]Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, United States, [6]Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States, [7]Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States

P372 The Financial and Societal Impact of Compromised Data Integrity in AD Trials and the Importance of Early Detection and Monitoring

Presenteur : Maycee A. Robison

Maycee A. Robison, Garrett B. Duncan, John Whetten, Mitchell B. Wassom, Samuel P. Dickson, Suzanne B. Hendrix
Pentara Corporation, Millcreek, United States

P373 Power analyses for stepped wedge designs with multivariate continuous outcomes

Presenteur : Kendra Plourde

Kendra Plourde[1], Monica Taljaard[2], Fan Li[3]
[1]Yale School of Public Health - New Haven (United States), New Haven, United States, [2]Ottawa Hospital Research Institute, Ottawa, Canada, [3]Yale School of Public Health, New Haven, United States

P374 MinDSet: Training to Support Clinical Research Sites to Help Individuals with Down Syndrome Thrive

Presenteur : Thomas Mahan

Kate O'Neill, Amy Shapley-Farrell, Lois Kelly, Thomas Mahan
NDSS,

P375 Leveraging Anti-Amyloid Clinical Trial Screening to Establish a Longitudinal Primary Prevention Cohort: APEX Recruitment Strategy and Baseline Findings

Presenteur : Oliver Langford

Doris Molina-Henry[1], Andy Liu[1], Oliver Langford[1], Rema Raman[1], Michael Donohue[1], Andrew Mellor[1], Gustavo Jimenez-Maggiora[1], Robert Rissman[1], Keith Johnson[2], Paul Aisen[1], Reisa Sperling[2]
[1]Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [2]Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, United States

P376 Improving efficiency of preclinical Alzheimer's disease anti-amyloid trial recruitment using a community-based recruitment registry (Dutch Brain Research Registry)

Presenteur : Marissa Zwan

Lisa Waterink[1, 2, 3], Elliz Scheijbeler[1, 2], Sietske Sikkes[1, 2, 4], Inge Verberk[1, 5], Jurgen Claassen[6, 7, 8], Ondine Van De Rest[9], Nynke Smidt[10], Sebastian Köhler[11], Esther Aarts[7], Everard Vijverberg[1, 2], Marissa Zwan[1, 2]
[1]Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, [2]Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands, [3]Precision Health Clinic, Amsterdam, The Netherlands, [4]Faculty of Behavioural and Movement Sciences, Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit, Amsterdam, The Netherlands, [5]Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, [6]Department of Geriatrics, Radboudumc Alzheimer Center, Radboud University Medical Center, Nijmegen, The Netherlands, [7]Cognition and Behaviour, Donders Institute for Brain, Radboud University, Nijmegen, The Netherlands, [8]Department of Cardiovascular Sciences, Leicester University, Leicester, United Kingdom, [9]Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands, [10]Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, [11]Mental Health and Neuroscience Research Institute (MHeNs), Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands

P377 Prognostic versus propensity-score covariates for trial efficiency across the Alzheimer's disease spectrum: an evaluation in dominantly-inherited and preclinical AD

Presenteur : Yuchen Cao

Yuchen Cao, Guoqiao Wang, Jorge Llibre-Guerra, Eric McDade, Randall Bateman
Washington University in St. Louis, St. Louis, United States

P378 Pragmatic Barriers to Inclusivity in Geriatric Clinical Trials

Presenteur : Saeed Hashem

Saeed Hashem
McLean Hospital, Belmont, United States

P379 Neighborhood Deprivation as a Moderator of the Association between Travel Time and Alzheimer's Disease Clinical Trial Enrollment and Completion

Presenteur : Sean Womack

Sean Womack, Sarah Starling, Colin Sauder
Adams Clinical, Watertown, United States

P380 2D or Not 2D: Transition from 2D to a 3D Analysis Model for Ioflupane I-123 SPECT

Presenteur : Victoria Hegedus

Victoria Hegedus[1], Nicole Hurley[1], Samuel Lockhart[1, 2], David Cash[1, 3], Elif Sikoglu[1], Joseph Petrulli[1]
[1]Perceptive, Burlington, United States, [2]Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, United States, [3]UCL Queen Square Institute of Neurology, London, United Kingdom

P381 Association of MAO-B Inhibitors with Cognitive Decline Over 10 Years in Parkinson's Disease: A Quasi-Experimental Study

Presenteur : Joao Pedro Ferrari-Souza

Joao Pedro Ferrari-Souza[1, 2], Alberto Serrano-Pozo[1, 2, 3]
[1]Mass General Brigham, Boston, United States, [2]Harvard Medical School, Boston, United States, [3]Massachusetts Alzheimer's Disease Research Center, Charlestown, United States

P382 Improving efficiency of preclinical Alzheimer's disease anti-amyloid trial recruitment using memory clinic-based screening

Presenteur : Elliz P. Scheijbeler

Elliz P. Scheijbeler[1, 2], Lisa Waterink[1, 2, 3], Sterre C. M. De Boer[1, 2], Betty M. Tijms[1, 2], Argonde C. Van Harten[1, 2], Everard G. B. Vijverberg[1, 2], Marissa D. Zwan[1, 2]
[1]Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, [2]Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands, [3]Precision Health Clinic, Amsterdam, The Netherlands

P383 Symmetric Centipolar Normalized Score (SCeNS): a standardization framework for fluid marker cross-comparability in Alzheimer's disease

Presenteur : Jigyasha Timsina

Jigyasha Timsina[1], Yike Chen[1], Menghan Liu[1], Rui Mu[1], Katherine Gong[1], John Budde[1], Guoqiao Wang[1], Yan Li[1], Suzanne E. Schindler[1], John C. Morris[1], David M. Holtzman[1], Randall J. Bateman[1], Timothy Hohman[2], Carlos Cruchaga[1]
[1]Washington University in St. Louis, St. Louis, United States, [2]Vanderbilt University Medical Center, Nashville, United States

P384 Expanded Access as a Dual-Mandate Model for Real-World Evidence Generation in Alzheimer's Disease: Lessons from a Decentralized ALS Program

Presenteur : Ildefonso Vicente-Suarez

Ildefonso Vicente-Suarez[1], Bjorn Oskarsson[2], Shona Allen[1], Ramana Sonty[3], Jess Rabourn[3]
[1]WideTrial, San Jose, United States, [2]Mayo Clinic Florida, Jacksonville, United States, [3]Strata Partners, San Jose, United States

P385 Portable, Low-field MRI Combined with Machine Learning Segmentation for Cognitively Impaired Individuals

Presenteur : Ava Farnan

Ava Farnan[1, 2], Annabel J. Sorby-Adams[1, 2], John R. Dickson[1], Liliana Ramirez Gomez[1], Arman Fesharaki-Zadeh[3], Christopher Van Dyck[4], Matthew S. Rosen[5], Kevin N. Sheth[4], J. Eugenio Iglesias[6], Adam De Havenon[4], Teresa Gomez-Isla[1], Alberto Serrano Pozo[1], W. Taylor Kimberly[7, 2]
[1]Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, United States, [2]Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States, [3]Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA, New Haven, United States, [4]Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA - United States, New Haven, United States, [5]Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA - United States, Boston, United States, [6]Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, United States, [7]Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA - United States, Boston, United States

P386 IMPACT-AD LATAM: A Regional Training Program to Strengthen ADRD Clinical Trial Capacity in Latin America

Presenteur : Lucia Crivelli

Ma. Florencia Clarens[1], Maria C. Carrillo[2], Joshua D. Grill[3], Rema Raman[4], Heather M. Snyder[2], Lucia Crivelli[1], Jorge Llibre-Guerra[5]
[1]Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina, [2]Division of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, United States, [3]Institute for Memory Impairments and Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University of California, Irivine, United States, [4]Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [5]Department of Neurology, Washington University in St. Louis, St Louis, United States

P387 Listening Before Recruiting: Community Listening Sessions to Improve Alzheimer's Research Engagement

Presenteur : Sonia Simons

Marilyn Wilson[1], B. Joy Snider[1], David Carr[1], Maryanna Milanez[2], Emily Dugan[1], Jordan Kulage[1], Sonia Simons[1]
[1]Washington University School of Medicine, St. Louis, United States, [2]Global Alzheimer's Platform Foundation, Inc., Chicago, United States

P388 Design considerations of a phase II multi-site randomized controlled trial of Harmony Dementia Care: a sensory-based intervention for people with Alzheimer's disease and related dementias

Presenteur : Elizabeth K. Rhodus

Elizabeth K. Rhodus[1], David S. Geldmacher[2], Rema Raman[3], Michael Donohue[3], Laura Henley[1], Clarissa Benzarti[1], April Stauffer[1], Nancy Wolff[1], Kennedy Walcott-George[1], Susan Westneat[1], Carolyn Baum[4], Paul Aisen[3]
[1]University of Kentucky, Lexington, United States, [2]University of Alabama at Birmingham, Birmingham, United States, [3]Alzheimer's Therapeutic Research Institute, San Diego, United States, [4]Washington University in St. Louis, St. Louis, United States

P389 Age-Dependent Sensitivity of the MMSE for Detecting Amyloid-Confirmed Alzheimer's Disease

Presenteur : Dorothy MacFarlane

Dorothy Macfarlane, Hale Hailie, Nolan Hadley, Vera Lukas, Poplyk Sophia, Namaky Nauder
Adams Clinical, Watertown, United States

P390 Advancing Alzheimer's Disease Clinical Trials Through the Critical Path for Alzheimer's Disease Consortium (CPAD)

Presenteur : Diane Stephenson

Yashmin Karten[1], Nicholas Henscheid[1], Colleen Jacobsen[1], Hartmuth Kolb[2], Klaus Romero[1], Gregory Klein[3], Diane Stephenson[1]
[1]Critical Path Insititute, Tucson, United States, [2]Enigma Biomedical Group, Knoxville, United States, [3]F. Hoffmann-La Roche Ltd., Basel, Switzerland

P391 Responsible Data Sharing at Scale: Building Tiered Open Science Infrastructure for ADRD Clinical Trials

Presenteur : Richard Gallardo

Richard Gallardo[1], Christian Navarro[1], Michael Donohue[1], Oliver Langford[1], Brenda Armenta-Copca[1], Hongmei Qiu[1], Paul Newhouse[2], Paul Aisen[1], Gustavo Jimenez-Maggiora[1]
[1]University of Southern California, San Diego, United States, [2]Vanderbilt University, Nashville, United States

P392 Achieving Greater Generalizability in Alzheimer's Clinical Trials through a Multi-sector Committee

Presenteur : Daphne Delgado

Christine Lee[1], Christopher Miller[2], Michelle Bruno[3], Daphne Delgado[2], Sam Dickson[4], Martine Meyer[5], Constantina Mizis[6], Jonathan Tobin[7], Charisse Winston[8], Michael Weiner[9]
[1]ACHIEVE Expertise, , United States, [2]UsAgainstAlzheimer's, , United States, [3]MB Insights, LLC, , United States, [4]Pentara Corporation, , United States, [5]The Janssen Pharmaceutical Companies of Johnson & Johnson, , United States, [6]Latino Alzheimer's and Memory Disorders Alliance, , United States, [7]Clinical Directors Network, , United States, [8]University of Southern California, , United States, [9]University of California, San Francisco, , United States

P393 From short-term data to long-term trajectories: Statistical modeling framework for predicting multidomain progression in Alzheimer's disease

Presenteur : Ryoichi Hanazawa

Ryoichi Hanazawa, Hiroyuki Sato, Shin Watanabe, Ryo Kitabayashi, Akihiro Hirakawa
Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan

P394 Clinical and operational determinants of amyloid-targeting therapies treatment initiation in early Alzheimer's Disease: A discrete choice experiment

Presenteur : Elena Garcia Arcelay

Juan Fortea[1], Elena Garcia Arcelay[2], Alberto Villarejo[3], Raquel Sanchez Del Valle[4], Neus Canal[5], Monica Sarmiento[5], Jorge Mauriño[2], Guillermo Garcia-Ribas[6], Gustavo Saposnik[7]
[1]Sant Pau Memory Unit, IR SANT PAU, Hospital Universitario de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona., Barcelona, Spain, [2]Medical Department, Roche Farma, Madrid, Spain, [3]Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain, [4]Department of Neurology, Hospital Clinic, FRCB- IDIBAPS, Universidad de Barcelona, Barcelona, Spain, [5]RWCS, IQVIA Information, Madrid, Spain, [6]Department of Neurology, Hospital Universitario Ramón y Cajal, Madrid, Spain, [7]Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Canada. Clinical Outcomes and Decision Neuroscience Unit, Li Ka Shing Institute, University of Toronto, Toronot, Canada

P395 Most Screening–Baseline MMSE Variability Is Individual Noise: Pooled Analysis of 17 Alzheimer's Trials

Presenteur : David Miller

David Miller[1], Alan Kott[2], Xingmei Wang[3]
[1]Signant Health, Philadelphia, United States, [2]Signant Health, Prague, Czechia, [3]Signant Health, Blue Bell, United States

P396 The Effects of Benzgalantamine (ZUNVEYL®) on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in the Treatment of Mild to Moderate Alzheimer's Dementia. RESOLVE: a Phase IV Open-label Study

Presenteur : Denis Kay

Michael McFadden, Denis Kay, Carson Harrod, Pavel Svintozelskiy, Andrew Wahlert, Kurt Grady
Alpha Cognition Inc., Grapevine, United States

P397 From Initial Enthusiasm to Routine Practice: Temporal Changes in Anti-Amyloid Therapy Uptake and Eligibility in Japan

Presenteur : Ryoko Ihara

Ryoko Ihara, Masanori Kurihara, Keiko Hatano, Taro Bannai, Ryosuke Shimasaki, Akira Hatakeyama, Ko Furuta, Fumio Suzuki, Aya Tokumaru, Kenji Ishii, Atsushi Iwata

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

COGNITIVE AND FUNCTIONAL OUTCOMES

P398 Cross-omic and clinicopathological profiling of cellular senescence signatures in Alzheimer's disease

Presenteur : Vidyani Suryadevara

Vidyani Suryadevara[1], Rohit Suresh[2], Vasudha Kannan[3]
[1]Department of Genetics, Stanford University, Stanford, United States, [2]All India Institute of Medical Sciences, New Delhi, Delhi, India, Delhi, India, [3]Department of Biotechnology, Indian Institute of Technology Madras, Chennai, India

P399 Capturing clinically meaningful change in preclinical Alzheimer's disease using the Amsterdam IADL Questionnaire as outcome measure

Presenteur : Roos Jutten

Roos Jutten, Luise Wagner, Angela Van Der Putten - Toorenburg, Sophie Van Der Landen, Federica Anastasi, Charlotte Teunissen, Everard Vijverberg, Betty Tijms, Argonde Van Harten, Sietske Sikkes
Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands

P400 Altered hippocampal gamma activity is linked to cortical-cerebrospinal fluid dynamics in Alzheimer's disease

Presenteur : Xiaoduo Liu

Xiaoduo Liu, Yuanyuan Lu, Yi Xing, Yi Tang
Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China

P401 Financial Vulnerability as an Early Functional Marker of Alzheimer's Disease: From Neuroimaging to Plasma Biomarker Considerations

Presenteur : Duke Han

Duke Han, Jenna Axelrod, Aaron Lim, Belinda Zhang, Daisy Noriega-Makarskyy, Cassidy Molinare, Emma Oyen, Melanie Leguizamon, Camdyn Wu, Maanya Agarwal, Laura Mosqueda, Hussein Yassine
University of Southern California, Los Angeles, United States

P402 Virtual Reality Measures of Everyday Function and Cognition Characterizes the Risk of Early-Stage Alzheimer's Disease

Presenteur : James Galvin

James Galvin, Mustafa Shuqair
University of Miami Miller School of Medicine, Boca Raton, United States

P403 Increasing granularity in the Clinical Dementia Rating: Does a 0.25 Memory box score signal faster cognitive decline?

Presenteur : Mark A. Dubbelman

Mark A. Dubbelman[1, 2], Vivienne Lubbat[2], Hairin Kim[1, 2], Lex R. Minto[1, 2], Dorene M. Rentz[1, 2], Rachel F. Buckley[1, 2], Reisa A. Sperling[1, 2], Gad A. Marshall[1, 2], Rebecca E. Amariglio[1, 2], Kathryn V. Papp[1, 2]
[1]Center for Alzheimer Research & Treatment, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, United States, [2]Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, United States

P404 Streamlining the Alzheimer's Disease Diagnostic Journey through Primary Care: Real-World Insights from the Better DX Study

Presenteur : Rhonna Shatz

Rhonna Shatz[1], Katherine Schmidt[1], Jinda Bowerman[1], Jackson Hearn[1], Feride Frech[2], Bryan Cobb[2], Courtney Adams[2], Yosuke Nakamura[2], Rifky Tkatch[2], Hideki Toyosaki[2]
[1]University of Cincinnati, Cincinnati, United States, [2]Eisai Inc., Nutley, United States

P405 Unawareness of medication self-administration errors as a clinical outcome and marker of cognitive decline.

Presenteur : A.M. Barrett

A.M. Barrett[1], Honghuang Lin[1], Joanne Murabito[2], Emily Muller[1]
[1]UMass Chan Medical School, Worcester, United States, [2]UMass Chan Medical School, Boston, United States

P406 Lecanemab Treatment in a New England Alzheimer's Disease Center: Real-World Outcomes From a Single-Center, Retrospective Case Series

Presenteur : Salvatore Napoli

Salvatore Napoli, Rachel O' Donnell, Lauren Nassr, Emily Maize
Alzheimer's Neurology and Infusion Centers of New England, Foxboro, United States

P407 Real-World Effectiveness, Safety, and Patient Experience of Lecanemab in the United States: A Systematic Literature Review

Presenteur : Gregory Jicha

Gregory Jicha[1], Chenyue Zhao[2], Dominic Igbelina[3], James Frampton[3], Henry Ogden[3], Feride Frech[2], Hideki Toyosaki[2], Joanna Campbell[3], Liana Apostolova[4]
[1]University of Kentucky College of Medicine, Lexington, United States, [2]Eisai Inc., Nutley, United States, [3]Thermo Fisher Scientific Inc., Waltham, United States, [4]Indiana University School of Medicine, Indianapolis, United States

P408 A Harmonized Multi-Cohort Evaluation of SOMI Stages for Predicting Cognitive Impairment

Presenteur : Priyanka Kumari

Priyanka Kumari[1], Richard B. Lipton[1, 2, 3], Cuiling Wang[3], Ellen Grober[1]
[1]Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, United States, [2]Montefiore Medical Center, Bronx, NY, United States, [3]Department of Epidemiology & Population Health, Bronx, NY, United States

P409 Measuring meaningful benefits across cultures in AD trials: feasibility, applicability, and user acceptability of the ePSOM tool in Japanese memory clinics

Presenteur : Ali Jannati

Stina Saunders[1, 2], Yuki Takeda[3], Hisatomo Kowa[4], Atsushi Iwata[5], Norio Chihara[6], Himanshi Malik[1], Ali Jannati[1, 7], Claudio Toro-Serey[1], Sean Tobyne[1], Ricky Kurzman[8], Yosuke Nakamura[9], Jo Vandercappellen[10], Álvaro Pascual-Leone[1, 7, 11]
[1]Linus Health, Boston, United States, [2]University of Edinburgh, Edinburgh, United Kingdom, [3]Kobe University, Graduate School of Medicine, Division of Neurology, Kobe, Japan, [4]Kobe University, Graduate School of Medicine, Department of Health Sciences, Suma-ku, Kobe, Japan, [5]Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [6]Kobe University, Graduate School of Medicine, Division of Neurology, Tokyo, Japan, [7]Department of Neurology, Harvard Medical School, Boston, United States, [8]Eisai Inc., Nutley, United States, [9]Eisai Co Ltd, Tokyo, Japan, [10]Eisai Pharma AG, Zurich, Switzerland, [11]Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States

P410 Advancing Personalized Outcome Assessment in Frontotemporal Dementia: A Standardized Goal Inventory for Goal Attainment Scaling (GAS) in Clinical Trials

Presenteur : Chere Chapman

Gunes Sevinc[1], Chere Chapman[2], Kaitlin Casaletto[3], Howie Rosen[3], Kenneth Rockwood[4]
[1]Ardea Outcomes, Vancouver, Canada, [2]Ardea Outcomes, Halifax, Canada, [3]University of California, San Francisco, San Francisco, Canada, [4]University of California, San Francisco, Halifax, Canada

P411 Real-World Cognitive,Safety and Biomarker Outcomes Among Patients Receiving Anti-Amyloid Monoclonal Antibodies in ALZ-NET

Presenteur : Gil Rabinovici

Gil Rabinovici[1], Alireza Atri[2], Kirk Daffner[3], Constantine Gatsonis[4], Oscar Lopez[5], Anton Porsteinsson[6], Katherine Possin[1], Stephen Salloway[7], Mary Sano[8], Christopher Whitlow[9], Charloes Windon[1], Michael Rafii[10], Maria Carrillo[11]
[1]Fein Memory and Aging Center, Depts. of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, United States, [2]Banner Alzheimer's & Research Institutes, Banner Research/Banner Health, Peoria, United States, [3]Harvard School of Medicine, Boston, United States, [4]Brown School of Public Health, Providence, United States, [5]University of Pittsburgh School of Medicine, Pittsburgh, United States, [6]University of Rochester School of Medicine, Rochester, United States, [7]Butler Hospital / Warren Alpert Medical School of Brown University, Providence, United States, [8]Mt Sinai School of Medicine, New York, United States, [9]Yale University / American College of Radiology, New Haven, United States, [10]Keck School of Medicine, University of Southern California, San Diego, United States, [11]Alzheimer's Association, Chicago, United States

P412 Estimating progression from MCI to dementia with a MoCA clock

Presenteur : Willem Huijbers

Willem Huijbers[1], Murray Gillies[1], Ziad Nasreddine[1], Suzanne Schindler[2], Kellen Petersen[2]
[1]MoCA Cognition, Montreal, Canada, [2]Department of Neurology, Washington University in St. Louis,, St.louis, United States

P413 Real-World Patient-Reported Outcomes with Subcutaneous Lecanemab Treatment in Early Alzheimer's Disease in the United States: A Case Series

Presenteur : Victor Faradji

Victor Faradji, Jaziel Rodriguez
First Choice Neurology and Visionary Investigators Network (VIN), Miami, United States

P414 Real-World Long-Term Persistence and Early Subcutaneous Maintenance Utilization of Lecanemab in the United States

Presenteur : Michael Rosenbloom

Diana Brixner[1], Chenyue Zhao[2], Hideki Toyosaki[2], Feride Frech[2], Michael Rosenbloom[3]
[1]Department of Pharmacotherapy, University of Utah College of Pharmacy,, Salt Lake City, United States, [2]Eisai Inc., Nutley, United States, [3]Memory and Brain Wellness Center, University of Washington, Seattle, United States

P415 Associations of frailty, cognition and amyloid status in preclinical Alzheimer's disease in prerandomization data from the AHEAD 3-45 study

Presenteur : Paul Yates

Andrew Huynh[1, 2, 3], David Ward[4], Scott Wrigley[1], Courtney Shelton[1], Sanka Amadoru[1, 2], Michael Woodward[1, 2], Louise Burrell[2], Paul Yates[1, 5]
[1]Department of Geriatric Medicine, Austin Health, Melbourne, Australia, [2]Department of Medicine, University of Melbourne, Melbourne, Australia, [3]Alzheimer's Research Australia, Melbourne, Australia, [4]Frazer Institute, Faculty of Health, Medicine & Behavioural Sciences, University of Queensland, Brisbane, Australia, [5]Department of Medicine, Melbourne, Australia

P416 High-Frequency Monitoring of Cognitive and Biomarker Changes in Healthy Aging Over One Year

Presenteur : Michelle Budman

Michelle Budman[1], Phyllis Tameilau[1], Alexandra N. Trelle[1], S. Subbulakshmi[2], Jintao Sheng[2, 3], Tran T. Nguyen[4], Divya Channappa[1], Gayle Deutsch[2], Holden T Maecker[5], Sharon Sha[1], Tony Wyss-Coray[1, 3], Anthony D. Wagner[2], Christina B. Young[6, 7], Joseph R. Winer[8], Elizabeth C. Mormino[1, 9]

[1]Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, United States, [2]Department of Psychology, Stanford University, Palo Alto, United States, [3]Phil and Penny Knight Initiative for Brain Resilience, Palo Alto, United States, [4]Institute for Immunity, Transplantation, and Infection Operations, Stanford University, Palo Alto, United States, [5]Department of Microbiology and Immunology, Stanford University, Palo Alto, United States, [6]Department of Radiology, UC Davis, Davis, United States, [7]Department of Neurology, UC Davis, Davis, United States, [8]Sutter Health Research Institute, San Francisco, United States, [9]Wu Tsai Neurosciences Institute, Palo Alto, United States

P417 A Retrospective, Case-Series Analysis of Lecanemab Treatment in Individuals with Early Alzheimer's at a Colorado Neurological Clinic

Presenteur : Adam Wolff

Adam Wolff

Porter Adventist Hospital, Colorado Neurological Clinic, Denver, United States

P418 Real-World Lecanemab Treatment in Early Alzheimer's Disease: A Retrospective Case Series from a Geriatric Medicine Clinical Practice

Presenteur : Margarita Reyes

Margarita Reyes, Mary Maxine Zapata Reyes

Office of Dr Reyes, Bristol, United States

P419 Repeated cognitive features for predicting clinical progression for preclinical Alzheimer's Disease

Presenteur : Shu Liu

Shu Liu[1], Yijing Xu[2], Chunming Xie[3], Hualou Liang[4, 5, 6], Xiaochuan Li[7], Qihong Lu[1]

[1]Department of Neuroscience, City University of Hong Kong, Hong Kong, China, [2]Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China, [3]Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Jiangsu Key Laboratory of Brain Science and Medicine, Southeast University, Nanjing, China, [4]Division of Artificial Intelligence and the Humanities, The Hong Kong Polytechnic University, Hong Kong, China, [5]Department of Language Science and Technology, The Hong Kong Polytechnic University, Hong Kong, China, [6]Departments of Data Science and Artificial Intelligence, The Hong Kong Polytechnic University, Hong Kong, China, [7]Hybribio Limited, Chaozhou, China

P420 Associations of episodic memory measures with Alzheimer's Disease biomarkers in clinically unimpaired participants: AHEAD3-45 screening data

Presenteur : MaryBeth Bailar

Marybeth Bailar, Karra Harrington, Jordan Barbone, Pam Ventola

Cogstate, New Haven, CT, United States

P421 Limitations of Cognitive Pre-sreening for Amyloid Enrichment in Early Alzheimer's Disease Trials. Results from Evoke programme at Neuroclnx Glasgow

Presenteur : Jennifer Lynch

Kanwal Aadil, Lucy Frenz, Sophie Mitchell, Areej Shaukat, Jennifer Lynch

Neuroclnx, Glasgow, United Kingdom

P422 Administration Fidelity of the Clinical Dementia Rating Scale: A Comparison of Central and Site Raters Across Alzheimer's Disease Clinical Trials

Presenteur : Svenja Wacker

Svenja Wacker[1], Jordan Barbone[2], Ed Bartolic[3], Robyn Leventhal[4], Aaron Vederman[5], Paul Maruff[6]

[1]Cogstate, Branford, United States, [2]Cogstate, Philadelphia, United States, [3]Cogstate, Newtown, United States, [4]Cogstate, Portland, United States, [5]Cogstate, New Castle, United States, [6]Cogstate, Melbourne, Australia

P423 Development of performance criteria to identify test compliance on the Online Repeatable Cognitive Assessment (ORCA)

Presenteur : Karra Harrington

Karra Harrington[1], Gabriel Stellman[1], Pam Ventola[1], Paul Maruff[2]

[1]Cogstate, New Haven, United States, [2]Cogstate, Melbourne, Australia

P424 Linguistic Profiles Based on Bilingualism and Verbal Fluency Are Associated with Longitudinal Cognitive Outcomes in a Multilingual Ageing Cohort

Presenteur : Gabriele Cattaneo

Gabriele Cattaneo[1], Simon Fankhauser[1], Gemma Albi-Villuendas[1], Alvaro Pascual-Leone[2], David Bartrés-Faz[3], Javier Solana-Sánchez[1]

[1]Guttmann Hospital de Neurorehabilitació, Badalona, Spain, [2]Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife, Boston, Spain, [3]Departament de Medicina, Facultat de Medicina i Ciències de la Salut, i Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain

P425 Experience, Not Education, Drives Rater Performance on the Clinical Dementia Rating Scale

Presenteur : Dorothee Schoemaker

Dorothee Schoemaker, Danielle Digregorio, Selam Negash, Cong Liu, Chris Randolph

Clario, part of Thermo Fisher Scientific, , United States

P426 Effects of regional tau accumulation on visual discrimination behaviors in clinically unimpaired older adults

Presenteur : Dhruv Kapadia

Dhruv Kapadia[1], Lucah Guerra[1], Isha Sai[1], Tyler Bonnen[2], Anthony Wagner[1], Elizabeth Mormino[1], Alexandra Trelle[1]
[1]Stanford University, Stanford, United States, [2]University of Pennsylvania, Philadelphia, United States

P427 Comparative analysis of lexical and acoustic speech biomarkers in mild cognitive impairment due to Lewy bodies and Alzheimer's disease

Presenteur : Min Seok Baek

Min Seok Baek[1, 2], Sung-Woo Kim[1], Han-Kyeol Kim[1], Mark Liberman[3], Sunghye Cho[4]
[1]Department of Neurology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of, [2]Linguistic Data Consortium & Linguistics Department, University of Pennsylvania, Philadelphia, United States, [3]Linguistic Data Consortium & Linguistics Department, University of Pennsylvania, Philadelphia, Korea, Republic of, [4]Department of Communication Sciences and Disorders, University of Cincinnati, Cincinnati, Korea, Republic of

P428 A Digital Clock and Recall (DCR)-First Clinical Workflow Substantially Increases Dementia Case-Finding in Primary Care

Presenteur : Ali Jannati

Ali Jannati[1], Claudio Toro-Serey[1], Connor Higgins[1], John Showalter[1], David Bates[1], Alvaro Pascual-Leone[1, 2], Sean Tobyne[1]
[1]Linus Health, Boston, United States, [2]Hebrew SeniorLife - Harvard Medical School

P429 Technical and Real-World Validation of the Digital Clock and Recall: A Scalable Cognitive Screener for Primary Care and Clinical Trial Enrichment

Presenteur : Ali Jannati

Claudio Toro-Serey[1], Karl Thompson[1], Daniel Schulman[1], Olivia Jacks[1], Connor Higgins[1], Alvaro Pascual-Leone[1, 2], Ali Jannati[1], Sean Tobyne[1]
[1]Linus Health, Boston, United States, [2]Hebrew SeniorLife - Harvard Medical School, Boston, United States

P430 Understanding NPI-C Rating Errors in AD Psychosis Trials: A Multi-Study Analysis of Hallucination and Delusion Domain Flags

Presenteur : Amanda Aedo

Amanda Aedo, Gila Barbati, Andrei Iacob, Sayaka Machizawa, Erica Appleman
Signant Health, Coral Springs, United States

P431 ADAS-Cog 11 vs 13 in early Alzheimer's disease: sensitivity to longitudinal change

Presenteur : Danielle DiGregorio

Catarina Cunha[1], Matt Welch[2], Daema Pina Delgado[2], Zsolt Ternei[3], Selam Negash[2], Chris Randolph[2], Danielle Digregorio[2]
[1]Clario, part of Thermo Fisher Scientific, Coimbra, Portugal, [2]Clario, part of Thermo Fisher Scientific, Philadelphia, United States, [3]Clario, part of Thermo Fisher Scientific, Budapest, Hungary

P432 Comparison-Based Subjective Cognitive Decline Predicts Objective Cognition in APOE ε4 Non-Carriers

Presenteur : Jee Wook Kim

Hye Ji Choi[1], Shin Gyeom Kim[2], Jee Wook Kim[1]
[1]Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of, [2]Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of

P433 Digital Cognitive Signatures of Biomarker-Defined Preclinical Alzheimer's Disease

Presenteur : Casey Vanderlip

Casey Vanderlip[1, 2], Karra Harrington[2], Paul Maruff[2], Pam Ventola[2]
[1]UC Irvine, Irvine, United States, [2]Cogstate Ltd, Melbourne, Australia

P434 Performance on a Multiday Digital Cognitive Assessment Is Associated with Plasma p-tau217 and Subjective Cognitive Concerns in a Large Remote Registry Cohort

Presenteur : Lex Minto

Lex Minto[1, 2], Cecily Jenkins[3], Rema Raman[3], Oliver Langford[3], Kedir Hussen[3], Reisa Sperling[1, 2], Paul Aisen[3], Daniel Soberanes[1], Gustavo Jimenez-Maggiora[3], Rebecca Amariglio[1, 2], Kathryn Papp[1, 2]

[1]Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States, [2]Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, [3]Epstein Family Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, United States

P435 Remote Multiday Digital Cognitive Assessment Among Patients Evaluated for Anti-Amyloid Treatment: Feasibility and Clinical Correlates

Presenteur : Rebecca Amariglio

Rebecca Amariglio, Daniel Soberanes, Vivienne Lubbat, Claudia Suarez Rodriguez, Risal Ilisa, Alberto Serrano Pozo, John Dickson, Beata-Gabriela Simpson, Teresa Gomez-Isla, Kathryn Papp

Mass General Brigham, Boston, United States

P436 A Digital Memory Task Enables Efficient Identification of Cognitive Impairment in Alzheimer's Disease Trials

Presenteur : Casey Vanderlip

Casey Vanderlip[1, 2, 3], Karra Harrington[2], Johnathan Wagg[3], Anahita Kyani[3], Charmaine Demanuele[3], Macarena Garcia Valdecasas Colell[3], Arthur Simen[3], Craig Stark[1], Paul Maruff[2], Pam Ventola[2]

[1]UC Irvine, Irvine, United States, [2]Cogstate Ltd, Melbourne, Australia, [3]Johnson and Johnson, New Brunswick, United States

P437 REACHED: Participant characteristics from a pilot pre-screening study designed to diversify clinical trial recruitment in understudied populations in Alzheimer's disease

Presenteur : Alexandria Wise Brown

Alexandria Wise Brown[1], Frank Boess[2], Frank Perilli[3], Ira Goodman[3], Erin Beck[3], Karra D. Harrington[4], Nicklas Linz[5], Alison Buick[5], Nicola Maiorano[2], Ruth Croney[6], Kelly Coultes[7], Janice Smith[6]

[1]Genentech, Inc., South San Francisco, California, United States, [2]F. Hoffmann-La Roche Ltd, Basel, Switzerland, [3]SiteRx, New York, New York, United States, [4]CogState Ltd, New Haven, Connecticut, United States, [5]Ki: Elements GmbH, Saarbrücken, Germany, [6]Roche Products Ltd, Welwyn Garden City, United Kingdom, [7]F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada

P438 Longitudinal Game-Based Monitoring in Older Adults With and Without Cognitive Impairment Using MIND GamePack

Presenteur : Anna Favaro

Anna Favaro[1, 2], Jake Galler[1], Beata-Gabriela K. Simpson[1], Yingnan He[1], Cathrine Young[1], Steven E. Arnold[1, 2], Mark Eldaief[1, 2], Sudeshna Das[1, 2]

[1]Massachusetts General Hospital, Boston, United States, [2]Harvard Medical School, Boston, United States

P439 Changes in Occipital Alpha Frequency Precede Clinical Conversion from Mild Cognitive Impairment to Alzheimer's Disease

Presenteur : Julie Clarot

Julie Clarot[1], Emma Depuydt[1], Gert Vanhollebeke[1], Velislava Zoteva[1], Lukas Gemein[2], Christoffer Hatlestad-Hall[2], Hanna Renvall[3, 4], Fernando Maestù[5, 6, 7], Camillo Marra[8, 9], Paolo Maria Rossini[8], Ira Hebold Haraldsen[2], Pieter Van Mierlo[1]

[1]Clouds of Care, Ghent, Belgium, [2]Department of Neurology, Oslo University Hospital, Oslo, Norway, [3]BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, Helsinki, Finland, [4]Department of Neuroscience and Biomedical Engineering, Aalto University,, Helsinki, Finland, [5]Center for Cognitive and Computational Neuroscience (C3N), Universidad Complutense de Madrid, Madrid, Spain, [6]Department of Experimental Psychology, Cognitive Psychology and Speech & Language Therapy, Universidad Complutense de Madrid, Madrid, Spain, [7]Health Research Institute of the Hospital Clínico San Carlos (IdISSC), Madrid, Spain, [8]Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, [9]Department of Psychology, Catholic University of the Sacred Hear, Rome, Italy

P440 Fully Remote Telehealth Evaluation and Delivery of Amyloid-Targeted Therapy in Early Symptomatic Alzheimer's Disease: Feasibility and Initial Experience

Presenteur : Oleg Yerstein

Oleg Yerstein[1], Jeremy Pruzin[1, 2], Mayra Reyna[1], Mercedes Guevara[1], Meagan Gates[1], Sonia Bajwa[1], Abigail O'Connell[1], Benjamin Williams[1], Erin Leahy[1], Eric Anderson[1], Melissa Yu[1]

[1]Synapticure, Chicago, United States, [2]Banner Health, Phoenix, United States

P441 Association of a Digital Speech Biomarker for Cognition (SB-C) with Functional Outcomes in Early Preclinical Alzheimer's Disease: Functional Equivalence to In-Clinic PACC Within the Beta AARC Cohort

Presenteur : Alexandra König

Alexandra König[1], Clàudia Porta-Mas[2, 3], Andreea Rădoi[2], Elisa Malick[1], Johannes Tröger[1], Oriol Grau-Rivera[2, 4], Gemma Salvadó[2, 5], Gonzalo Sánchez-Benavides[2, 6]

[1]ki:elements, Saarbrücken, Germany, [2]Barcelona eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, [3]IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain, [4]Universitat Pompeu Fabra, Barcelona, Spain, [5]Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III,, Madrid, Spain, [6]IMIM (Hospital del Mar Medical Research Institute),, Barcelona, Spain

P442 Maximizing Signal in Early AD: How Digital Assessments Outperform the CDR-SB and ADAS-Cog

Presenteur : Katelyn Miller

Katelyn Miller, Samuel Dickson, Suzanne Hendrix
Pentara Corporation, Millcreek, Ut, United States

P443 SpeechDx: Advancing Prognostic Speech Markers for Alzheimer's Disease

Presenteur : Melissa Lee

Shirine Moukaled[1], Andréa Lessa Benedet[2], Henrik Zetterberg[2], Stephan Meylan[1, 3], Jerica Reeder[1], Speech Dx The Speechdx Consortium[1], Aishwarya Sukumar[4], Laura Nisenbaum[1], Lampros Kourtis[1, 4], Melissa Lee[1]
[1]Alzheimer's Drug Discovery Foundation, New York, United States, [2]University of Gothenburg, Mölndal, Sweden, [3]Surprisal B.V., Amsterdam, The Netherlands, [4]Gates Ventures, Kirkland, United States

P444 Associations between Alzheimer's disease biomarkers and multiday digital cognitive performance in older adults at elevated vascular risk

Presenteur : Lex Minto

Lex Minto[1, 2], Hairin Kim[1, 2], Mark Dubbelman[1, 2], Daniel Soberanes[1], Vivienne Lubbat[1], Laura Baker[3], Mark Espeland[3], Susan Landau[4], Rebecca Amariglio[1, 2], Kathryn Papp[1, 2]
[1]Mass General Brigham, Boston, United States, [2]Harvard Medical School, Boston, United States, [3]Wake Forest University School of Medicine, Winston-Salem, United States, [4]University of California, Berkeley, Berkeley, United States

P445 Promoting dementia research participation in high-risk communities – co-creating a Research Ambassador Program.

Presenteur : Sarah Walter

Sarah Walter[1], Joe Costello[2], Cynthia Huling Hummel[3], Paul Aisen[1], Colin Chandler[4], Leah Macaden[5]
[1]Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [2]Alzheimer's Clinical Trials Consortium, Research Ambassador Community Collective - San Diego (United States), San Diego, United States, [3]Alzheimer's Clinical Trials Consortium, Research Ambassador Community Collective, San Diego, United States, [4]School of Health in Social Science, University of Edinburgh, Edinburgh, United Kingdom, [5]4. Nursing Studies, School of Health in Social Science, University of Edinburgh, Edinburgh, United Kingdom

P446 Noise-cancellation variability as a source of longitudinal drift in speech-based digital endpoints for Alzheimer's disease trials

Presenteur : Lisa Chiang

Adrian Ortiz, Lisa Chiang
Cephalgo, Strasbourg, France

P447 Cognitive Benefit from the Structured Lifestyle Intervention in U.S. POINTER Replicated and Extended with Digital Cognitive Outcomes

Presenteur : Kathryn Papp

Kathryn Papp[1], Sarah Farias[2], Sarah Evans[3], Magdalene Harki[4], Joni Evans[3], Athene Lee[5], Bonnie Sachs[6], Christy Tangney[7], Maria Carrillo[8], Katie Garcia[3], Amber Thro[6], Iris Leng[6], Kristin Ijeh[9], Mark Espeland[6], Laura Baker[6]
[1]Mass General Brigham, [2]UCDavis, [3]Advocate Health, [4]AAH, [5]Brown University, [6]Wake Forest, [7]Rush, [8]Alzheimer Association, [9]BCM

P448 Refer-MCI: Enriching Referrals of Patients to Memory Clinics for Mild Cognitive Impairment (MCI)

Presenteur : Emrah Duezel

Emrah Duezel[1, 2, 3], Jochen René Thyrian[4], Vanessa Kurth[5], Nadine Diersch[3], Anne Boehlen[6], Hannes Vossfeldt[3], David Berron[1, 3], Frank Jessen[6, 7], Annika Spottke[6], Stefan Teipel[8]
[1]German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, [2]Otto-von-Guericke University, Institute of Cognitive Neurology and Dementia Research (IKND), Magdeburg, Germany, [3]neotiv GmbH, Magdeburg, Germany, [4]German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany, [5]Lilly Germany, Bad Homburg, Germany, [6]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, [7]University of Cologne, , Cologne, Germany, [8]German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany

P449 Understanding Cognitive Impairment Through Analysis of Process Metrics Derived from the Digital Assessment of Cognition

Presenteur : Tanya Talkar

Tanya Talkar[1], Connor Higgins[1], Ali Jannati[1], David Libon[1, 2, 3], Rod Swenson[1, 4], Sean Tobyne[1]
[1]Linus Health, Boston, United States, [2]Department of Geriatrics and Gerontology, New Jersey Institute for Successful Aging, Rowan University-School of Osteopathic Medicine, Glassboro, United States, [3]Department of Psychology, Rowan University, Glassboro, United States, [4]University of North Dakota School of Medicine and Health Sciences, Grand Forks, United States

P450 Tracking Cognitive Change in Mild Cognitive Impairment Using Repeated Speech-Based Digital Cognitive Assessments: Comparison with the Clinical Dementia Rating Scale

Presenteur : Alexandra König

Johannes Tröger[1], Elisa Mallick[1], Alexandra König[1], Alison Buick[1], Mathias Bähr[2], Emrah Düzel[3], Björn Falkenburger[4], Gabor Petzold[5], Josef Pillar[6], Annika Spottke[5], Stefan Teipel[7], Michael Wagner[5], Jens Wiltfang[2], Inga Zerr[2], Stefanie Köhler[7]
[1]ki elements GmbH, Saarbrücken, Germany, [2]German Center for Neurodegenerative Diseases DZNE, Göttingen, Germany, [3]German Center for Neurodegenerative Diseases DZNE, Magdeburg, Germany, [4]German Center for Neurodegenerative Diseases DZNE, Dresden, Germany, [5]German Center for Neurodegenerative Diseases DZNE, Bonn, Germany, [6]German Center for Neurodegenerative Diseases DZNE, Berlin, Germany, [7]German Center for Neurodegenerative Diseases DZNE, Rostock, Germany

P451 Smartphone-based User-adaptive Assessment of Cognitive Functions in Patients with Mild Cognitive Impairment

Presenteur : Shibeshih Belachew

Antonio Rodríguez-Romero[1], Katarzyna Kita[1], Alexa Burk[2], Emmanuel Bartholomé[1], Claudia Mazzà[1], Carlos Luque[1], Òscar Reyes[1], Corrado Bernasconi[1], Shibeshih Belachew[1], Rhoda Au[2]
[1]Indivi AG, Basel, Switzerland, [2]Boston University Chobanian & Avedisian School of Medicine, Boston, United States

P452 A/B-test results of XpressO-Mix: a remote cognitive prescreener that mitigates practice effects

Presenteur : Willem Huijbers

Willem Huijbers[1], Hans-Aloys Wischmann[2], Murray Gillies[1], Ziad Nasreddine[1]
[1]MoCA Cognition, Montreal, Canada, [2]Charité, Berlin, Germany

P453 The Person, Not the Device: Evidence from Ten Years of In-Home Remote Monitoring Research in Dementia

Presenteur : Ramin Nilforooshan

Ramin Nilforooshan[1, 2], Chloe Walsh[1, 3], Sai-Bo Cheung[1], Payam Barnaghi[3]
[1]Surrey and Borders Partnership NHS Foundation Trust, Chertsey, United Kingdom, [2]University of Surrey, Guildford, United Kingdom, [3]Imperial College London, London, United Kingdom

P454 Digital cognitive assessments discriminate early tau pathology in cognitively unimpaired older adults

Presenteur : Karra D. Harrington

Karra D. Harrington[1], Casey R. Vanderlip[1], Charles O'Connor[2], Pam Ventola[1], Paul Maruff[2]
[1]Cogstate, New Haven, United States, [2]Cogstate, Melbourne, Australia

P455 Digital Phenotyping For Detecting Subtle Longitudinal Changes In Alzheimer's Treatment

Presenteur : Byun Andrew

Byun Andrew[1], Meaghan McKenna[2], Ko Woon Kim[3], Margaret Yang[1], John Torous[1], Chun Lim[1]
[1]BIDMC, Boston, United States, [2]University of Rochester, Rochester, United States, [3]Jeonbuk National University Medical School & Hospital, Jeonju, Korea, Democratic people's republic of

P456 Prognostic enrichment of AD studies with a brief at-home digital assessment: predicting 12-month decline and projected reductions in trial sample size

Presenteur : Brian Murphy

Brian Murphy[1], Florentine Barbey[1], Hugh Nolan[1], George Stothart[2]
[1]Cumulus Neuroscience, Dublin, Ireland, [2]Cumulus Neuroscience, Belfast, United Kingdom

P457 Passive smartwatch wear adherence as a digital biomarker of cognitive function, depression, and nutritional status in community-dwelling older adults: a 4-week observational study

Presenteur : Choi Jung Yeon

Choi Jung Yeon, Kim Min Seon, Park Ji Hye
Seoul National University Bundang Hospital, Seongnam Si, Korea, Republic of

P458 Improving Early Detection of Cognitive Impairment with Cognivue Clarity Across Diverse Clinical Settings: Accounting for Age, Education and Race Differences in Performance

Presenteur : James Galvin

James Galvin[1], Paul Estes[2], Heather Harris[2], Lun-Ching Chang[3]
[1]University of Miami Miller School of Medicine, Boca Raton, United States, [2]Cognivue, Inc, Victor, United States, [3]Florida Atlantic University, Boca Raton, United States

P459 Remote Odor Percept Identification as a Scalable Marker of Alzheimer's Disease

Presenteur : Benoît Jobin

Benoît Jobin, Colin Magdamo, Hengbin Zhang, Beyzanur Ergun, Sean Reineke, Alefiya Dhilla-Albers, Mark Albers
Mass General Brigham/Harvard Medical School, Boston, United States

P460 Implementing the CMS GUIDE Dementia Care Model in a Community Neurology Practice with Digital Tools, Standardized Scales, Community Partners and Embedded Clinical Trial Recruitment

Presenteur : Gregory Sahagian

Gregory Sahagian
The Neurology Center of Southern California, Carlsbad, United States

P461 Longitudinal digital speech assessment in progressive supranuclear palsy

Presenteur : Charlie Weige Zhao

Kyurim Kang[1], Ilkay Potter[2], Ram Mishra[2], Rylee Cole[2], Tejas Pawar[2], Charlie Weige Zhao[3], Antje Mefferd[4], Michael De Riesthal[5], Ashkan Vaziri[2], Anne-Marie Wills[3], Alexander Pantelyat[3]

[1]Johns Hopkins University, Baltimore, United States, [2]Biosensics LLC, Newton, United States, [3]Mass General Brigham, Boston, United States, [4]Vanderbilt University Medical Center, Nashville, United States, [5]Vanderbilt University, Nashville, United States

P462 Automated verbal fluency as a digital cognitive biomarker in progressive supranuclear palsy: a longitudinal study

Presenteur : Charlie Weige Zhao

Jesse Wang[1], Ilkay Potter[2], Charlie Weige Zhao[1], Ram Mishra[2], Kyurim Kang[3], Tejas Pawar[2], Rylee Cole[2], Ashkan Vaziri[2], Alexander Pantelyat[3], Anne-Marie Wills[1]

[1]Mass General Brigham, Boston, United States, [2]Biosensics LLC, Newton, United States, [3]Johns Hopkins University, Baltimore, United States

P463 Ensuring Demographic Equity: Evaluating the SB-C Speech-Based Cognitive Assessment Across Ethnic Groups in US

Presenteur : Alexandra König

Johannes Tröger, Louisa Schwed, Simona Schäfer, Alison Buick, Nicklas Linz, Alexandra König

ki elements GmbH, Saarbrücken, Germany

P464 Diagnosed Too Late to Treat: Nationwide Real-World Evidence on Diagnostic Delay, Treatment Coverage and Persistence in Dementia Care

Presenteur : Petra Marica Halmos

Petra Marica Halmos, Balázs Dobi, Dániel Bereczki, Tibor Kovács
Semmelweis University, Budapest, Hungary

P465 From readiness to real-world implementation: a national Community of Practice for novel Alzheimer's disease therapies in Australia

Presenteur : Paul Yates

Paul Yates[1, 2], Christopher Belder[3], Oneil Bhalala[4], Antonia Clarke[5], Emma Devenney[6], Kathryn Goozee[7], Colin Masters[8], Christopher Rowe[9], Cathy Short[10], Ashwin Shukla[11], Stephanie Ward[12], Michael Woodward[1, 2], Mark Yates[13], Ranjeev Chrysanth Pulle[14], Amy Brodtmann[5]
[1]Department of Geriatric Medicine, Austin Health, Heidelberg, Australia, [2]Department of Medicine, Austin Health, University of Melbourne , Heidelberg, Australia, [3]Royal Adelaide Hospital/Queen Elizabeth Hospital, Adelaide, Australia, [4]Walter and Eliza Hall Institute, Parkville, Australia, [5]Monash University, Clayton, Australia, [6]NeuRA, Sydney, Australia, [7]KaraMinds, Sydney, Australia, [8]University of Western Australia, Perth, Australia, [9]Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia, [10]The Queen Elizabeth and Royal Adelaide Hospitals,, Adelaide, Australia, [11]SA Geriatrics Pty Ltd, Adelaide, Australia, [12]University of NSW, Sydney, Australia, [13]Grampians Health, Ballarat, Australia, [14]The Prince Charles Hospital, Brisbane, Australia

P466 National Real-World Use of Amyloid-Targeting Therapies in Australia: Early Experience from the ADNeT mAbs Registry

Presenteur : Paul Yates

Paul Yates[1, 2, 3], Robert Adam[4], Susannah Ahern[5], Rohit Bansal[6], James Bice[7], Bruce Brew[8], Henry Brodaty[9], Roger Clarnette[10], Yun Tae Hwang[11], Penny King[12], Michael Leihy[13], Karen Robinson[14], Courtney Shelton[3, 1], Paul Viray[15], Stephanie Ward[9]
[1]Department of Geriatric Medicine, Austin Health, Heidelberg, Australia, [2]Department of Medicine, Austin Health, University of Melbourne , Heidelberg, Australia, [3]Warringal Private Hospital, Heidelberg, Australia, [4]Robert Adam Neurology, Brisbane, Australia, [5]Monash University, Clayton, Australia, [6]Healthy Ageing Gold Coast, Tugun, Australia, [7]Specialist Memory Services, Box Hill, Australia, [8]St Vincent's Hospital, Sydney, Australia, [9]University of NSW, Sydney, Australia, [10]Cardiometabolic Services, Nedlands, Australia, [11]Central Coast Neurosciences, Erina, Australia, [12]Aurora Health, Robina, Australia, [13]The Healthy Brain and Memory Centre, Southport, Australia, [14]Mebourne Cognitive Services, Melbourne, Australia, [15]Cabrini Hospital, Malvern, Australia

P467 A Safety Comparison of Lecanemab and Donanemab Across Three Clinical Institutions

Presenteur : Michael Rosenbloom

Varun Mehta[1], Daniel Fisher[1], Andrea Schnee[1], David Weisman[2], Kala Zingle[2], Jordyn Kelman[2], Emily Kuhlmann[3], Ryan Townley[3], Faris Shaker[3], Michael Rosenbloom[1]
[1]University of Washington, Seattle, United States, [2]Abington Neurological Associates, Abington, United States, [3]KUMC, Kansas City, United States

P468 Higher baseline mean arterial pressure predicts moderate-to-severe ARIA and ARIA-related treatment discontinuation in a real-world population

Presenteur : Elizabeth Moore

Elizabeth Moore[1, 2], Era Laho[1], Sokratis Charisis[1, 2], Ron Danziger[1, 2], Jasmeer Chhatwal[1, 2], Bradford Dickerson[1, 2], Reisa Sperling[1, 2], Sheena Baratono[1, 2], John Dickson[1, 2], Michael Erkkinen[3], Nathan Praschan[4, 2], Liliana Ramirez-Gomez[1, 2], Kirk Daffner[1, 2], Teresa Gomez-Isla[1, 2], Wai-Ying Wendy Yau[1, 2]
[1]Department of Neurology, Mass General Brigham, Boston, United States, [2]Harvard Medical School, Boston, United States, [3]Department of Neurology, University of California Davis, Sacramento, United States, [4]Department of Psychiatry, Mass General Brigham, Boston, United States

P469 Building Real-World Dementia Data Infrastructure in the Community: Early Findings from a Provincial Registry in Ontario

Presenteur : Christa Studzinski

Christa Studzinski[1], Caitlin Siu[1], Daniela Testani[1], Adam Morrison[2], Julie Datta[2], Ngozi Ironanyah[2], Shawn Paron[2], Ibukun-Oluwa Omolade Abejirinde[3], Christina Stergiou-Dayment[2]
[1]Ontario Brain Institute, Toronto, Canada, [2]Alzheimer Society of Ontario, Toronto, Canada, [3]Trillium Health Partners, Toronto, Canada

P470 Door-to-Needle Time for Anti-Amyloid Therapy in a Community Neurology Practice: A Retrospective Cohort Study of a Primary Care and Outpatient Neurology Partnership

Presenteur : Molly Budhiraja

Molly Budhiraja[1], Samar Quadir[1], Rohan Vallamshetla[2], Karan Vallamshetla[3], Dominic Alamsjah[4], Aarav Sabnekar[5], Aashi Singhai[6], Kinsey Gudenkauf[7], Hemant Pandey[8]
[1]Arizona State University, Tempe, United States, [2]University of California, Berkeley, Berkeley, United States, [3]Cornell University, Ithaca, United States, [4]Arizona State Univeristy, Tempe, United States, [5]Basis Chandler, Chandler, United States, [6]Hamilton High School, Chandler, United States, [7]Banner - University Medical Center Phoenix, Phoenix, United States, [8]Brain and Spine Center, Chandler, United States

P471 Real-world Experience of Amyloid-Targeting Therapies at Sutter Health - a Large Integrated Healthcare System

Presenteur : Armen Moughamian

Armen Moughamian[1, 2], Joe Winer[3], Amanda Pickett[3], Julian De La Cruz[3], Jane Kim[3], Aria Sengupta[3], Avery Razavi[3], Julinna Cheung[3], Juliana Van Cleve[3], Lisamarie La Vallee[2], Shawn Kile[2, 4]
[1]Ray Dolby Brain Health Center, Sutter Health, San Francisco, United States, [2]Sutter Health Neuroscience Service Line, Sacramento, United States, [3]Sutter Health Research Institute, Sutter Health, Emeryville, United States, [4]Sacramento Memory Center, Sutter Health, Sacramento, United States

P472 A Multidisciplinary Model to Facilitate Safe Access to Amyloid-Targeting Therapies in General Neurology Across the Sutter Health System

Presenteur : Armen Moughamian

Armen Moughamian[1, 2], Lisamarie La Vallee[2], Shawn Kile[2, 3], Travis Urban[1], Austin Momii[1], Michelle Manifield[2], Jean Minton[2]
[1]Ray Dolby Brain Health Center, Sutter Health, San Francisco, United States, [2]Sutter Health Neuroscience Service Line, Sacramento, United States, [3]) Sacramento Memory Center, Sutter Health, Sacramento, United States

P473 Evaluation of Cognitive and Functional Outcomes of Lecanemab Treatment Using Real-World Data

Presenteur : John Dickson

John Dickson[1, 2], Chao-Yi Wu[1, 2], Sokratis Charisis[1, 2], Katelyn Horan[1], Wedgina Norelus[1], Cinthya Aguero[1, 2], Yingnan He[1], Sudeshna Das[1, 2], Hiroko Dodge[1, 2], Teresa Gomez-Isla[1, 2]
[1]Mass General Brigham, Boston, United States, [2]Harvard Medical School, Boston, United States

P474 Cardiovascular changes during lecanemab treatment and subsequent amyloid-related imaging abnormalities

Presenteur : Park Hee Kyung

Park Hee Kyung[1], Sungjoo Lee[2], Heekyoung Kang[3], Lee Jungah[4], Lee Kyungbok[4], Yim Sohyun[5], Shin Daeun[6], Kim Seonghyeon[7], Kim Jun Pyo[1], Kim Hee Jin[1], Seo Sang Won[1]
[1]Department of Neurology, Samsung Medical Center, Sun, Seoul, Korea, Republic of, [2]Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea, Republic of, [3]Department of Neurology, Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of, [4]Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Korea, Republic of, [5]Department of Neurology, Inje University Haeundae Paik Hospital, Busan, Korea, Republic of, [6]Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, [7]Department of Neurology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of

P475 When willingness is not enough: participation fit and potentially modifiable person-study mismatches in dementia trial recruitment

Presenteur : Patricia Fuller

Patricia Fuller[1, 2], Andrew Claxton[3], Helen Pocock[4, 5], Samantha Willaims[3], Nicola Claxton[3], Amanda Wollam[6], Daniel Blackburn[7], George Devitt[8], Sarah Fearn[1, 2], Christopher Kipps[9, 10]
[1]University of Southampton;, Southampton, United Kingdom, [2]NIHR Applied Research Collaboration Wessex, , Southampton, United Kingdom, [3]South Central Ambulance Service NHS Foundation Trust, Bicester, England, UK, Bicester, United Kingdom, [4]South Central Ambulance Service NHS Foundation Trust, Bicester, England, UK;, Bicester, United Kingdom, [5]University of Warwick, Warwick Clinical Trials Unit, Coventry, United Kingdom, [6]Patient and Public Involvement and Engagement, NIHR Applied Research Collaboration Wessex, Southampton, England, UK, Southampton, United Kingdom, [7]The University of Sheffield Institute for Translational Neuroscience, Sheffield, England, UK, Sheffield, United Kingdom, [8]University Hospital Southampton NHS Foundation Trust, Neurodegenerative Research, Southampton, England, UK, Southampton, United Kingdom, [9]University of Southampton, Southampton, UK;, Southampton, United Kingdom, [10]University Hospital Southampton NHS Foundation Trust, Neurodegenerative Research, , Southampton, United Kingdom

P476 ALZEVIT: A Nationwide Digital Registry of APOE 4/ 4 Carriers to Enable Prevention Trials in Alzheimer's Disease

Presenteur : Audrey Gabelle

Audrey Gabelle[1], Federica Zilli[2], Margaux Faurie[2], Miguel Casanova[3], Stéphanie Boutillier[3], Renaud David[4], Gaël Nicolas[5], David Wallon[5], Eloi Magnin[6], François Sellal[7], Frédéric Blanc[8], Hüseyin Firat[2]
[1]CHU Montpellier, Montpellier, France, [2]Firalis, Huningue, France, [3]Amoneta Diagnostics, Huningue, France, [4]CHU Nice, Nice, France, [5]CHU Rouen, Rouen, France, [6]CHU Besançon, Besançon, France, [7]Hôpitaux Civils, Colmar, France, [8]CHRU, Strasbourg, France

P477 iconsortium ad: A 10-Year, AI-Powered Longitudinal Real-World Data Registry to Advance Alzheimer's Disease Care and Standardize Neuroimaging Outcomes

Presenteur : Wim Van Hecke

Wim Van Hecke[1, 2], Nuno Pedrosa De Barros[1, 2], Dirk Smeets[1, 2]
[1]icometrix, Leuven, Belgium, [2]GEHC, Diegem, Belgium

P478 Real-World Biomarker Changes During Amyloid-Targeting Therapy in a Treatment Clinic

Presenteur : Nicholas Schwartz

Nicholas Schwartz[1, 2], Tara Ellingson[1], Hong Nguyen[1], Connor Dietz[1], Nicholas Ashton[3], Jeff Dage[4], Rowan Saloner[1], Peter Ljubenkov[1], Julio Rojas[1], Marlene Lin[1], Renaud La Joie[1], Gil Rabinovici[1, 5], Bruce Miller[1], Adam Boxer[1], Lawren Vandevrede[1]
[1]Edward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States, [2]Univerity of Maryland, Balitmore, Baltimore, MD, United States, [3]Banner Sun Health Research Institute, Sun City, AZ, United States, [4]Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, United States, [5]Department of Radiology & Biomedical Imaging, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States

P479 Bridging the Gap from Real-World Data to Real-World Impact: A Roadmap for Common Data Element (CDE) Development and Adoption in AD/ADRD Research

Presenteur : Zoe Arvanitakis

Zoe Arvanitakis[1], Ronald Petersen[2], Licong Cui[3], Yong Chen[4], Hongfang Liu[5], Guo-Qiang Zhang[3]
[1]Rush University Med Ctr, Chicago, United States, [2]Mayo Clinic, Rochester, United States, [3]University of Texas Health Sciences, Houston, United States, [4]University of Pennsylvania, Philadelphia, United States, [5]University of Texas, Austin, United States

P480 Real-world effectiveness and safety of sodium oligomannate in patients with mild-to-moderate Alzheimer's disease

Presenteur : Li Xia

Li Xia[1], Dong Qiang[2], Guo Qihao[3]
[1]Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China, [2]Huashan Hospital, Fudan University, Shanghai, China, [3]Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

P481 Eighteen-month real-world safety, cognitive outcomes, and amyloid clearance with lecanemab in Chinese patients with early Alzheimer's disease

Presenteur : Wenyan Kang

Wenyan Kang[1, 2], Hongxiang Yu[1], Cao Gao[1], Xiaoyan Li[2], Jun Liu[1]
[1]Department of Neurology and Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, [2]Department of Neurology, Hainan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Qionghai, Hainan, Shanghai, China

P482 Clinical and real-world experience with the synaptic regenerative drug, tazbentetol, in Alzheimer's patients

Presenteur : Sharron Gargosky

Lauren Priest[1], Bruce Brew[2], Allison Perrin[3], Cazyer Aimee[1], Bramah Valerie[2], Peter Vanderklish[4], Craig Erickson[4], Ernest Pedapati[5], Sharron Gargosky[4], Stella Sarraf[4]
[1]Flinders Medical Center, Adelaide, Australia, [2]St Vincent's Hospital, Sydney, Australia, [3]Banner Alzheiners Health, Scottsdale, United States, [4]Spinogenix, Los Angeles, United States, [5]Cincineuro, Cincinatti, United States

P483 Real-World Practice Patterns and Clinical Considerations in Lecanemab Administration: A Survey-Based Analysis of Dosing Strategies, Schedule Flexibility, and Economic Workarounds

Presenteur : Young Ho Park

Young Hee Jung[1], Young Ho Park[2], Seong Hye Choi[3], Kee Hyung Park[4], Geon Ha Kim[5], Hojin Choi[6], Dong Won Yang[7]
[1]Hallym Sacred Heart Hospital, Anyang, Korea, Republic of, [2]Seoul National University Bundang Hospital, Bundang, Korea, Republic of, [3]Inha University, Incheon, Korea, Republic of, [4]Gacheon University Gil Medical Center, Incheon, Korea, Republic of, [5]Ewha Womans University, Seoul, Korea, Republic of, [6]Hanyang University Guri Hospital, Guri, Korea, Republic of, [7]Seoul St. Mary's Hospital, Seoul, Korea, Republic of

P484 Optimizing Recruitment Resources for Underrepresented Latino Older Adults in Alzheimer's Research: A Randomized Trial of Community-Based Recruitment

Presenteur : Yuhsuan (olivia) Wang

Yuhsuan (Olivia) Wang[1, 2], Jonathan N Cloughesy[1, 3], Tom Chang[4], Doris P Molina-Henry[5], Mireille Jacobson[1]
[1]1Leonard D. Schaeffer Center for Health Policy & Economics, Los Angeles, United States, [2]Department of Gerontology and Long-term Care, Taipei Medical University, Taipei, Taiwan, [3]2Mann School of Pharmacy, University of Southern California, Los Angeles, United States, [4]3Department of Finance and Business Economics, University of Southern California,, Los Angeles, United States, [5]Epstein Family Alzheimer's Therapeutic Research Institute, San Diego, United States

P485 ROAD-US: An evaluation of the utilization and clinical utility of Alzheimer's disease blood biomarkers in US community practices, a pre-post time series study

Presenteur : Martin Guess

Martin Guess[1], Daniel Gautieri[2], Daniel Barulli[2], David Henley[2], Soeren Mattke[3], Sophie Roth[1], Maria-Magdalena Patru[4], Matthew Denave[4], Bora Plaku[5], Margaret K. Ogongo[4], Pierre Tariot[6]
[1]Roche Diagnostics International Ltd, Rotkreuz, Switzerland, [2]SiteRx, New York, NY, United States, [3]USC Brain Health Observatory, USC Dornsife, Los Angeles, CA, United States, [4]Roche Diagnostics Corporation, Indianapolis, IN, United States, [5]Roche Diagnostics GmbH, Penzberg, Germany, [6]Banner Alzheimer's Institute, Phoenix, AZ, United States

P486 Real-World Safety and Rates of Interrupted Treatment with Modified Donanemab Titration in an Urban Academic Memory Clinic

Presenteur : Adrianna Carrasco

Leila Parand, Adrianna Carrasco, Tim Chang, Essence Horton, Daniel Silverman, Thao Rodriguez, Kelsey Stander, Ceylan Cankurtaran, Massoud Yeganegi, Kyle Kern, Jason Hinman
UCLA, Los Angeles, United States

P487 Real-world data analysis of post 12-months donanemab, amyloid targeting therapy, from a memory and cognitive disorders clinic

Presenteur : Maileen Ulep

Maileen Ulep, Charles Bernick
Cleveland Clinic Nevada Lou Ruvo Center for Brain Health, Las Vegas, United States

P488 Implementing Lecanemab at a Veteran Affairs Medical Center: Evaluation of Operational Challenges and Neurology Resident Knowledge

Presenteur : Neal Nathan

Neal Nathan
Brigham and Women's Hospital, Boston, MA, United States

P489 Clinical Effectiveness of Primary Care-Led Post-Diagnostic Dementia Management: One-Year Real-World Outcomes from a Nationwide Cohort in Korea

Presenteur : Sun Min Lee

Sun Min Lee[1, 2], Kiyoung Kim[3], Kyoung Chang Kim[3], Yungi Hwang[3], Im Seok Koh[1, 2], Choi Jisook[3]
[1]Department of Neurology, National Medical Center, Seoul, Korea, Republic of, [2]National Institute of Dementia, National Medical Center, Seoul, Korea, Republic of, [3]Health Insurance Review and Assessment Research Department, Health Insurance Review & Assessment Service, Wonju, Korea, Republic of

P490 Patient Outcomes and Real-World Treatment Review and Assessment of Infusion Therapies with Donanemab

Presenteur : Maya Ibrahim

Ruhaan Shah, Maya Ibrahim, Ira Katigbak, Omar Almashharawi, Lee Watson, Eduardo Chacon, Kevin Aimua, Bella Principe, Rory Roberts, Monica Crane
Tennessee Memory Disorders Foundation, Knoxville, United States

P491 Patient Outcomes and Real-World Treatment Review and Assessment of Infusion Therapies with Lecanemab

Presenteur : Ira Katigbak

Ira Katigbak, Ruhaan Shah, Maya Ibrahim, Omar Almashharawi, Lee Watson, Eduardo Chacon, Isabella Principe, Kevin Aimua, Rory Roberts, Monica Crane
Tennessee Memory Disorders Foundation, Knoxville, United States

P492 Community Brain Health Network: A Web-Based Registry Platform for Engagement, Participation, and Retention in Dementia Research

Presenteur : Paula Aduen

Paula Aduen[1], Steven Smith[2], John Lucas[1], Angela Lunde[2], Maria Vassilaki[2], Elizabeth Boots[2], Nikki Stricker[2], Jonathan Graff-Radford[2], Gregory Day[1], Neill Graff-Radford[1], Bradley Boeve[2], Ronald Petersen[2]
[1]Mayo Clinic, Jacksonville FL, United States, [2]Mayo Clinic, Rochester MN, United States

P493 Door-to-Needle Time for Anti-Amyloid Therapy in a Community Neurology Practice: A Retrospective Cohort Study of a Primary Care and Outpatient Neurology Partnership

Presenteur : Molly Budhiraja

Molly Budhiraja[1], Samar Quadir[1], Karan Vallamshetla[2], Rohan Vallamshetla[3], Dominic Alamsjah[1], Aarav Sabnekar[4], Aashi Singhai[5], Kinsey Gudenkauf[6], Hemant Pandey[7]
[1]Arizona State University, Tempe, United States, [2]Cornell University, Ithaca, United States, [3]University of California, Berkeley, Berkeley, United States, [4]Basis Chandler, Chandler, United States, [5]Hamilton High School, Chandler, United States, [6]Banner - University Medical Center Phoenix, Phoenix, United States, [7]Brain and Spine Center, Chandler, United States

P494 Evaluating Research Attitudes and Willingness to Participate in Alzheimer's Disease and Related Dementias Clinical Trials Across Disaggregated AANHPI Subgroups: Data from the CARE Registry

Presenteur : Kenny Li

Kenny Li[1], Muskan Jain[2], Thomas Hoffmann[2], Tsoh Janice[3], Van Park[2], Joshua Grill[1]
[1]Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, United States, [2]Department of Community Health Systems, University of California, San Francisco (UCSF), San Francisco, United States, [3]Department of Psychiatry and Behavioral Sciences, UCSF, San Francisco, United States

P495 Utilization and reimbursement of blood-based pTau181 and pTau217 tests in Medicare Part B from January 2025 to April 2026

Presenteur : Lee Honigberg

Lee Honigberg[1], Theo Devos[2], Teodora Stoica[1], James Pistorino[3], Soeren Mattke[4]
[1]ALZpath, Inc., Carlsbad, CA, United States, [2]Boudicca Dx, Seattle, WA, United States, [3]Lumaclaims, LLC, Tampa, FL, United States, [4]USC Brain Health Observatory, University of Southern California, Los Angeles, CA, United States

P496 Study partner availability and willingness to be contacted about clinical trials in a local recruitment registry

Presenteur : Eunji Russ

Eunji Russ[1, 2], Dan Hoang[2], Joshua Grill[1, 3, 2], Dan Gillen[4, 2]
[1]Department of Neurobiology and Behavior, University of California, Irvine, IRVINE, United States, [2]Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, IRVINE, United States, [3]Department of Psychiatry and Human Behavior, University of California, Irvine, IRVINE, United States, [4]Department of Statistics, University of California, Irvine, IRVINE, United States

P497 Cognitive Testing as a Predictor of Anti-Amyloid Therapy Eligibility: An Exploratory Analysis of Real-World Memory Clinic Data

Presenteur : Wedgina Norelus

Wedgina Norelus[1], Katelyn Horan[1], Sokratis Charisis[1, 2], Cinthya Aguero[1, 2], Kathryn Papp[1, 2], John Dickson[1, 2], Teresa Gomez-Isla[1, 2]
[1]Mass General Brigham, Boston, United States, [2]Harvard Medical School, Boston, United States

P498 Evolving Real-World Diagnostic Pathways to Alzheimer's Disease-Modifying Treatment: Longitudinal EHR Evidence from the SiteRx Real-World Database

Presenteur : Matthew Qiao

Matthew Qiao, Daniel Barulli
SiteRx, New York, United States

P499 Smart Triage for Amyloid-Targeting Therapies (STATT)

Presenteur : William Powell

William Powell[1], Albert Lai[1], Suzanne Schindler[2], Barbara Snider[2, 3], Zachary Posey[2], Carson Woodfin[2], Inez Oh[1], Abigail Lewis[1], Philip Payne[1], Mackenzie Hofford[1, 4], Aditi Gupta[1]
[1]Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine, St. Louis, United States, [2]Department of Neurology, Washington University School of Medicine, St. Louis, United States, [3]Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, United States, [4]Division of General Medicine, Washington University School of Medicine in St. Louis, St. Louis, United States

P500 The Effect of Messaging on Research Enrollment

Presenteur : Megan Witbracht

Megan Witbracht[1], Sarah Schlund[2], Thuy Lu[3], Dan Hoang[1], Amy Kind[4], Daniel Gillen[2], Joshua Grill[1]
[1]Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, United States, [2]Department of Statistics, University of California, Irvine, Irvine, United States, [3]Arrowhead Pharmaceuticals, Inc, Pasadena, United States, [4]Center for Health Disparities Research and Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States

P501 Automated speech analysis of a semantic verbal fluency task for the detection of cognitive impairment

Presenteur : Ricardo Sainz-Fuertes

Ricardo Sainz-Fuertes[1, 2], Patricia Laura Maran[1, 3], Sergi Valero[4, 5], Berta Calm[4], Brian Murphy[2], Carla Zaldua[1]
[1]Accexible Impacto s.l., Barcelona, Spain, [2]Cumulus Neuroscience, Belfast, United Kingdom, [3]Psychiatry, Mental Health and Addictions Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigaci´on Sanitaria Acreditado Instituto de Investigaci´on - Hospital Universitario Vall d'Hebron (IR-HUVH, Barcelona, Spain, [4]Ace Alzheimer Center, Barcelona, Spain, [5]Universitat Internacional de Catalunya, Barcelona, Spain

P502 Baseline Completion and Retention with a New Cognitive Assessment in an Online Alzheimer's Disease Trial Registry: Results from the APT Webstudy

Presenteur : Margaret D. Mastrolorenzo

Margaret D. Mastrolorenzo[1], Marina Ritchie[1], Kedir Hussen[1], Oliver Langford[1], Gustavo Jimenez-Maggiora[1], Paul Aisen[1], Kathryn V. Papp[2], Rebecca E. Amariglio[2], Reisa A. Sperling[2], Cecily Jenkins[1], Rema Raman[1]
[1]Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [2]Department of Neurology, Mass General Brigham, Harvard Medical School, Boston, United States

P503 Infusion-Related Reactions Associated with Anti-Amyloid Monoclonal Antibodies: A Real-World Comparison of Lecanemab and Donanemab

Presenteur : Katelyn Horan

Katelyn Horan[1], Wedgina Norelus[1], Sokratis Charisis[1, 2], Cinthya Aguero[1, 2], Yingnan He[1], Sudeshna Das[1, 2], John Dickson[1, 2], Teresa Gomez-Isla[1, 2]
[1]Massachusetts General Hospital, Boston, United States, [2]Harvard Medical School, Boston, United States

P504 Temporal Relationship between pTau-217 and Beta-amyloid 42/40 Blood-based Biomarkers in Real-World Data

Presenteur : David Alfego

Kathleen Bailey[1], David Alfego[2], Joseph Volpe[3]
[1]Labcorp, Los Angeles, Ca, United States, [2]Labcorp, San Diego, Ca, United States, [3]Labcorp, Durham, Nc, United States

P505 Digital cognitive assessments in primary care: Outcomes from a real-world implementation study

Presenteur : Kyra O'brien

Louis McKinnon, Wheeler Maxwell, Stacy Iannone, Kyra O'Brien
University of Pennsylvania Perelman School of Medicine, Philadelphia, United States

P506 Real-world safety with Lecanemab: An initial experience from Singapore

Presenteur : Kim En Lee

Kim En Lee
Lee Kim En Neurology Pte Ltd, Mount Elizabeth Medical Centre, #11-14/15, Singapore, Singapore

P507 Divergent cognitive trajectories in patients with suspected co-pathology receiving lecanemab

Presenteur : Nick Frost

Nick Frost, Bethany Curd, Camilla Zubrick, Christine Cliatt Brown, Michelle Sorweid, Yoshimi Anzai, Satoshi Minoshima
University of Utah, Salt Lake City, United States

P508 Implementation of a Standardized, Digitally Enabled Memory Clinic Pathway Accelerates Diagnosis and Improves Early Alzheimer's Disease and Mild Cognitive Impairment Detection in Community Neurology

Presenteur : Gregory Sahagian

Gregory Sahagian
The Neurology Center of Southern California, Carlsbad, United States

P509 Frequency and Predictors of Non-Progression in Lecanemab-Treated Alzheimer's Disease: A Retrospective Cohort Study

Presenteur : David Weisman

David Weisman
Abington Neurological Associates, Elkins Park, United States

P510 Retrospective analysis of aducanumab and lecanemab treatment switches to donanemab in Alzheimer's disease (AD) patients with mild cognitive impairment (MCI) or mild dementia stage of disease[TS1] and presence of amyloid beta pathology

Presenteur : Christen Kutz

Christen Kutz
Rocky Mountain Research and Consulting, Colorado Springs, United States

P511 Completeness of Clinical Documentation Among Long-Term Care Residents With Dementia: A Retrospective Study

Presenteur : Beatriz Canonico Pagoto

Beatriz Canonico Pagoto[1], Gustavo Alves A. Dos Santos[2], Beatriz Carassato Pires Da Silva[3], Camile Carvalho[4]
[1]São Leopoldo Mandic School of Medicine, Pirassununga, Brazil, [2]São Leopoldo Mandic School of Medicine, São Paulo, Brazil, [3]São Leopoldo Mandic School of Medicine, São Carlos, Brazil, [4]São Leopoldo Mandic School of Medicine, Araraquara, Brazil

P512 Optimizing Pre-Screening in Alzheimer's Disease Clinical Trials: Using SLUMS Delayed Memory Index to Minimize Screen Failures and Maximize Inclusion

Presenteur : Susan Nguyen

Susan Nguyen[1], Criselle Penamante[1], Alfreda Wright[1], Marissa Sandoval[1], Myoungin Bae[1], T. Richard Parenteau[1, 2], Ralph Lee[3]
[1]Irvine Clinical Research - Oakland Clinical, Oakland, United States, [2]University of California, San Francisco, Division of Geriatrics, San Francisco, United States, [3]Irvine Clinical Research, Irvine, United States

P512 bis Quantification of Benefit-Risk in Amyloid-Targeting Therapies for Early Symptomatic Alzheimer's Disease: Perspectives of Patients, Care Partners, and Physicians

Presenteur : Jaein Seo

Oralee J. Varnado[1], Jaein Seo[2], Matthew Quaife[3], Antje Tockhorn-Heidenreich[1], Malavika Venkatraman[3], Frances-Catherine Quevenco[1], Niklas Mattsson-Carlgren[4, 5]
[1]Eli Lilly and Company - Indianapolis, IN (United States), [2]Evidera Patient-Centered Research, Thermo Fisher Scientific - Waltham, MA (United States), [3]Evidera Patient-Centered Research, Thermo Fisher Scientific - London (United Kingdom), [4]Clinical Memory Research Unit, Department of Clinical Sciences Malmö - Lund (Sweden), [5]Memory Clinic, Skåne University Hospital, - Malmö (Sweden)

P513 Solving the Alzheimer Equation

Presenteur : Flemming Villalona

Flemming Villalona[1], Ricardo Francisco Allegri[2]
[1]The Alzheimer Project, AI Robotix, Santo Domingo, Dominican Republic, [2]The Alzheimer Project, AI Robotix, Buenos Aires, Argentina

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : Zhihan Yang

Zhihan Yang, Qingyang Zhang, Chong Dai
Gate Core Biotechnology, Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : Fred Kim

Tianyang Xi[1], Fred Kim[1], Vitella Fomenko[1], James Rock[1], Jai Jun Choung[2]
[1]AriBio Co., Ltd., San Diego, United States, [2]AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra[1, 2], Joshin Kumar[1, 2], Spondita Goswami[3], Robert C. Elliot[1], Rajan K. Chakrabarty[1, 2]
[1]Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, [2]Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, [3]Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : Amir Meghdadi

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P518 The "Memory Pacemaker": A non-invasive brain stimulation to improve episodic memory using ultra-high-frequency visual stimulation

Presenteur : Fabian Queisner

Fabian Queisner, Markus Müschenich, Julian Keil
Nuuron GmbH, Berlin, Germany

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : DaeKeun Kim

Daekeun Kim[1], Morihiro Tsujishita[2], Seung Wan Kang[1], Jun Yeop Kim[1], Nam Heon Kim[1], Paolo Cassano[3]
[1]iMediSync Inc, Seoul, Korea, Republic of, [2]Naragakuen University, Nara, Japan, [3]Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : Gaurav Malik

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain–Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : Volker Herrmann

Volker Herrmann, Guillaume Blivet
REGEnLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : Shmuel (sam) Agus

Shmuel (Sam) Agus[1], Oren Fuerst[2], Yaron Ilan[2]
[1]Oberon Sciences, Boston, United States, [2]Oberon Sciences, Herzelia, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : James Galvin

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States

Notes

Notes

CTAD 2026

Clinical Trials on Alzheimer's Disease

FIND OUR COMPLETE POSTER LIST

by scanning the QR Code
or discover on our website :

www.ctad-alzheimer.com/program

KEEP IN TOUCH!

Visit our website

Follow us on Social Media

Subscribe to our newsletter